

INDEX

account of profits

- Australia 47.1.03, 47.1.06, 47.1.07
- Canada 47.2.11–47.2.14
- India 47.4.11, 47.4.12
- Netherlands 47.11.07, 47.11.08
- United Kingdom 47.12.06, 47.12.07,
47.12.15–47.12.20

acts done to obtain regulatory approval *see***Bolar exemption****addressee**

- see also* **skilled addressee**
- notional addressee of patent
specification 1.04–1.08

agricultural chemicals

- see also* **agricultural chemicals
regulatory approval**

data exclusivity

- Australia 80.1.01–80.1.10
- Canada 80.2.01, 80.2.02
- China 80.3.01–80.3.04
- Europe 80.7.01
- France 80.8.01
- Germany 80.9.01
- India 80.4.01
- Italy 80.5.04
- Japan 80.5.01
- Netherlands 80.11.01
- overview 73.16
- United Kingdom 80.12.01
- United States 80.6.01–80.6.03

agricultural chemicals regulatory approval

- Australia 69.1.01–69.1.14
 - Pesticides and Veterinary Medicines
Authority 69.1.06–69.1.14
- Canada 69.2.01–69.2.23
- China 69.3.01–69.3.04
- Europe
 - adverse data 69.7.35
 - authorization of plant protection
product 69.7.18–69.7.21
 - data exclusivity 69.7.33, 69.7.34
 - data protection 69.7.33
 - extensions of use 69.7.32
 - inclusion of active substance in
Annex I 69.7.12–69.7.17
 - interaction between
legislation 69.7.37–69.7.39
 - maximum residue levels 69.7.30–69.7.31
 - minor uses approvals 69.7.32
 - mutual recognition of
approvals 69.7.22, 69.7.23
 - regulatory regime 69.7.01, 69.7.02

- review of Directive 91/414/EEC 69.7.36
- scope of Directive 91/414/EEC 69.7.03–69.7.06
- transitional arrangements 69.7.24–69.7.29
- types of approval 69.7.07–69.7.11

France

- basic principles 69.8.01–69.8.04
- provisional authorizations 69.8.05

Germany 69.9.01, 69.9.02**India 69.4.01–69.4.03****Italy****plant protection**

- products 69.10.13–69.10.21
- REACH Regulation 69.10.01–69.10.12

Japan

- agricultural chemicals 69.5.04–69.5.15
- veterinary medicines 69.5.01–69.5.03

Netherlands 69.11.01–69.11.04**United Kingdom**

- competent authorities 69.12.04
- legislation 69.12.01–69.12.03

United States

- FDC Act 69.6.02–69.6.06
- FIFRA 69.6.07–69.6.10
- overview 69.6.01

see also **agricultural chemicals****agricultural methods****India 19.4.08****allowable amendments**

- Australia 34.1.01–34.1.15
- Canada 34.2.01–34.2.10
- Europe 34.7.01–34.7.30
- France 34.8.01, 34.8.02
- Germany 34.9.01–34.9.20
- India 34.4.01–34.4.05
- Italy 34.10.01, 34.10.02
- Japan 34.5.01–34.5.11
- Netherlands 34.11.01–34.11.08
- overview 32.05–32.06
- United Kingdom 34.12.01–34.12.23
- United States 34.6.01–34.6.04

amended specifications

- Australia 35.1.01–35.1.03
- Canada 35.2.01–35.2.07
- China 35.3.01–35.3.06
- Europe 35.7.01–35.7.06
- France 35.8.01, 35.8.02
- Germany 35.9.01
- India 35.4.01, 35.4.02
- Japan 35.5.01
- Netherlands 35.11.01, 35.11.02
- overview 32.07, 32.08
- United Kingdom 35.12.01–35.12.07

amendment

see also allowable amendments; amended specifications; certificates of correction; reissue applications; timing of amendment

applications

Australia 33.2.03, 33.2.04, 34.2.02–34.2.05, 35.2.11–35.2.27
 Canada 33.2.03, 33.2.04, 34.2.02–34.2.05, 35.2.11–35.2.27
 China 35.3.01–35.3.06
 Europe 34.7.16, 34.7.17
 Germany 33.9.03–33.9.07
 India 35.4.03
 Japan 33.5.01, 33.5.02, 34.5.01, 34.5.02
 United States 35.6.05–35.6.12

Australia

allowable amendments 34.1.01–34.1.15
 amended specifications 35.1.01–35.1.03
 certificates of correction 35.1.01–35.1.03
 reissue applications 35.1.01–35.1.03
 timing 33.1.01–33.1.08

Canada

allowable amendments 34.2.01–34.2.10
 certificates of correction 35.2.28–35.2.38
 clerical errors 33.2.09–33.2.13
 disclaimer 33.2.05–33.2.07, 35.2.01–35.2.07
 generally 33.2.01, 33.2.02
 invalidation, during 34.3.14–34.3.16
 nullification, during 34.3.14–34.3.16
 re-examination 33.2.08, 34.3.07–34.3.13, 35.2.08–35.2.10
 reissue applications 33.2.03, 33.2.04, 34.2.02–34.2.05, 35.2.11–35.2.27

China

amended specification 35.3.01–35.3.06
 reissue applications 35.3.01–35.3.06
 timing 33.3.01, 33.3.02

Europe

allowable amendments 34.7.01–34.7.30
 amended specifications 35.7.01–35.7.06
 divisional applications 34.7.16, 34.7.17
 patents 34.7.27–34.7.29
 test for allowability 34.7.18–34.7.26
 timing 33.7.01–33.7.06

France

allowable amendments 34.8.01, 34.8.02
 amended specifications 35.8.01, 35.8.02
 post-grant amendments 33.8.07–33.8.11
 pre-grant amendments 33.8.02–33.8.06
 principle 33.8.01

Germany

allowable amendments 34.9.01–34.9.20
 amended specifications 35.9.01
 applications 33.9.03–33.9.07
 conflict between new matter and extension of scope of protection 34.9.18–34.9.20
 correction of obvious errors 33.9.02
 extension of scope of protection 34.9.12–34.9.17
 generally 33.9.01
 new matter 34.9.02–34.9.11
 opposition proceedings 38.9.32–38.9.35

patents 33.9.08–33.9.11
 reissue applications 35.9.02
 restriction applications 35.9.03–35.9.05

India

allowable amendments 34.4.01–34.4.05
 amended specifications 35.4.01, 35.4.02
 certificates of correction 35.4.04
 reissue applications 35.4.03
 timing 33.4.01–33.4.06

Italy

allowable amendments 34.10.01, 34.10.02
 amended specifications 35.10.01, 35.10.02
 timing 33.10.01–33.10.3

Japan

allowable amendments 34.5.01–34.5.11
 amended specifications 35.5.01
 appeal 33.5.05
 appeal against final rejection 33.5.04
 final notice of refusal 33.5.03, 34.5.03–34.5.06
 notice of grant 33.5.06–33.5.09, 34.5.08–34.5.11
 pendency of application 33.5.01, 33.5.02, 34.5.01, 34.5.02

Netherlands

allowable amendments 34.11.01–34.11.08
 amended specifications 35.11.01, 35.11.02
 certificates of correction 35.11.01
 timing 33.11.01–33.11.06

overview 32.01–32.08

United Kingdom

allowable amendments 34.12.01–34.12.23
 amended specification 35.12.01–35.12.07
 definitions 33.12.01, 33.12.02
 post-grant amendments 33.12.10–33.12.18
 pre-grant of patent 33.12.03–33.12.09, 34.12.03–34.12.18

United States

allowable amendments 34.6.01–34.6.04
 certificates of correction 35.6.01–35.6.03
 disclaimers 35.6.04
 re-examination 35.6.13–35.6.15
 reissue applications 35.6.05–35.6.12
 timing 33.6.01, 33.6.02

anti-counterfeiting

United States 72.6.13–72.6.16

appeals

Australia 56.1.01–56.1.05
 Canada 56.2.21–56.2.25, 57.2.49–57.2.56
 France 56.8.02–56.8.04
 Germany 56.9.09–56.9.11, 56.9.17, 56.9.18
 India 56.4.11
 Italy 56.10.02, 56.10.03
 Japan 56.5.10, 56.5.11
 United Kingdom 56.12.07–56.12.12
 United States
 interference proceedings 5.6.36

applications

see also Lapse of patent applications; Withdrawal of patent applications

amendment

Australia 33.2.03, 33.2.04, 34.2.02–34.2.05, 35.2.11–35.2.27

- Canada 33.2.03, 33.2.04, 34.2.02–34.2.05, 35.2.11–35.2.27
- China 35.3.01–35.3.06
- Europe 34.7.16, 34.7.17
- Germany 33.9.03–33.9.07
- India 35.4.03
- Japan 33.5.01, 33.5.02, 34.5.01, 34.5.02
- United States 35.6.05–35.6.12
- Australia 13.1.01–13.1.09
- Canada 13.2.01–13.2.10
- China 13.3.01–13.3.03
- Europe
 - divisional applications 13.7.01–13.7.44
 - types 13.7.01–13.7.44
- France 13.8.01–13.8.14
- Germany
 - divisional applications 13.9.02
 - generally 13.9.01
 - supplementary patents 13.9.03–13.9.05
 - supplementary protection certificates 13.9.06–13.9.15
 - types 13.9.01–13.9.15
- India
 - addition, patents of 13.4.15–13.4.19
 - appropriate office 13.4.09
 - controller's power to make orders respecting division 13.4.20, 13.4.21
 - Convention application 13.4.04–13.4.07
 - designating and/or electing India 13.4.11, 13.4.12
 - filing of priority document 13.4.13
 - ordinary applications 13.4.03
 - PCT international application 13.4.08
 - PCT national phase application 13.4.14
 - procedure 13.4.10
 - terms of patent of addition 13.4.16, 13.4.17
 - types 13.4.01
 - validity of patents of addition 13.4.18, 13.4.19
 - who can apply 13.4.02
- Italy 13.10.01
- Japan
 - divisional application 13.5.02–13.5.08
 - ordinary application 13.5.01
 - types 13.5.01–13.5.08
- Netherlands
 - Aruba 13.11.08
 - concurrence 13.11.06, 13.11.07
 - divisional applications 13.11.04
 - enforcement of patents 13.11.09, 13.11.10
 - Netherlands Antilles 13.11.08
 - non pre-examined patent 12.11.01, 13.11.05
 - territorial scope 13.11.08
 - types 13.11.01–13.11.10
- types
 - Australia 13.1.01–13.1.09
 - Canada 13.2.01–13.2.10
 - China 13.3.01–13.3.03
 - Europe 13.7.01–13.7.44
 - France 13.8.01–13.8.14
 - Germany 13.9.01–13.9.15
 - India 13.4.01–13.4.17
 - Italy 13.10.01
 - Japan 13.5.01–13.5.08
 - Netherlands 13.11.01–13.11.10
 - overview 7.21–7.23
 - United Kingdom 13.12.01–13.12.14
 - United States 13.6.01–13.6.14
- United Kingdom
 - conversion applications 13.12.12–13.12.14
 - divisional applications 13.12.02–13.12.08
 - replacement applications 13.12.09–13.12.11
 - types 13.12.01–13.12.14
- United States
 - continuation applications 13.6.10
 - continuation-on-part applications 13.6.12
 - continuing applications 13.6.07–13.6.09
 - divisional applications 13.6.11
 - non-provisional utility applications 13.6.06
 - original applications 13.6.02
 - overview 13.6.01
 - provisional applications 13.6.03–13.6.05
 - reissue applications 13.6.02
 - requests for continued examination 13.6.13, 13.6.14
 - types 13.6.01–13.6.14
- approval of generic drugs**
 - Australia 77.1.01–77.1.05
 - Canada 77.2.01–77.2.29
 - China 77.3.01, 77.3.02
 - Europe 77.7.01
 - France 77.8.01
 - Germany 77.9.01
 - India 77.4.01
 - Italy 77.10.01–77.10.05
 - Japan 77.5.01–77.5.07
 - Netherlands 77.11.01
 - overview 73.07, 73.08
 - United Kingdom 77.12.01
 - United States
 - approval 77.6.09–77.6.19
 - Orange Book listing 77.6.01–77.6.19
 - overview 77.6.01–77.6.04
 - therapeutic equivalence 77.6.20–77.6.28
- assignments**
 - Australia 97.1.01–97.1.05
 - Canada 97.2.01–97.2.15
 - China 97.3.01–97.3.03
 - Europe
 - competition law 97.7.03
 - formalities 97.7.02
 - generally 97.7.01
 - France
 - duties 97.8.06–97.8.13
 - nullity 97.8.14
 - overview 97.8.01–97.8.04
 - publicity 97.8.05
 - registration 97.8.05
 - Germany
 - invalidity of assigned patent 97.9.09, 97.9.10
 - overview 97.9.01–97.9.03
 - right deriving from patent 97.9.08
 - right to grant of patent 97.9.07
 - right to patent 97.9.04–97.9.06

- assignments (cont.)**
- India 97.4.01–97.4.04
 - Italy 97.10.01–97.10.03
 - Japan
 - assign-back 97.5.10
 - employee inventions 97.5.11
 - exclusive licences 97.5.01–97.5.03
 - grant-back 97.5.10
 - joint ownership 97.5.08, 97.5.09
 - non-exclusive licences 97.5.04–97.5.06
 - right to obtain patents 97.5.07
 - transfer of patent rights 97.5.01–97.5.03
 - Netherlands
 - content of agreement 97.11.02, 97.11.03
 - effect of invalidity 97.11.06
 - form of agreement 97.11.02, 97.11.03
 - overview 97.11.01
 - registration 97.11.04, 97.11.05
 - overview 93.15
 - United Kingdom
 - estoppel 97.12.09
 - formalities 97.12.02–97.12.06
 - generally 97.12.01
 - registration 97.12.07, 97.12.08
 - United States
 - generally 97.6.01–97.6.03
 - recording assignments 97.6.04
 - witnessing assignments 97.6.05
- Australia**
- account of profits 47.1.03, 47.1.06, 47.1.07
 - agricultural chemicals regulatory
 - approval 69.1.01–69.1.14
 - Pesticides and Veterinary Medicines Authority 69.1.06–69.1.14
 - allowable amendments 34.1.01–34.1.15
 - amended specifications 35.1.01–35.1.03
 - amendment
 - allowable amendments 34.1.01–34.1.15
 - amended specifications 35.1.01–35.1.03
 - certificates of correction 35.1.01–35.1.03
 - reissue applications 35.1.01–35.1.03
 - timing 33.1.01–33.1.08
 - appeals 56.1.01–56.1.05
 - applications 13.1.01–13.1.09
 - assignments 97.1.01–97.1.05
 - biodiversity 72.1.17–72.1.34
 - biological regulatory approval 67.01.01–67.01.04
 - block exemptions 83.1.09–83.1.13
 - Bolar exemption 52.1.01–52.1.04
 - case management 46.1.08
 - certificates of correction 35.1.01–35.1.03
 - clarity 27.1.01–27.1.04
 - commercialization strategies 95.1.01–95.1.11
 - competition law
 - disclosure to standard setting
 - organizations 86.01.01–86.1.05
 - intellectual property rights as
 - exception 82.1.01–82.1.06
 - licences 85.1.01–85.1.04
 - settlement of litigation 88.1.01–88.1.09
 - technology transfer
 - arrangements 83.1.01–83.1.13
 - tie-in/tie-out clauses 84.1.01–84.1.07
 - unjustified infringement
 - proceedings 87.1.01–87.1.04
 - compulsory licensing 99.1.01–99.1.05
 - confidential information 90.1.01–90.1.08
 - costs 47.1.10, 47.1.11
 - court hierarchies 56.1.01–56.1.05
 - damages 47.1.03–47.1.05
 - data exclusivity
 - comparison with other rights 74.1.01–74.1.11
 - generic companies 79.1.01–79.1.17
 - innovator companies 78.1.01–78.1.04
 - medical devices 80.1.01–80.1.05
 - new chemical entity 75.1.01–75.1.05
 - non-pharmaceuticals 80.1.01–80.1.10
 - other periods 76.1.01
 - data exclusivity strategies for generic companies 79.1.01–79.1.17
 - data exclusivity strategies for innovator companies 78.1.01–78.1.04
 - declarations of validity 41.1.01–41.1.04
 - declaratory judgments 60.1.01–60.1.07
 - defences to infringement
 - Bolar exemption 52.1.01–52.1.04
 - exhaustion of rights 54.1.01–54.1.09
 - experimental use 51.1.01–51.1.05
 - non-infringement
 - declarations 53.1.01–53.1.08
 - parallel importing 54.1.01–54.1.09
 - prior secret use 50.1.01–50.1.10
 - delivery up 47.1.09
 - disclosure of information to patent offices 14.1.01–14.1.03
 - disclosure to standard setting
 - organizations 86.01.01–86.1.05
 - drafting bioscience patents 8.1.05, 8.1.05–8.1.07, 8.1.01–8.1.11
 - human beings etc 8.1.02
 - innovation patents 8.1.03
 - novel gene encoding 8.1.04
 - reach-through claims 8.1.09–8.1.11
 - standard patents 8.1.02
 - drafting pharmaceutical patents 9.1.01–9.1.09
 - due diligence 98.1.01–98.1.08
 - enablement 24.01.01–24.01.04
 - entitlement to the invention 31.1.01–31.1.03
 - equivalents doctrine 44.1.01–44.1.05
 - evidence 46.1.09, 46.1.10
 - examination 11.1.01–11.1.18
 - exhaustion of rights 54.1.01–54.1.09
 - experimental use 51.1.01–51.1.05
 - expert witnesses
 - interpretation of patent claims/ specifications 4.1.05–4.1.08
 - extensions of term 17.1.25–17.1.28
 - application requirements 17.1.25–17.1.28
 - disclosed in complete
 - specification 17.1.08–17.1.10
 - five years from first regulatory approval
 - date 17.1.21
 - grant of extension 17.1.22, 17.1.23
 - per se, pharmaceutical substance 17.1.13–17.1.18

- pharmaceutical substance 17.1.03–17.1.07
- recombinant DNA technology 17.1.19
- rights of patentee during extension 17.1.24
- scope of claim 17.1.11, 17.1.12
- standard pharmaceutical patent 17.1.01, 17.1.02
- timing 17.1.25–17.1.28
- formalities requirement 10.1.01–10.1.08
- forum 46.1.01, 46.1.02
- fraud 30.1.01–30.1.04
- full description 25.1.01, 25.02
- generic company filing strategies 71.1.01–71.1.04
- genetic modified organisms 72.1.01–72.1.16
- Gillette* defence 50.1.09, 50.1.10
- government use or acquisition of
 - licences 100.1.01–100.1.03
- grace periods 22.1.01, 22.1.02
- indirect infringement 45.1.01–45.1.11
- infringement proceedings
 - case management 46.1.08
 - evidence 46.1.09, 46.1.10
 - facts 46.1.09, 46.1.10
 - forum 46.1.01, 46.1.02
 - onus of proof 46.1.13
 - plaintiff 46.1.03, 46.1.04
 - pleadings 46.1.05–46.1.07
 - trial 46.1.11, 46.1.12
- infringing acts 43.1.01–43.1.05
- injunctions 47.1.02
- innocent infringement 48.1.04, 48.1.05
- innovation patents 8.1.03
 - lapse 16.1.14
 - term 16.1.13
 - withdrawal 16.1.15
- innovator company strategies 70.1.01–70.1.05
- inspection 47.1.08
- internal fair basis 24.1.01–24.1.04
- interpretation of patent claims/specifications
 - construction 4.1.01–4.1.05
 - expert witnesses 4.1.05–4.1.08
 - principles 4.1.01–4.1.05
 - purposive construction 4.1.09, 4.1.10
- inventive step 23.1.01–23.1.14
- inventorship
 - basic principles 5.1.01–5.1.05
 - definition of inventor 5.1.03
 - entitlement 5.1.06–5.1.13
 - persons 5.1.02
- lapse of patent applications 16.1.10–16.1.15
- licences 85.1.01–85.1.04
- licensing 96.1.01–96.1.11
- limitation period 48.1.01, 48.1.02
- literal infringement 43.1.06, 43.1.07
- litigation 57.1.01–57.1.09
 - practicalities 62.1.01–62.1.09
- manner of manufacture 19.1.01–19.1.12
- medical device data exclusivity 80.1.01–80.1.10
- medical device regulatory approval 68.1.01–68.1.10
- misrepresentation 30.1.01–30.1.04
- multi-jurisdictional strategy 61.1.01–61.1.03
- non-infringement declarations 53.1.01–53.1.08
- non-literal infringement 44.1.01–44.1.05
- novelty 21.1.01–21.1.06
- nullification proceedings 40.1.01–40.1.03
- onus of proof 46.1.13
- opposition proceedings 38.1.01–38.1.27
- ownership 6.1.01–6.1.09
 - employer-employee relationship 6.1.06–6.1.09
- parallel importing 54.1.01–54.1.09
- passing off 92.1.23–92.1.26
- patent term 16.1.01–16.1.07
- patentable subject matter 19.1.01–19.1.12
- pharmaceutical regulatory approval
 - manufacturing approval
 - process 66.1.04–66.1.11
 - marketing approval process 66.1.12–66.1.19
 - overview 66.1.01–66.1.3
- plant breeders' rights
 - exclusive rights 91.1.09–91.1.14
 - overview 91.1.01
 - PBR Act 91.1.02–91.1.08
- pleadings 46.1.05–46.1.07
- practicalities of litigation 62.1.01–62.1.09
- preliminary injunctions 58.1.01–58.1.07
- prior secret use 50.1.01–50.1.10
- priority dates 20.1.01–20.1.03
- procedure from filing to grant 10.1.01–10.1.08
- prosecution strategies 12.1.01–12.1.10
- publication 48.1.03
- re-examination 39.1.01–39.1.09
- regulatory bodies
 - Therapeutic Goods
 - Administration 65.1.01–65.1.03
- regulatory legislation
 - Therapeutic Goods Act 1989 65.1.04
 - Therapeutic Goods (Charges) Act 1989 65.1.07
 - Therapeutic Goods (Charges)
 - Regulations 1990 65.1.08
 - Therapeutic Goods (Medical Devices)
 - Regulations 2002 65.1.06
 - Therapeutic Goods Regulations 1990 65.1.05
- reissue applications 35.1.01–35.1.03
- remedies for infringement
 - account of profits 47.1.03, 47.1.06, 47.1.07
 - amendment of patent
 - specification 48.1.06–48.1.08
 - costs 47.1.10, 47.1.11
 - damages 47.1.03–47.1.05
 - delivery up 47.1.09
 - generally 47.1.01
 - injunctions 47.1.02
 - innocent infringement 48.1.04, 48.1.05
 - inspection 47.1.08
 - limitation period 48.1.01, 48.1.02
 - limitations on equitable remedies 48.1.09
 - publication 48.1.03
 - restored patents 48.1.10, 48.1.11
 - restrictions 48.1.01–48.1.11
- renewal fees 16.1.08, 16.1.09
- research and development
 - collaboration 94.1.01–94.1.10
- revocation 40.1.01–40.1.03
- secret use 28.1.01, 28.01.02
- settlement of litigation 63.1.01–63.1.03, 88.1.01–88.1.09

Australia (cont.)

- skilled addressee
 - attributes 3.1.05, 3.1.06
 - generally 3.1.01, 3.1.02
 - international character of patent
 - evidence 3.1.07–3.1.09
 - skilled team 3.1.10–3.1.13
 - use in patent proceedings 3.1.03, 3.1.04
- split trials 59.1.01–59.1.06
- sufficiency 25.1.01, 25.02
- summary judgments 60.1.01–60.1.07
- technology transfer arrangements
 - block exemptions 83.1.09–83.1.13
 - confidentiality agreements 83.1.02
 - deed of assignment 83.1.04
 - generally 83.1.01
 - joint ventures 83.1.06
 - licensing 83.1.05
 - material transfer agreements 83.1.03
 - spin-out companies 83.1.07
 - technology incubators 83.1.08
- third party interventions 37.1.01–37.1.09
- tie-in/tie-out clauses 84.1.01–84.1.07
- timing of amendment 33.1.01–33.1.14
- trade marks
 - application process 92.1.09, 92.1.10
 - deceptive similarity 92.1.17–92.1.21
 - defences 92.1.22
 - enforcement 92.1.12
 - overview 92.1.01
 - pharmaceutical trade marks 92.1.11
 - registrability issues 92.1.02–92.1.08
 - substantially identical 92.1.16
 - use as trade mark 92.1.13–92.1.15
- traditional knowledge 72.1.35–72.1.37
- trial 46.1.11, 46.1.12
- unfair competition 92.1.27–92.1.35
- unity of invention 29.1.01
- unjustified infringement
 - proceedings 87.1.01–87.1.04
- utility 26.1.01, 26.1.02
- withdrawal of patent applications 16.1.10–16.1.15
- written description 25.01.01

Berne Convention

- overview 2.30–2.32

biodiversity

- Australia 72.1.17–72.1.34
- Europe 72.7.01–72.7.10
- India 72.4.06
- Japan 72.5.03
- Netherlands 72.11.01–72.11.04
- United Kingdom 72.12.01

bioengineered foods

- United States 72.6.17–72.6.20

bioinformatics

- Japan 19.5.07, 19.5.08
- United States 8.6.53, 8.6.54, 19.6.23–19.6.25

biological regulatory approval

- Australia 67.01.01–67.01.04
- Canada 67.2.01–67.2.16
- China 67.3.01

Europe 67.7.01–67.7.25

- advanced therapy medicinal
 - products 67.7.19–67.7.25
- biosimilar products 67.7.10–67.7.18
- EMA guidelines 67.7.06–67.7.09

France

- basic principles 67.8.01, 67.8.02
- labile blood products 67.8.03

Germany 67.9.01**India 67.4.01–67.4.03****Italy 67.10.01–67.10.19****Japan 67.5.01–67.5.11**

- biological products 67.5.04, 67.5.05
- cell/tissue based products 67.5.10
- specified biological products 67.5.06–67.5.09

Netherlands 67.11.01**United Kingdom 67.12.01–67.12.04****United States 67.6.01–67.6.08**

- biological product approval 67.6.02–67.6.03
- follow-on biologics 67.6.04–67.6.08
- overview 67.6.01

block exemptions *see* technology transfer arrangement**Bolar exemption****Australia 52.1.01–52.1.04****Canada 52.2.01–52.2.03****China 52.3.01****Europe 52.7.01–52.7.13****France 52.8.01–52.8.05****Germany 52.9.01, 52.9.02****India 52.4.01****Italy 52.10.01–52.10.06****Japan 52.5.01****Netherlands 52.11.01, 52.11.02****overview 49.04****United Kingdom 52.12.01–52.12.09****United States 52.6.01–52.6.16****business methods****Canada 19.2.26, 19.2.27****United States 19.6.15–19.6.17****Canada****account of profits 47.2.11–47.2.14****agricultural chemicals regulatory****approval 69.2.01–69.2.23****allowable amendments 34.2.01–34.2.10****amended specifications 35.2.01–35.2.07****amendment****allowable amendments 34.2.01–34.2.10****certificates of correction 35.2.28–35.2.38****clerical errors 33.2.09–33.2.13****disclaimer 33.2.05–33.2.07, 34.2.06, 34.2.07, 35.2.01–35.2.07****generally 33.2.01, 33.2.02****invalidation, during 34.3.14–34.3.16****nullification, during 34.3.14–34.3.16****re-examination 33.2.08, 34.3.07–34.3.13, 35.2.08–35.2.10****reissue 33.2.03, 33.2.04, 34.2.02–34.2.05****reissue applications 35.2.11–35.2.27****appeals 56.2.21–56.2.25, 57.2.49–57.2.56****applications 13.2.01–13.2.10, 57.2.45–57.2.48****approval of generic drugs 77.2.01–77.2.29**

- art 19.2.05–19.2.08
- assignments 97.2.01–97.2.15
- biological regulatory approval 67.2.01–67.2.16
- Bolar exemption 52.3.01
- business methods 19.2.26, 19.2.27
- case management 57.2.57–57.2.64
- certificates of correction 35.2.28–35.2.38
- certified patents 77.2.01–77.2.29
- clarity 27.2.01–27.2.11
- commercialization strategies 95.2.01–95.2.33
- competition law
 - disclosure to standard setting
 - organizations 86.2.01–86.2.10
 - intellectual property rights as
 - exception 82.2.01–82.2.28
 - licences 85.2.01–85.2.09
 - settlement of litigation 88.2.01–88.2.19
 - technology transfer arrangements 83.2.01–83.2.11
 - tie-in/tie-out clauses 84.2.01–84.2.10
 - unjustified infringement
 - proceedings 87.2.01–87.2.08
- composition of matter 19.2.12–19.2.16
- compulsory licensing
 - abuse of monopoly 99.2.03–99.2.14
 - aircraft 99.2.31, 99.2.32
 - generally 99.2.01, 99.2.02
 - international humanitarian
 - purposes 99.2.15–99.2.30
 - vessels 99.2.31, 99.2.32
- computer inventions 19.2.28–19.2.31
- confidential information
 - access to information 90.2.23–90.2.26
 - litigation, confidentiality during 90.2.27–90.2.33
 - overview 90.2.01–90.2.22
- conflict proceedings
 - inventorship 5.2.06–5.2.13
- costs 57.2.65–57.2.71
- court hierarchies
 - choice of forum 56.2.14–56.2.20
 - federal courts 56.2.01–56.2.13
- damages 47.2.03–47.2.08
- data exclusivity
 - comparison with other rights 74.2.01–74.2.17
 - generic companies 79.2.01–79.2.63
 - innovator companies 78.2.01–78.2.46
 - medical devices 80.2.01, 80.2.02
 - new chemical entity 75.2.01–75.2.10
 - non-pharmaceuticals 80.2.01, 80.2.02
 - other periods 76.2.01–76.2.06
- data exclusivity strategies for generic companies 79.2.01–79.2.63
- data exclusivity strategies for innovator companies 78.2.01–78.2.46
- declarations of validity 41.2.01–41.2.04
- declaratory judgments 60.2.18–60.2.20
- dedication to the public 16.2.15, 16.2.16
- defences to infringement
 - Bolar exemption 52.3.01
 - exhaustion of rights 54.2.01–54.2.11
 - experimental use 51.2.01–51.2.06
 - non-infringement declarations 53.2.01–53.2.08
 - parallel importing 54.2.01–54.2.11
 - prior secret use 50.2.01–50.2.12
 - delivery up 47.2.17
 - disclaimer 33.2.05–33.2.07, 34.2.06, 34.2.07, 35.2.01–35.2.07
 - disclosure of information to patent
 - offices 14.2.01–14.2.09
 - disclosure to standard setting
 - organizations 86.2.01–86.2.10
 - discovery 57.2.14–57.2.34
 - drafting bioscience patents 8.2.01–8.2.22
 - biomolecules 8.2.14
 - deposits 8.2.19
 - disclosure 8.2.18
 - human beings 8.2.12
 - lower and higher life forms 8.2.02, 8.2.07–8.2.10
 - medical treatment 8.2.15
 - microbial culture system 8.2.03
 - organs and tissues 8.2.12
 - replication of invention 8.2.20
 - sequence listing 8.2.22
 - drafting pharmaceutical patents 9.2.01–9.2.41
 - due diligence 98.2.01–98.2.16
 - enablement 24.2.01–24.2.15
 - entitlement to the invention 31.2.01–31.2.05
 - equivalents doctrine 44.2.01–44.2.12
 - examination 11.2.01–11.2.10
 - exhaustion of rights 54.2.01–54.2.11
 - experimental use 51.2.01–51.2.06
 - expert evidence 3.2.06
 - interpretation of patent
 - claims/specifications 4.2.05
 - expiry of patent 16.2.14
 - extensions of term 17.2.01–17.2.03
 - forum 46.2.02–46.2.09
 - fraud 30.2.01–30.2.14
 - full description 25.2.01–25.2.15
 - games 19.2.32
 - generic company filing strategies 71.2.01–71.2.19
 - government use or acquisition of
 - licences 100.2.01–100.2.07
 - grace periods 22.2.01–22.2.07
 - human beings
 - drafting bioscience patents 8.2.12
 - indefiniteness 27.2.01–27.2.11
 - indirect infringement 45.2.01–45.2.03
 - inequitable conduct 30.2.01–30.2.14
 - infringement proceedings
 - defendants 46.2.15, 46.2.16
 - forum 46.2.02–46.2.09
 - generally 46.2.01
 - geographic jurisdiction 46.2.10, 46.2.11
 - onus of proof 46.2.17, 46.2.18
 - plaintiffs 46.2.12–46.2.14
 - selection of venue 46.2.02–46.2.09
 - infringing acts 43.2.01–43.2.05
 - injunctions 47.2.01, 47.2.02
 - innocent infringement 48.2.03–48.2.05
 - innovator company strategies 70.2.01–70.2.14
 - interest 47.2.15, 47.2.16
 - interference proceedings
 - inventorship 5.2.04, 5.2.05
 - internal fair basis 24.2.01–24.2.15

- Canada (cont.)**
- interpretation of patent claims/specifications
 - construction 4.2.01–4.2.09
 - expert evidence 4.2.05
 - purposive construction 4.2.06–4.2.09
 - inventorship
 - conflict proceedings 5.2.06–5.2.13
 - definition of inventor 5.2.01–5.2.03
 - interference proceedings 5.2.04, 5.2.05
 - lapse of patent applications 16.2.13
 - licences 85.2.01–85.2.09
 - licensing 96.2.01–96.2.14
 - limitation period 48.2.01
 - literal infringement 43.2.06–43.2.10
 - litigation
 - appeals 57.2.49–57.2.56
 - applications 57.2.45–57.2.48
 - case management 57.2.57–57.2.64
 - costs 57.2.65–57.2.71
 - discovery 57.2.14–57.2.34
 - generally 57.2.01–57.2.04
 - pleadings 57.2.05–57.2.13
 - practicalities 62.2.01–62.2.29
 - pre-trial procedure 57.2.35–57.2.37
 - trial 57.2.38–57.2.44
 - living matter 19.2.17–19.2.19
 - machine 19.2.10
 - manufacture 19.2.11
 - medical device data exclusivity 80.2.01, 80.2.02
 - medical device regulatory
 - approval 68.2.01–68.2.20
 - misrepresentation 30.2.01–30.2.14
 - multi-jurisdictional strategy 61.2.01–61.2.19
 - Natural Health Products
 - Regulations 72.2.17–72.2.23
 - non-infringement
 - declarations 53.2.01–53.2.08
 - non-literal infringement 44.2.01–44.2.12
 - novelty 21.2.01–21.2.19
 - nullification proceedings 40.2.01–40.2.22
 - opposition proceedings 38.2.01–38.2.03
 - ownership 6.2.01–6.2.12
 - inventorship disputes 6.2.13–6.2.22
 - parallel importing 54.2.01–54.2.11
 - passing off 92.2.47–92.2.51
 - patent term 16.2.01, 16.2.02
 - patentable subject matter
 - art 19.2.05–19.2.08
 - business methods 19.2.26, 19.2.27
 - composition of matter 19.2.12–19.2.16
 - computer inventions 19.2.28–19.2.31
 - definition of invention 19.2.02–19.2.04
 - games 19.2.32
 - generally 19.2.01–19.2.04
 - living matter 19.2.17–19.2.19
 - machine 19.2.10
 - manufacture 19.2.11
 - process 19.2.09
 - scientific principles 19.2.20
 - selection patents 19.2.21–19.2.25
 - Patented Medicines Prices Review
 - Board 72.2.07–72.2.16
 - pharmaceutical regulatory
 - approval 66.2.01–66.2.27
 - plant breeders' rights 91.2.01–91.2.28
 - pleadings 57.2.05–57.2.13
 - practicalities of litigation 62.2.01–62.2.29
 - pre-trial procedure 57.2.35–57.2.37
 - preliminary injunctions 58.2.01–58.2.22
 - prior art filing 12.2.06, 12.2.07
 - prior secret use
 - first to file 50.2.05–50.2.08
 - first to invent 50.2.09–50.2.11
 - Gillette* defence 50.2.12
 - immunity for prior acquisition 50.2.01–50.2.04
 - priority dates 20.2.01–20.2.07
 - procedure from filing to grant 10.2.01–10.2.26
 - process 19.2.09
 - prosecution strategies 12.2.01–12.2.11
 - re-examination 39.2.01–39.2.17
 - regulatory bodies 65.2.01–65.2.07
 - regulatory legislation 65.2.08–65.2.13
 - reissue applications 33.2.03, 33.2.04, 35.2.11–35.2.27
 - remedies for infringement
 - account of profits 47.2.11–47.2.14
 - costs 47.2.18–47.2.21
 - damages 47.2.03–47.2.08
 - delivery up 47.2.17
 - equitable remedies 48.2.02
 - injunctions 47.2.01, 47.2.02
 - innocent infringement 48.2.03–48.2.05
 - interest 47.2.15, 47.2.16
 - limitation period 48.2.01
 - reasonable compensation 47.2.09, 47.2.10
 - restrictions 48.2.01–48.2.05
 - renewal fees 16.2.03–16.2.12
 - research and development
 - collaboration 94.2.01–94.2.16
 - revocation 40.2.01–40.2.22
 - scientific principles 19.2.20
 - secret use 28.2.01–28.2.11
 - selection patents 19.2.21–19.2.25
 - settlement of litigation 63.2.01–63.2.19, 88.2.01–88.2.19
 - skilled addressee 3.2.01–3.2.12
 - special access program 72.2.01–72.2.06
 - split trials 59.2.01–59.2.16
 - Markman hearings 59.2.05–59.2.08
 - separate determination of infringement and
 - invalidity issues 59.2.12–59.2.16
 - separate determination of liability of
 - damages 59.2.09–59.2.11
 - sufficiency 25.2.01–25.2.15
 - summary judgments 60.2.01–60.2.17
 - technology transfer arrangements 83.2.01–83.2.11
 - third party interventions 37.2.01–37.2.09
 - tie-in/tie-out clauses 84.2.01–84.2.10
 - timing of amendment 33.2.01–33.2.13
 - trade marks 92.2.01–92.2.51
 - trial 57.2.38–57.2.44
 - unity of invention 29.2.01–29.2.13
 - unjustified infringement
 - proceedings 87.2.01–87.2.08

- utility 26.2.01–26.2.20
- withdrawal of patent applications 16.2.17, 16.2.18
- written description 25.2.01–25.2.15
- case management**
 - Australia 46.1.08
 - Canada 57.2.57–57.2.64
 - France 57.8.11
 - United Kingdom 57.12.14–57.12.18
 - United States 57.6.02–57.6.06
- certificates of correction**
 - Australia 35.1.01–35.1.03
 - Canada 35.2.28–35.2.38
 - China 35.3.01–35.3.06
 - India 35.4.04
 - Netherlands 35.11.01, 35.11.02
 - overview 32.07, 32.08
 - United States 35.6.01–35.6.03
- certified patents**
 - Australia 77.1.01–77.1.05
 - Canada 77.2.01–77.2.29
 - China 77.3.01, 77.3.02
 - Europe 77.7.01
 - France 77.8.01
 - Germany 77.9.01
 - India 77.4.01
 - Italy 77.10.01–77.10.05
 - Japan 77.5.01–77.5.07
 - Netherlands 77.11.01
 - overview 73.07, 73.08
 - United Kingdom 77.12.01
 - United States 77.6.01–77.6.28
- China**
 - agricultural chemicals regulatory approval 69.3.01–69.3.04
 - amended specifications 35.3.01–35.3.06
 - amendment
 - amended specification 35.3.01–35.3.06
 - certificates of correction 35.3.01–35.3.06
 - reissue applications 35.3.01–35.3.06
 - timing 33.3.01, 33.3.02
 - applications 13.3.01–13.3.03
 - approval of generic drugs 77.3.01, 77.3.02
 - assignments 97.3.01–97.3.03
 - biological regulatory approval 67.3.01
 - certificates of correction 35.3.01–35.3.06
 - certified patents 77.3.01, 77.3.02
 - clarity 27.3.01–27.3.05
 - commercialization strategies 95.3.01
 - competition law
 - disclosure to standard setting organizations 86.3.01
 - intellectual property rights as exception 82.3.01–82.3.04
 - licences 85.3.01
 - settlement of litigation 88.3.01–88.3.03
 - technology transfer arrangements 83.3.01–83.3.10
 - tie-in/tie-out clauses 84.3.01–84.3.03
 - unjustified infringement proceedings 87.3.01–87.3.03
 - compulsory licensing 99.3.01–99.3.04
 - confidential information 90.3.01–90.3.05
 - court hierarchies 56.3.01–56.3.06
 - data exclusivity
 - agricultural chemicals 80.3.01–80.3.04
 - comparison with other rights 74.3.01–74.3.05
 - generic companies 79.3.01
 - innovator companies 78.3.01–78.3.03
 - medical devices 80.3.01–80.3.04
 - new chemical entity 75.3.01
 - other periods 76.3.01
 - data exclusivity strategies for generic companies 79.3.01
 - data exclusivity strategies for innovator companies 78.3.01–78.3.03
 - declarations of validity 41.3.01
 - declaratory judgments 60.3.03
 - defences to infringement
 - exhaustion of rights 54.3.01
 - experimental use 51.3.01
 - non-infringement declarations 53.3.01–53.3.03
 - parallel importing 54.3.01
 - prior secret use 50.3.01
 - disclosure of information to patent offices 14.3.01–14.3.04
 - disclosure to standard setting organizations 86.3.01
 - drafting bioscience patents 8.3.01–8.3.11
 - genetic engineering 8.3.08
 - genetic resources 8.3.02, 8.3.03
 - microorganisms 8.3.09–8.3.11
 - strategies 8.3.11
 - drafting pharmaceutical patents 9.3.01–9.3.15
 - due diligence 98.3.01–98.3.07
 - enablement 24.3.01–24.3.02
 - entitlement to the invention 31.3.01–31.3.07
 - equivalents doctrine 44.3.01, 44.3.02
 - examination 11.3.01–11.3.10
 - exhaustion of rights 54.3.01
 - experimental use 51.3.01
 - extensions of term 17.3.01, 17.3.02
 - fraud 30.3.01–30.3.06
 - full description 25.3.01–25.3.08
 - generic company filing strategies 71.3.01
 - genetic modified organisms 72.3.01
 - government use or acquisition of licences 100.3.01
 - grace periods 22.3.01–22.3.12
 - academic/technological meetings 22.3.08, 22.3.09
 - disclosed by another person without applicant's consent 22.3.10–22.3.12
 - international exhibitions 22.3.06, 22.3.07
 - indefiniteness 27.3.01–27.3.05
 - indirect infringement 45.3.01, 45.3.02
 - inequitable conduct 30.3.01–30.3.06
 - infringement proceedings 46.3.01–46.3.05
 - infringing acts 43.3.01
 - innovator company strategies 70.3.01–70.3.03
 - internal fair basis 24.3.01–24.3.02
 - interpretation of patent claims/specifications
 - eclectic interpretation 4.3.08–4.3.10
 - legislative background 4.3.01–4.3.20
 - inventive step 23.3.01–23.3.14
 - inventorship 5.3.01–5.3.08
 - lapse of patent applications 16.3.05–16.3.08
 - licences 85.3.01

China (cont.)

- licensing 96.3.01–96.3.06
- literal infringement 43.3.02
- litigation 57.3.01–57.3.08
 - practicalities 62.3.01–62.3.06
- medical device data exclusivity 80.3.01–80.3.04
- medical device regulatory approval 68.3.01–68.3.05
- misrepresentation 30.3.01–30.3.06
- multi-jurisdictional strategy 61.3.01, 61.3.02
- non-infringement declarations 53.3.01–53.3.03
- non-literal infringement 44.3.01, 44.3.02
- novelty 21.3.01–21.3.08
- nullification proceedings 40.3.01–40.3.15
- opposition proceedings 38.3.01
- ownership 6.3.01–6.3.06
- parallel importing 54.3.01
- patent term 16.3.01–16.3.04
- patentable subject matter 19.3.01–19.3.05
- pharmaceutical regulatory approval 66.3.01
- plant breeders' rights 91.3.01–91.3.03
- practicalities of litigation 62.3.01–62.3.06
- preliminary injunctions 58.3.01–58.3.07
- prior secret use 50.3.01
- priority dates 20.3.01–20.3.10
- procedure from filing to grant 10.3.01
- prosecution strategies 12.3.01
- regulatory bodies 65.3.01, 65.3.02
- regulatory legislation 65.3.03–65.3.05, 65.5.08–65.5.11
- reissue applications 35.3.01–35.3.06
- remedies for infringement 47.3.01–47.3.03
 - restrictions 48.3.01, 48.3.02
- renewal fees 16.3.09
- research and development
 - collaboration 94.3.01–94.3.05
- revocation 40.3.01–40.3.15
- secret use 28.3.01–28.3.06
- settlement of litigation 63.3.01–63.3.04
- skilled addressee 3.3.01–3.3.06
- split trials 59.3.01–59.3.03
- sufficiency 25.3.01–25.3.08
- summary judgments 60.3.01, 60.3.02
- supplementary protection
 - certificates 17.3.01, 17.3.02
- technology transfer arrangements 83.3.01–83.3.10
- third party interventions 37.3.01–37.3.04
- tie-in/tie-out clauses 84.3.01–84.3.03
- timing of amendment 33.3.01, 33.3.02
- trade marks 92.3.01–92.3.13
- unity of invention 29.3.01–29.3.09
- unjustified infringement
 - proceedings 87.3.01–87.3.03
- utility 26.3.01–26.3.06
- written description 25.3.01–25.3.08

clarity

- Australia 27.1.01–27.1.04
- Canada 27.2.01–27.2.11
- China 27.3.01–27.3.05
- Europe 27.7.01–27.7.18
- France 27.8.01–27.8.03
- Germany 27.9.01
- India 27.4.01–27.4.03

Italy 27.10.01

Japan 27.5.01–27.5.07

Netherlands 27.11.01–27.11.05

requirement 18.36, 18.37

United Kingdom 27.12.01–27.12.03

United States 27.6.01–27.6.08

classification of patents

- Strasbourg Agreement concerning the International Patent Classification 1971 2.15, 2.16

cloning

United States 19.6.07, 19.6.08

commercialization strategies

Australia 95.1.01–95.1.11

Canada 95.2.01–95.2.33

China 95.3.01

Europe

exhaustion of rights 95.7.03–95.7.06

IP rights 95.7.02

over-stickering of pharmaceutical products 95.7.07–95.7.09

overview 95.7.01

re-packaging of pharmaceutical products 95.7.07–95.7.09

France 95.8.01, 95.8.02

Germany 95.9.01, 95.9.02

India 95.4.01–95.4.06

Italy 95.10.01–95.10.07

Japan 95.5.01

Netherlands 95.11.01

overview 93.08–93.11

United Kingdom 95.12.01–95.12.13

United States

180-day exclusivity 95.6.15

biologics 95.6.16

clearance search 95.6.20

drafting patent claims 95.6.19

due diligence 95.6.20

FDA approval process 95.6.03–95.6.05

generic biologics 95.6.16

new chemical entity exclusivity 95.6.11

new clinical study exclusivity 95.6.12

non-patent exclusivity periods for

drugs 95.6.10–95.6.15

Orange Book practice 95.6.06–95.6.09

orphan drugs 95.6.13

overview 95.6.01, 95.6.02

patent licensing 95.6.25

patent term extension 95.6.23, 95.6.24

pediatric exclusivity 95.6.14

prior art 95.6.17, 95.6.18

safe harbour 95.6.21, 95.6.22

common general knowledge

Europe 3.7.14–3.7.16

United Kingdom 3.12.07–3.12.10

competition law*see also* disclosure to standard setting organizations;

licences; technology transfer arrangements;

tie-in/tie-out clauses; unjustified patent

infringement proceedings

Australia

disclosure to standard setting

organizations 86.01.01–86.1.05

- intellectual property rights as
 - exception 82.1.01–82.1.06
- licences 85.1.01–85.1.04
- settlement of litigation 88.1.01–88.1.09
- technology transfer
 - arrangements 83.1.01–83.1.13
- tie-in/tie-out clauses 84.1.01–84.1.07
- unjustified infringement
 - proceedings 87.1.01–87.1.04
- Canada
 - disclosure to standard setting
 - organizations 86.2.01–86.2.10
 - intellectual property rights as
 - exception 82.2.01–82.2.28
 - licences 85.2.01–85.2.09
 - settlement of litigation 88.2.01–88.2.19
 - technology transfer
 - arrangements 83.2.01–83.2.11
 - tie-in/tie-out clauses 84.2.01–84.2.10
 - unjustified infringement
 - proceedings 87.2.01–87.2.08
- China
 - disclosure to standard setting
 - organizations 86.3.01
 - intellectual property rights as
 - exception 82.3.01–82.3.04
 - licences 85.3.01
 - settlement of litigation 88.3.01–88.3.03
 - technology transfer
 - arrangements 83.3.01–83.3.10
 - tie-in/tie-out clauses 84.3.01–84.3.03
 - unjustified infringement
 - proceedings 87.3.01–87.3.03
- Europe
 - disclosure to standard setting
 - organizations 86.7.01–86.7.14
 - intellectual property rights as
 - exception 82.7.01–82.7.18
 - licences 85.7.01, 85.7.02
 - licensing 96.7.02, 96.7.03
 - technology transfer arrangements 83.7.01–83.7.26
 - tie-in/tie-out clauses 84.7.01–84.7.10
 - unjustified infringement
 - proceedings 87.7.01–87.7.07
- France
 - disclosure to standard setting
 - organizations 86.8.01–86.8.07
 - intellectual property rights as
 - exception 82.8.01–82.8.19
 - licences 85.8.01–85.8.05
 - settlement of litigation 88.8.01–88.8.07
 - technology transfer
 - arrangements 83.8.01–83.8.05
 - tie-in/tie-out clauses 84.8.01–84.8.07
 - unjustified infringement
 - proceedings 87.8.01–87.8.10
- Germany
 - disclosure to standard setting
 - organizations 86.9.01–86.9.13
 - intellectual property rights as
 - exception 82.9.01–82.9.03
 - licences 85.9.01, 85.9.02
 - settlement of litigation 88.9.01–88.9.03
 - technology transfer arrangements 83.9.01
 - tie-in/tie-out clauses 84.9.01–84.9.03
 - unjustified infringement
 - proceedings 87.9.01–87.9.10
- India
 - disclosure to standard setting
 - organizations 86.4.01
 - intellectual property rights as
 - exception 82.4.01–82.4.04
 - licences 85.4.01
 - settlement of litigation 88.4.01
 - technology transfer
 - arrangements 83.4.01, 83.4.02
 - tie-in/tie-out clauses 84.4.01, 84.4.02
 - unjustified infringement proceedings 87.4.01
- intellectual property rights as exception
 - Australia 82.1.01–82.1.06
 - Canada 82.2.01–82.2.28
 - China 82.3.01–82.3.04
 - Europe 82.7.01–82.7.18
 - France 82.8.01–82.8.19
 - Germany 82.9.01–82.9.03
 - India 82.4.01–82.4.04
 - Italy 82.10.01–82.10.03
 - Japan 82.5.01–82.5.06
 - Netherlands 82.11.01–82.11.03
 - overview 81.01–81.03
 - United Kingdom 82.12.01–82.12.05
 - United States 82.6.01–82.6.11
- Italy
 - disclosure to standard setting
 - organizations 86.10.01–86.10.04
 - intellectual property rights as
 - exception 82.10.01–82.10.03
 - licences 85.10.01–85.10.03
 - settlement of litigation 88.10.01–88.10.18
 - technology transfer
 - arrangements 83.10.01–83.10.03
 - tie-in/tie-out clauses 84.10.01–84.10.06
 - unjustified infringement
 - proceedings 87.10.01–87.10.04
- Japan
 - disclosure to standard setting
 - organizations 86.5.01–86.5.07
 - intellectual property rights as
 - exception 82.5.01–82.5.06
 - licences 85.5.01–85.5.03
 - technology transfer
 - arrangements 83.5.01–83.5.10
 - tie-in/tie-out clauses 84.5.01–84.5.03
 - unjustified infringement
 - proceedings 87.5.01–87.5.04
- Netherlands
 - disclosure to standard setting organizations 86.11.01
 - intellectual property rights as
 - exception 82.11.01–82.11.03
 - licences 85.11.01, 85.11.02
 - technology transfer
 - arrangements 83.11.01–83.11.05
 - tie-in/tie-out clauses 84.11.01–84.11.02
 - unjustified infringement proceedings 87.11.01

- competition law** (*cont.*)
 settlement of litigation
 Australia 88.1.01–88.1.09
 Canada 88.2.01–88.2.19
 China 88.3.01–88.3.03
 Europe 88.7.01–88.7.10
 France 88.8.01–88.8.07
 Germany 88.9.01–88.9.03
 India 88.4.01
 Italy 88.10.01–88.10.18
 Japan 88.5.01–88.5.06
 Netherlands 88.11.01
 overview 81.21, 81.22
 United Kingdom 88.12.01
 United States 88.6.01–88.6.17
- United Kingdom
 disclosure to standard setting
 organizations 86.12.01
 intellectual property rights as
 exception 82.12.01–82.12.05
 licences 85.12.01
 technology transfer arrangements 83.12.01
 tie-in/tie-out clauses 84.12.01
 unjustified infringement
 proceedings 87.12.01–87.12.04
- United States
 disclosure to standard setting
 organizations 86.6.01–86.6.14
 intellectual property rights as
 exception 82.6.01–82.6.11
 licences 85.6.01–85.6.04
 settlement of litigation 88.6.01–88.6.17
 technology transfer
 arrangements 83.6.01–83.6.04
 tie-in/tie-out clauses 84.6.01–84.6.09
 unjustified infringement
 proceedings 87.6.01–87.6.04
- compulsory licensing**
see also government use or acquisition of licences;
 licences; licensing
- Australia 99.1.01–99.1.05
- Canada
 abuse of monopoly 99.2.03–99.2.14
 aircraft 99.2.31, 99.2.32
 generally 99.2.01, 99.2.02
 international humanitarian
 purposes 99.2.15–99.2.30
 vessels 99.2.31, 99.2.32
- China 99.3.01–99.3.04
- Europe
 competition law 99.7.02, 99.7.03
 Doha declaration 99.7.04
 generally 99.7.01
- France
 dependency licences 99.8.07, 99.8.08
 generally 99.8.01
 non-use 99.8.02–99.8.08
- Germany
 antitrust law 99.9.09–99.9.12
 dependent inventions 99.9.06
 generally 99.9.01, 99.9.02
 manufacturing of medicinal product for export
 to developing country 99.9.08
 procedure 99.9.07
 public interest 99.9.03–99.9.05
- India
 applications 99.4.03–99.4.05
 conditions 99.4.08, 99.4.09
 generally 99.4.01, 99.4.02
 grant of licence 99.4.06
 non-working patents 99.4.07
 procedure for application 99.4.07
 terms of licence 99.4.08, 99.4.09
- Italy 99.10.01–99.10.06
- Japan
 dependent invention 99.5.13
 generally 99.5.01
 licences of right 99.5.22–99.5.26
 non-working patents 99.5.02–99.5.05
 public interest 99.5.06–99.5.12
 related to patented inventions 99.5.21
 working own patented
 invention 99.5.14–99.5.20
- Netherlands
 defence related patents 99.11.10
 Doha declaration 99.11.06
 EURATOM Treaty 99.11.11
 generally 99.11.01
 legal effects 99.11.14
 non-use 99.11.04
 plant breeders' rights 99.11.07, 99.11.08
 procedure 99.11.12, 99.11.13
 public interest 99.11.02, 99.11.03
 semiconductor technology 99.11.09
 younger patent, enabling use of 99.11.05
- overview 93.20–93.23
- United Kingdom
 abuse of monopoly 99.12.02–99.12.06
 Doha declaration 99.12.07
 generally 99.12.01
 licences of right 99.12.08–99.12.14
- United States
 Bayh-Dole Act 99.6.08–99.6.10
 march-in rights 99.6.08–99.6.10
 overview 99.6.01–99.6.07
- computer inventions**
 Canada 19.2.28–19.2.31
 Europe 19.7.13–19.7.14
 France 19.8.03
 Germany 19.9.14–19.9.15
 United Kingdom 19.12.06–19.12.09
- confidential information**
 Australia 90.1.01–90.1.08
- Canada
 access to information 90.2.23–90.2.26
 litigation, confidentiality during 90.2.27–90.2.33
 overview 90.2.01–90.2.22
- China 90.3.01–90.3.05
- Europe 90.7.01
- France
 know-how 90.8.01–90.8.04
 manufacturing trade secrets 90.8.05–90.8.07

- Germany
 - Act Against Unfair Practices 90.9.08–90.9.14
 - civil law protection 90.9.15–90.9.24
 - criminal law protection 90.9.25, 90.9.26
 - definition 90.9.02–90.9.07
 - overview 90.9.01
- India
 - legislation 90.4.05, 90.4.06
 - overview 90.4.01
 - trade secrets 90.4.02–90.4.04
- Italy 90.10.01–90.10.11
- Japan
 - access restraint 90.5.07
 - contracts 90.5.01
 - protective orders 90.5.05, 90.5.06
 - tort 90.5.02
 - trade secrets 90.5.03, 90.5.04
- Netherlands 90.11.01–90.11.05
- overview 89.02–89.08
- United Kingdom
 - definition of confidential information 90.12.05
 - duty of confidentiality 90.12.06
 - employee confidentiality 90.12.10–90.12.14
 - overview 90.12.01–90.12.04
 - public interests 90.12.07–90.12.09
- United States 57.6.07
 - disclosure of a trade secret 90.6.10–90.6.13
 - overview 90.6.01, 90.6.02
 - patent protection 90.6.14–90.6.16
 - protection of trade secrets 90.6.07–90.6.09
 - trade secrets 90.6.03–90.6.06
- construction of patent claims/specifications *see*
interpretation of patent claims/specifications
- contributory infringement *see* indirect infringement
- costs
 - Australia 47.1.10, 47.1.11
 - Canada 57.2.65–57.2.71
 - Germany 62.9.06–62.9.12
 - India 47.4.14
 - Japan 62.5.05
 - Netherlands 56.11.06
 - United Kingdom 62.12.07–62.12.09
- court hierarchies
 - Australia 56.1.01–56.1.05
 - Canada
 - choice of forum 56.2.14–56.2.20
 - federal courts 56.2.01–56.2.13
 - China 56.3.01–56.3.06
 - Europe 56.7.01
 - France
 - choice of forum 56.8.07
 - competent courts 56.8.01–56.8.06
 - Germany
 - appeals 56.9.09–56.9.11, 56.9.17, 56.9.18
 - complaint against opposition
 - decision 56.9.15, 56.9.16
 - infringement actions 56.9.05–56.9.08
 - invalidity proceedings 56.9.19–56.9.25
 - opposition proceedings 56.9.12–56.9.14
 - separation of infringement and invalidity
 - proceedings 56.9.01–56.9.04
 - importance 55.01
 - India 56.4.01–56.4.14
 - Italy
 - choice of forum 56.10.06–56.10.08
 - Court of Appeal 56.10.02, 56.10.03
 - Court of Cassation 56.10.04, 56.10.05
 - generally 56.10.01
 - Japan
 - expertise of judges 56.5.07, 56.5.08
 - Intellectual Property
 - High Court 56.5.04–56.5.06
 - Osaka District Court 56.5.01
 - Supreme Court 56.5.10, 56.5.11
 - suspension of enforcement of District Court
 - decisions 56.5.09
 - Tokyo District Court 56.5.01
 - venue 56.5.02, 56.5.03
 - Netherlands 56.11.01–56.11.06
 - overview 55.01–55.04
 - United Kingdom
 - Court of Appeal 56.12.07–56.12.10
 - courts of first instance 56.12.01–56.12.06
 - Supreme Court 56.12.11, 56.12.12
 - United States 56.6.01–56.6.09

damages

 - Australia 47.1.03–47.1.05
 - Canada 47.2.03–47.2.08
 - Germany 47.9.2–47.9.06
 - India 47.4.09, 47.4.10
 - Italy 47.10.07–47.10.10
 - Japan 47.5.05–47.5.11
 - Netherlands 47.11.07, 47.11.08
 - United Kingdom 47.12.06–47.12.14
 - United States 47.6.06–47.6.17

data exclusivity
see also certified patents; data exclusivity strategies for pharmaceuticals; data exclusivity strategies for generic companies; generic drug approval; data exclusivity strategies for innovator companies

agricultural chemicals

 - Australia 80.1.01–80.1.10
 - Canada 80.2.01, 80.2.02
 - China 80.3.01–80.3.04
 - Europe 80.7.01
 - France 80.8.01
 - Germany 80.9.01
 - India 80.4.01
 - Italy 80.5.04
 - Japan 80.5.01
 - Netherlands 80.11.01
 - United Kingdom 80.12.01
 - United States 80.6.01–80.6.03

Australia

 - agricultural chemicals 80.1.01–80.1.10
 - comparison with other rights 74.1.01–74.1.11
 - generic companies 79.1.01–79.1.17
 - innovator companies 78.1.01–78.1.04
 - medical devices 80.1.01–80.1.05
 - new chemical entity 75.1.01–75.1.05
 - non-pharmaceuticals 80.1.01–80.1.10

data exclusivity (*cont.*)

Canada

- agricultural chemicals 80.2.01, 80.2.02
- comparison with other rights 74.2.01–74.2.17
- generic companies 79.2.01–79.2.63
- innovator companies 78.2.01–78.2.46
- medical devices 80.2.01, 80.2.02
- new chemical entity 75.2.01–75.2.10
- non-pharmaceuticals 80.2.01, 80.2.02

China

- agricultural chemicals 80.3.01–80.3.04
- comparison with other rights 74.3.01–74.3.05
- generic companies 79.3.01
- innovator companies 78.3.01–78.3.03
- medical devices 80.3.01–80.3.04
- new chemical entity 75.3.01
- non-pharmaceuticals 80.3.01–80.3.04

comparison with other rights 73.01–73.04

Australia 74.1.01–74.1.11

Canada 74.2.01–74.2.17

China 74.3.01–74.3.05

Europe 74.7.01–74.01.07

France 74.8.01

Germany 74.9.01

India 74.4.01–74.4.03

Italy 74.10.01–74.10.19

Japan 74.5.01–74.5.15

Netherlands 74.11.01–74.11.06

United Kingdom 74.12.01, 74.12.02

United States 74.6.01–74.6.13

Europe

- agricultural chemicals 80.7.01
- comparison with other rights 74.7.01–74.01.07
- generic companies 79.7.01–79.7.06
- innovator companies 78.7.01–78.7.10
- medical devices 80.7.01
- new chemical entity 75.7.01–75.7.03
- non-pharmaceuticals 80.7.01
- orphan medical products 76.7.14–76.7.17
- other periods 76.7.01–76.7.17

France

- agricultural chemicals 80.8.01
- comparison with other rights 74.8.01
- generic companies 79.8.01
- innovator companies 78.8.01
- medical devices 80.8.01
- new chemical entity 75.8.01
- non-pharmaceuticals 80.8.01
- other periods 76.8.01

Germany

- agricultural chemicals 80.9.01
- comparison with other rights 74.9.01
- generic companies 79.9.01
- new chemical entity 75.9.01
- non-pharmaceuticals 80.9.01
- other periods 76.9.01

India

- agricultural chemicals 80.4.01
- comparison with other rights 74.4.01–74.4.03
- generic companies 79.4.01
- innovator companies 78.4.01
- medical devices 80.4.01

- new chemical entity 75.4.01
- non-pharmaceuticals 80.4.01

Italy

- agricultural chemicals 80.5.04
- comparison with other rights 74.10.01–74.10.19
- generic companies 79.10.01–79.10.08
- innovator companies 78.10.01–78.10.11
- medical devices 81.10.01
- medicinal products 74.10.02–74.10.13
- new chemical entity 75.10.01–75.10.07
- new indication 75.10.02, 75.10.03
- non-pharmaceuticals 80.10.01
- other periods 76.10.01
- reference medicinal product 75.10.01
- switching from prescription medicine to non-prescription medicine 75.10.04–75.10.07

Japan

- agricultural chemicals 80.5.01
- comparison with other rights 74.5.01–74.5.15
- generic companies 79.5.01, 79.5.02
- innovator companies 78.5.01
- medical devices 80.5.01–80.5.04
- new chemical entity 75.5.01
- non-pharmaceuticals 80.5.01–80.5.04
- patent term extension 74.5.08–74.5.15

medical devices

Australia 80.1.01–80.1.05

Canada 80.2.01, 80.2.02

China 80.3.01–80.3.04

Europe 80.7.01

France 80.8.01

India 80.4.01

Italy 81.10.01

Japan 80.5.01–80.5.04

Netherlands 80.11.01

United Kingdom 80.12.01

United States 80.6.01–80.6.03

Netherlands

- comparison with other rights 74.11.01–74.11.06
- generic companies 79.11.01–79.11.04
- innovator companies 78.11.01
- medical devices 80.11.01
- new chemical entity 75.11.01–75.11.04
- other periods 76.11.01–76.11.03

non-pharmaceuticals

Australia 80.1.01–80.1.10

Canada 80.2.01, 80.2.02

China 80.3.01–80.3.04

Europe 80.7.01

France 80.8.01

Germany 80.9.01

India 80.4.01

Italy 80.10.01

Japan 80.5.01–80.5.04

overview 73.16

United States 80.6.01–80.6.03

United Kingdom

- agricultural chemicals 80.12.01
- comparison with other rights 74.12.01, 74.12.02
- generic companies 79.12.01
- innovator companies 78.12.01

- medical devices 80.12.01
- new chemical entity 75.12.01
- United States
 - agricultural chemicals 80.6.01–80.6.03
 - combination drugs 75.6.06, 75.6.07
 - comparison with other rights 74.6.01–74.6.13
 - drug, meaning of 75.6.03–75.6.05
 - extensions of patent term 74.6.05–74.6.09
 - generic companies 79.6.01–79.6.07
 - innovator companies 78.6.01–78.6.09
 - interim patent term extensions 74.6.10–74.6.13
 - medical devices 80.6.01–80.6.03
 - new chemical entity 75.6.01–75.6.14
 - old antibiotics 75.6.11–75.6.14
 - orphan drugs 76.6.10–76.6.35
 - pediatric exclusivity 76.6.07–76.6.09
 - single enantiomers of previously approved racemates 75.6.08–75.6.10
 - term of patents 74.6.04
 - three-year exclusivity 76.6.01–76.6.06
- data exclusivity periods for pharmaceuticals**
 - Australia
 - new chemical entity 75.1.01–75.1.05
 - other periods 76.1.01
 - Canada
 - new chemical entity 75.2.01–75.2.10
 - other periods 76.2.01–76.2.06
 - China
 - new chemical entity 75.3.01
 - other periods 76.3.01
 - Europe
 - orphan medical products 76.7.14–76.7.17
 - other periods 76.7.01–76.7.17
 - pediatric use 76.7.11–76.7.13
 - France
 - new chemical entity 75.8.01
 - other periods 76.8.01
 - Germany
 - new chemical entity 75.9.01
 - other periods 76.9.01
 - India
 - new chemical entity 75.4.01
 - other periods 76.4.01
 - Italy
 - new chemical entity 75.10.01–75.10.07
 - other periods 76.10.01
 - Japan
 - new chemical entity 75.5.01
 - other periods 76.5.01
 - Netherlands
 - new chemical entity 75.11.01–75.11.04
 - other periods 76.11.01–76.11.03
- new chemical entity
 - Australia 75.1.01–75.1.05
 - Canada 75.2.01–75.2.10
 - China 75.3.01
 - Europe 75.7.01–75.7.03
 - France 75.8.01
 - Germany 75.9.01
 - India 75.4.01
 - Italy 75.10.01–75.10.07
 - Japan 75.5.01
 - Netherlands 75.11.01–75.11.04
 - overview 73.05
 - United Kingdom 75.12.01
 - United States 75.6.01–75.6.14
- other periods
 - Australia 76.1.01
 - Canada 76.2.01–76.2.06
 - China 76.3.01
 - Europe 76.7.01–76.7.17
 - France 76.8.01
 - Germany 76.9.01
 - India 76.4.01
 - Italy 76.10.01
 - Japan 76.5.01
 - Netherlands 76.11.01–76.11.03
 - overview 73.06
 - United Kingdom 76.12.01
 - United States 76.6.01–76.6.35
- United Kingdom
 - new chemical entity 75.12.01
 - other periods 76.12.01
- United States
 - combination drugs 75.6.06, 75.6.07
 - drug, meaning of 75.6.03–75.6.05
 - new chemical entity 75.6.01–75.6.14
 - old antibiotics 75.6.11–75.6.14
 - orphan drugs 76.6.10–76.6.35
 - other periods 76.6.01–76.6.35
 - pediatric exclusivity 76.6.07–76.6.09
 - single enantiomers of previously approved racemates 75.6.08–75.6.10
 - three-year exclusivity 76.6.01–76.6.05
- data exclusivity strategies for generic companies**
 - agricultural chemicals
 - overview 73.16
 - Australia 79.1.01–79.1.17
 - Canada 79.2.01–79.2.63
 - China 79.3.01
 - Europe 79.7.01–79.7.06
 - France 79.8.01
 - Germany 79.9.01
 - India 79.4.01
 - Italy 79.10.01–79.10.08
 - Japan 79.5.01, 79.5.02
 - medical devices
 - overview 73.16
 - Netherlands 79.11.01–79.11.04
 - overview 73.13–73.15
 - United Kingdom 79.12.01
 - United States 79.6.01–79.6.07
- data exclusivity strategies for innovator companies**
 - Australia 78.1.01–78.1.04
 - Canada 78.2.01–78.2.46
 - China 78.3.01–78.3.03
 - Europe 78.7.01–78.7.10
 - brand companies 78.7.01–78.7.10
 - France 78.8.01, 79.8.01
 - Germany 78.9.01
 - India 78.4.01
 - Italy 78.1.01–78.1.11
 - Japan 78.5.01
 - Netherlands 78.11.01

data exclusivity strategies for innovator**companies (cont.)**

overview 73.09–73.12

United Kingdom 78.12.01

United States 78.6.01, 78.6.01–78.6.09

authorized generics 78.6.05–78.6.07

citizen positions 78.6.08, 78.6.09

discontinued labelling 78.6.04

follow-on products 78.6.02, 78.6.03

dates see priority dates**declarations of non-infringement see****non-infringement declarations****declarations of validity**

Australia 41.1.01–41.1.04

Canada 41.2.01–41.2.04

China 41.3.01

Europe 41.7.01

France 41.8.01–41.8.07

Germany 41.9.01

India 41.4.01

Italy 41.10.01

Japan 41.5.01

Netherlands 41.11.01

overview 36.16, 36.17

United Kingdom 41.12.01, 41.12.02

United States 41.6.01

declaratory judgments

Australia 60.1.01–60.1.07

Canada 60.2.18–60.2.20

China 60.3.03

Europe 60.7.01

France 60.8.06

Germany 60.9.07–60.9.11

India 60.4.01–60.4.07

Italy 60.10.01, 60.10.02

Japan 60.5.02, 60.5.03

Netherlands 60.11.01, 60.11.02

overview 55.28–55.34

United States 60.6.06–60.6.12, 60.7.01

dedication to the public

Canada 16.2.15, 16.2.16

defences to infringement**Australia**

Bolar exemption 52.1.01–52.1.04

exhaustion of rights 54.1.01–54.1.09

experimental use 51.1.01–51.1.05

non-infringement declarations 53.1.01–53.1.08

parallel importing 54.1.01–54.1.09

prior secret use 50.1.01–50.1.10

Bolar exemption

Australia 52.1.01–52.1.04

Canada 52.3.01

Europe 52.7.01–52.7.13

France 52.8.01–52.8.05

Germany 52.9.01, 52.9.02

India 52.4.01

Italy 52.10.01–52.10.06

Japan 52.5.01

Netherlands 52.11.01, 52.11.02

overview 49.04

United Kingdom 52.12.01–52.12.09

United States 52.6.01–52.6.16

Canada

Bolar exemption 52.3.01

exhaustion of rights 54.2.01–54.2.11

experimental use 51.2.01–51.2.06

non-infringement declarations 53.2.01–53.2.08

parallel importing 54.2.01–54.2.11

prior secret use 50.2.01–50.2.12

China

exhaustion of rights 54.3.01

experimental use 51.3.01

non-infringement declarations 53.3.01–53.3.03

parallel importing 54.3.01

prior secret use 50.3.01

Europe

Bolar exemption 52.7.01–52.7.13

exhaustion of rights 54.7.01–54.7.28

experimental use 51.7.01

non-infringement declarations 53.7.01

parallel importing 54.7.01–54.7.28

prior secret use 50.7.01

exhaustion of rights

Australia 54.1.01–54.1.09

Canada 54.2.01–54.2.11

China 54.3.01

Europe 54.7.01–54.7.28

France 54.8.01–54.8.13

Germany 54.9.01–54.9.07

India 54.4.01, 54.4.02

Italy 54.10.01

Japan 54.5.01–54.5.11

Netherlands 54.11.01, 54.11.02

overview 49.06

United Kingdom 54.12.01–54.12.07

experimental use

Australia 51.1.01–51.1.05

Canada 51.2.01–51.2.06

China 51.3.01

Europe 51.7.01

France 51.8.01–51.8.18

Germany 51.9.01–51.9.06

India 51.4.01, 51.04.02

Italy 51.10.01–51.10.07

Japan 51.5.01–51.5.08

Netherlands 51.11.01–51.11.08

overview 49.03

United Kingdom 51.12.01–51.12.13

United States 51.6.01–51.6.03

France

Bolar exemption 52.8.01–52.8.05

exhaustion of rights 54.8.01–54.8.13

experimental use 51.8.01–51.8.18

non-infringement declarations 53.8.01–53.8.16

parallel importing 54.8.01–54.8.13

prior secret use 50.8.01–50.8.14

Germany

Bolar exemption 52.9.01, 52.9.02

exhaustion of rights 54.9.01–54.9.07

experimental use 51.9.01–51.9.06

non-infringement

declarations 53.9.01–53.9.11

parallel importing 54.9.01–54.9.07

prior secret use 50.9.01–50.9.06

India

- Bolar exemption 52.4.01
- exhaustion of rights 54.4.01, 54.4.02
- experimental use 51.4.01, 51.04.02
- non-infringement declarations 53.4.01–53.4.08
- parallel importing 54.4.01, 54.4.02
- prior secret use 50.4.01–50.4.06

Italy

- Bolar exemption 52.10.01–52.10.06
- exhaustion of rights 54.10.01
- experimental use 51.10.01–51.10.07
- non-infringement
 - declarations 53.10.01–53.10.07
- parallel importing 54.10.01
- prior secret use 50.10.01–50.10.07

Japan

- Bolar exemption 52.5.01
- exhaustion of rights 54.5.01–54.5.11
- experimental use 51.5.01–51.5.08
- non-infringement declarations 53.5.01–53.5.11
- parallel importing 54.5.01–54.5.11
- prior secret use 50.5.01–50.5.07

Netherlands

- Bolar exemption 52.11.01, 52.11.02
- experimental use 51.11.01–51.11.08
- non-infringement
 - declarations 53.11.01–53.11.10
- parallel importing 54.11.01, 54.11.02
- prior secret use 50.11.01–50.11.06

non-infringement declarations

- Australia 53.1.01–53.1.08
- Canada 53.2.01–53.2.08
- China 53.3.01–53.3.03
- Europe 53.7.01
- France 53.8.01–53.8.16
- Germany 53.9.01–53.9.11
- India 53.4.01–53.4.08
- Italy 53.10.01–53.10.07
- Japan 53.5.01–53.5.11
- Netherlands 53.11.01–53.11.10
- overview 49.05
- United Kingdom 53.12.01–53.12.12
- United States 53.6.01

overview 49.01–49.06

parallel importing

- Australia 54.1.01–54.1.09
- Canada 54.2.01–54.2.11
- China 54.3.01
- Europe 54.7.01–54.7.28
- France 54.8.01–54.8.13
- Germany 54.9.01–54.9.07
- India 54.4.01, 54.4.02
- Italy 54.10.01
- Japan 54.5.01–54.5.11
- Netherlands 54.11.01, 54.11.02
- overview 49.06
- United Kingdom 54.12.01–54.12.07
- United States 54.6.01–54.6.11

prior secret use

- Australia 50.1.01–50.1.10
- Canada 50.2.01–50.2.12
- China 50.3.01

Europe 50.7.01

- France 50.8.01–50.8.14
- Germany 50.9.01–50.9.06
- India 50.4.01–50.4.06
- Italy 50.10.01–50.10.07
- Japan 50.5.01–50.5.07
- Netherlands 50.11.01–50.11.06
- overview 49.02
- United Kingdom 50.12.01–50.12.12
- United States 50.6.01–50.6.04

United Kingdom

- Bolar exemption 52.12.01–52.12.09
- exhaustion of rights 54.12.01–54.12.07
- experimental use 51.12.01–51.12.13
- non-infringement declarations 53.12.01–53.12.12
- parallel importing 54.12.01–54.12.07
- prior secret use 50.12.01–50.12.12

United States

- Bolar exemption 52.6.01–52.6.16
- experimental use 51.6.01–51.6.03
- non-infringement declarations 53.6.01
- parallel importing 54.6.01–54.6.11
- prior secret use 50.6.01–50.6.04

delivery up

- Australia 47.1.09
- Canada 47.2.17
- United Kingdom 47.12.21, 47.12.22

disclaimers

- Canada 33.2.05–33.2.07, 34.2.06, 34.2.07, 35.2.01–35.2.07
- interpretation of patent claims/specifications
 - Europe 4.7.16–4.7.18
 - Netherlands 4.11.06
 - United States 35.6.04

disclosure of information to patent offices

- Australia 14.1.01–14.1.03
- Canada 14.2.01–14.2.09
- China 14.3.01–14.3.04
- Europe 14.7.01
- France 14.8.01, 14.8.02
- Germany 14.9.01
- India 14.4.01–14.4.03
- Italy 14.10.01
- Japan 14.5.01–14.5.07
- Netherlands 14.11.01
- overview 7.24, 7.25
- United Kingdom 14.12.01, 14.12.02
- United States 14.6.01–14.6.12

disclosure to standard setting organizations

- Australia 86.01.01–86.1.05
- Canada 86.2.01–86.2.10
- China 86.3.01
- Europe 86.7.01–86.7.14
- France 86.8.01–86.8.07
- Germany 86.9.01–86.9.13
- India 86.4.01
- Italy 86.10.01–86.10.04
- Japan 86.5.01–86.5.07
- Netherlands 86.11.01
- overview 81.13–81.16
- United Kingdom 86.12.01
- United States 86.6.01–86.6.14

- discovery**
 Canada 57.2.14–57.2.34
 France 57.8.01–57.8.04
 India 57.4.01–57.4.15
 Japan 57.5.10, 57.5.11
 Netherlands 57.11.02–57.11.09
 United States 57.6.02–57.6.06
 interference proceedings 5.6.32–5.6.34
- dispute resolution**
 TRIPS 2.09
- doctrine of equivalence**
 interpretation of patent claims/specifications
 France 4.8.04, 4.8.05
 Germany 4.9.11–4.9.14
 United Kingdom 4.12.10
- drafting bioscience patents**
 Australia 8.1.01–8.1.11
 human beings etc 8.1.02
 innovation patents 8.1.03
 microorganisms 8.1.05–8.1.07
 novel gene encoding 8.1.04
 reach-through claims 8.1.09–8.1.11
 standard patents 8.1.02
 Canada 8.2.01–8.2.22
 biomolecules 8.2.14
 deposits 8.2.19
 disclosure 8.2.18
 lower and higher life forms 8.2.02, 8.2.07–8.2.10
 medical treatment 8.2.15
 microbial culture system 8.2.03
 microorganisms 8.2.06
 organs and tissues 8.2.12
 replication of invention 8.2.20
 sequence listing 8.2.22
 China 8.3.01–8.3.11
 genetic engineering 8.3.08
 genetic resources 8.3.02, 8.3.03
 microorganisms 8.3.09–8.3.11
 strategies 8.3.11
 Europe
 competitive situation of applicant 8.7.51
 dependent claims 8.7.13
 description drafting 8.7.17–8.7.25
 different set of claims 8.7.15, 8.7.16
 economic factors 8.7.41
 filing strategies 8.7.40–8.7.51
 independent claims 8.7.11, 8.7.12
 MO deposit requirements 8.7.26–8.7.39
 number of claims 8.7.14
 one-part claims 8.7.09, 8.7.10
 process claims 8.7.07
 product claims 8.7.03–8.7.06
 purpose of patent 8.7.52–8.7.54
 time 8.7.42–8.7.50
 two-part claims 8.7.09, 8.7.10
 types of claims 8.7.02
 types of patents 8.7.01
 use claims 8.7.08
 France
 amendments 8.8.06
 divisional applications 8.8.07
 drafting strategies 8.8.05–8.8.12
 filing strategies 8.8.13–8.8.20
 format of claim 8.8.08
 language for filing 8.8.19
 living matter deposit 8.8.09–8.8.11
 priority right 8.8.16
 routes for filing 8.8.17, 8.8.18
 sequence listings 8.8.12
 types of claims 8.8.03, 8.8.04
 types of patents 8.8.01, 8.8.02
 unity of invention 8.8.07
 Germany
 biological patents 8.9.16, 8.9.17
 embryo protection 8.9.14, 8.9.15
 European Directive 8.9.01
 human genes, restrictions on
 patents for 8.9.09–8.9.13
 strategies 8.9.06–8.9.08
 types of claims 8.9.02–8.9.05
 types of patents 8.9.02–8.9.05
 India 8.4.01–8.4.05
 second medical use claims 8.4.04
 sequence listings 8.4.03
 Italy
 basic principles 8.10.01
 claims 8.10.02, 8.10.03
 deposit requirements 8.10.04–8.10.6
 microorganisms 8.10.04–8.10.06
 Japan 8.5.01–8.5.18
 genes 8.5.03, 8.5.04
 proteins 8.5.05–8.5.18
 types of patents and claims 8.5.01, 8.5.02
 Netherlands
 basic principles 8.11.01
 regulations 8.11.04–8.11.07
 rules 8.11.04–8.11.07
 strategies 8.11.09–8.11.11
 types of claims 8.11.08
 types of patents 8.11.02, 8.11.03
 overview 7.02–7.07
 United Kingdom
 basic principles 8.12.01
 biological material 8.12.29, 8.12.30
 biotechnological inventions 8.12.02
 claims 8.12.11–8.12.13
 example of claims 8.12.14–8.12.28
 exclusions from patentability 8.12.03–8.12.10
 information 8.12.31
 sequence listing 8.12.29, 8.12.30
 United States
 antibodies 8.6.38–8.6.42
 antisense nucleic acids 8.6.28–8.6.32
 bioinformatics 8.6.53, 8.6.54
 deposits 8.6.44, 8.6.45
 different technologies 8.6.09
 dosages 8.6.46
 expressed sequence tags 8.6.22–8.6.25
 gene therapy 8.6.33
 interfering RNA 8.6.28–8.6.32
 nucleic acids 8.6.10–8.6.21
 proteins 8.6.34–8.6.42
 reach-through claims 8.6.50–8.6.52
 research tools 8.6.47–8.6.49

- scope of claims 8.6.02–8.6.06
- single nucleotide polymorphism 8.6.26, 8.6.27
- strategy 8.6.01
- types of claims 8.6.07, 8.6.08
- drafting pharmaceutical patents**
 - Australia 9.1.01–9.1.09
 - Canada 9.2.01–9.2.41
 - China 9.3.01–9.3.15
 - Europe
 - medical use claims 9.7.02–9.7.06
 - France 9.8.01
 - Germany
 - basic principles 9.9.01–9.9.03
 - claims 9.9.35–9.9.37
 - dependent claims 9.9.37
 - description 9.9.38
 - filing strategies 9.9.39–9.9.48
 - independent claims 9.9.36
 - intermediate products 9.9.10
 - one part claims 9.9.35
 - patents 9.9.28
 - process claims 9.9.18
 - product claims 9.9.05–9.9.08
 - product-by-process claims 9.9.09
 - selection inventions 9.9.11–9.9.17
 - two part claims 9.9.35
 - types of claims 9.9.04–9.9.25
 - types of IP rights 9.9.26–9.9.34
 - use claims 9.9.19–9.9.25
 - utility models 9.9.29–9.9.34
 - India 9.4.01–9.4.04
 - Italy
 - claims 9.10.02, 9.10.03
 - filing strategies 9.10.04
 - generally 9.10.01
 - Japan 9.5.01–9.5.20
 - basic rules 9.5.01, 9.5.02
 - description requirements 9.5.13–9.5.16
 - human being, method of treating or diagnosing 9.5.17
 - novel crystal forms of known compounds 9.5.19, 9.5.20
 - prodrugs 9.5.18
 - types of pharmaceutical inventions 9.5.03–9.5.12
 - Netherlands
 - filing strategies 9.11.10
 - generally 9.11.01
 - strategies 9.11.07–9.11.09
 - types of claims 9.11.04–9.11.06
 - types of patents 9.11.02, 9.11.03
 - overview 7.08–7.11
 - United Kingdom
 - composition claims 9.12.02–9.12.09
 - first medical use claims 9.12.10–9.12.17
 - generally 9.12.01
 - information 9.12.28
 - second medical use claims 9.12.18–9.12.27
 - United States
 - compositions, pharmaceutical 9.6.29–9.6.31
 - drug discovery 9.6.44–9.6.46
 - manufacturing methods 9.6.36–9.6.38
 - product-by-process claims 9.6.33–9.6.35
- research tools 9.6.44–9.6.46
- scope of claim 9.6.02–9.6.07
- screening methods 9.6.44–9.6.46
- strategy 9.6.01
- treatment methods 9.6.39–9.6.43
- type of claim 9.6.08–9.6.16
- due diligence**
 - Australia 98.1.01–98.1.08
 - Canada 98.2.01–98.2.16
 - China 98.3.01–98.3.07
 - Europe
 - audit 98.7.05–98.7.11
 - overview 98.7.01–98.7.04
 - transactions involving IP assets 98.7.12–98.7.14
 - France 98.8.01–98.8.22
 - Germany
 - collecting information 98.9.05, 98.9.06
 - economic information 98.9.13–98.9.18
 - encumbrance of ownership 98.9.07, 98.9.08
 - instruments for invalidation 98.9.09–98.9.12
 - overview 98.9.01–98.9.04
 - restriction of use 98.9.07, 98.9.08
 - India 98.4.01–98.4.05
 - Italy 98.10.01–98.10.06
 - Japan 98.5.01
 - Netherlands 98.11.01
 - overview 93.16–93.19
 - United Kingdom 98.12.01
 - United States
 - analysis of patent rights 98.6.14–98.6.21
 - confidentiality 98.6.08–98.6.10
 - counsel's opinion 98.6.08–98.6.10
 - deal documents 98.6.11–98.6.13
 - freedom to operate issues 98.6.22–98.6.32
 - general procedures 98.6.04–98.6.07
 - overview 98.6.01–98.6.03
 - representations 98.6.11–98.6.13
 - warranties 98.6.11–98.6.13
- employee inventions**
 - assignments
 - Japan 97.5.11
 - ownership
 - France 6.8.06–6.8.09
 - Germany 6.9.07–6.9.15
 - Italy 6.10.02–6.10.09
 - Japan 6.5.07–6.5.09
 - Netherlands 6.11.05
 - United Kingdom 6.12.04–6.12.19
 - United States 6.6.08
 - research and development collaboration
 - Japan 94.5.11–94.5.15
- enablement**
 - Australia 24.01.01–24.01.04
 - Canada 24.2.01–24.2.15
 - China 24.3.01–24.3.02
 - Europe 24.7.01
 - France 24.8.01
 - Germany 24.9.01
 - India 24.4.01
 - Italy 24.10.01
 - Japan 24.5.01–24.5.07

enablement (cont.)

- Netherlands 24.11.01
- overview 18.26, 18.27
- United Kingdom 24.12.01
- United States 24.6.01–24.6.19

entitlement to the invention

- Australia 31.1.01–31.1.03
- Canada 31.2.01–31.2.05
- China 31.3.01–31.3.07
- Europe 31.7.01
- France 31.8.01, 31.8.02
- Germany 31.9.01, 31.9.02
- India 31.4.01–31.4.04
- Italy 31.10.01–31.10.06
- Japan 31.5.01–31.5.03
- Netherlands 31.11.01–31.11.04
- overview 18.45–18.47
- United Kingdom 31.12.01–31.12.12
 - alternative remedies 31.12.08, 31.12.09
 - grounds for disputed
 - ownership 31.12.04–31.12.06
 - legal framework 31.12.01–31.12.03
 - rules governing disputes 31.12.10–31.12.12
 - subject matter of dispute 31.12.07
- United States 31.6.01–31.6.05
 - bona fide purchasers 31.6.03
 - correcting inventorship 31.6.05
 - employee/employer relationship 31.6.04
 - limitations on ownership 31.6.04

equivalents doctrine

- Australia 44.1.01–44.1.05
- Canada 44.2.01–44.2.12
- China 44.3.01, 44.3.02
- France
 - background 44.8.01
 - examples of infringement 44.8.10–44.8.14
 - function must be essential
 - element 44.8.06–44.8.08
 - importance of the function 44.8.02–44.8.05
 - obviousness of equivalence 44.8.09
- Germany
 - background 44.9.01–44.9.03
 - rationale 44.9.01–44.9.03
 - Schneidmesser questions 44.9.04–44.9.10
 - statements of ranges and numbers 44.9.11
- India 44.4.03–44.4.05
- Italy
 - background 44.10.01
 - chemical equivalents 44.10.03, 44.10.04
 - inventive idea 44.10.02
 - mechanical equivalents 44.10.05–44.10.07
 - partial infringement 44.10.02
 - rationale 44.10.01
- Japan 44.5.01–44.5.09
- Netherlands
 - function, method, result test 44.11.01–44.11.03
 - non pre-examined patents 44.11.04–44.11.06
 - pre-examined patents 44.11.04–44.11.06
- overview 42.04–42.06
- United Kingdom 44.12.01–44.12.03
- United States 44.6.01–44.6.13

Europe

- accelerated examination 11.7.06–11.7.08
- agricultural chemicals regulatory approval
 - adverse data 69.7.35
 - authorization of plant protection
 - product 69.7.18–69.7.21
 - data exclusivity 69.7.33, 69.7.34
 - data protection 69.7.33
 - extensions of use 69.7.32
 - inclusion of active substance in
 - Annex I 69.7.12–69.7.17
 - interaction between legislation 69.7.37–69.7.39
 - maximum residue levels 69.7.30–69.7.31
 - minor uses approvals 69.7.32
 - mutual recognition of approvals 69.7.22, 69.7.23
 - regulatory regime 69.7.01, 69.7.02
 - review of Directive 91/414/EEC 69.7.36
 - scope of Directive 91/414/EEC 69.7.03–69.7.06
 - transitional arrangements 69.7.24–69.7.29
 - types of approval 69.7.07–69.7.11
- allowable amendments 34.7.01–34.7.30
- amended specifications 35.7.01–35.7.06
- amendment
 - allowable amendments 34.7.01–34.7.30
 - amended specifications 35.7.01–35.7.06
 - divisional applications 34.7.16, 34.7.17
 - patents 34.7.27–34.7.29
 - test for allowability 34.7.18–34.7.26
 - timing 33.7.01–33.7.06
- applications 13.7.01–13.7.44
- approval of generic drugs 77.7.01
- assignments
 - competition law 97.7.03
 - formalities 97.7.02
 - generally 97.7.01
- biodiversity 72.7.01–72.7.10
- biological regulatory approval 67.7.01–67.7.05
 - advanced therapy medicinal
 - products 67.7.19–67.7.25
 - biosimilar products 67.7.10–67.7.18
 - EMA guidelines 67.7.06–67.7.09
- Bolar exemption 52.7.01–52.7.13
- certificates of correction 77.7.01
- certified patents 77.7.01
- clarity 27.7.01–27.7.18
- commercialization strategies
 - exhaustion of rights 95.7.03–95.7.06
 - IP rights 95.7.02
 - over-stickering of pharmaceutical
 - products 95.7.07–95.7.09
 - overview 95.7.01
 - re-packaging of pharmaceutical
 - products 95.7.07–95.7.09
- common general knowledge 3.7.14–3.7.16
- competition law
 - disclosure to standard setting
 - organizations 86.7.01–86.7.14
 - intellectual property rights as
 - exception 82.7.01–82.7.18
 - licences 85.7.01, 85.7.02
 - licensing 96.7.02, 96.7.03

- technology transfer
 - arrangements 83.7.01–83.7.26
- tie-in/tie-out clauses 84.7.01–84.7.10
- unjustified infringement
 - proceedings 87.7.01–87.7.07
- compulsory licensing
 - competition law 99.7.02, 99.7.03
 - Doha declaration 99.7.04
 - generally 99.7.01
- confidential information 90.7.01
- court hierarchies 56.7.01
- data exclusivity 76.7.14–76.7.17
 - comparison with other rights 74.7.01–74.01.07
 - generic companies 79.7.01–79.7.06
 - innovator companies 78.7.01–78.7.10
 - medical devices 80.7.01
 - new chemical entity 75.7.01–75.7.03
 - non-pharmaceuticals 80.7.01
 - orphan medical products 76.7.14–76.7.17
 - other periods 76.7.01–76.7.17
- data exclusivity periods
 - paediatric use 76.7.11–76.7.13
- data exclusivity strategies for generic companies 79.7.01–79.7.06
- data exclusivity strategies for innovator companies 78.7.01–78.7.10
 - brand companies 78.7.01–78.7.10
- declarations of validity 41.7.01
- declaratory judgments 60.7.01
- defences to infringement
 - Bolar exemption 52.7.01–52.7.13
 - exhaustion of rights 54.7.01–54.7.28
 - experimental use 51.7.01
 - non-infringement declarations 53.7.01
 - parallel importing 54.7.01–54.7.28
 - prior secret use 50.7.01
- disclosure of information to patent offices 14.7.01
 - organizations 86.7.01–86.7.14
- divisional applications 13.7.01–13.7.44
- drafting bioscience patents
 - competitive situation of applicant 8.7.51
 - dependent claims 8.7.13
 - description drafting 8.7.17–8.7.25
 - different set of claims 8.7.15, 8.7.16
 - economic factors 8.7.41
 - filing strategies 8.7.40–8.7.51
 - independent claims 8.7.11, 8.7.12
 - MO deposit requirements 8.7.26–8.7.39
 - number of claims 8.7.14
 - one-part claims 8.7.09, 8.7.10
 - process claims 8.7.07
 - product claims 8.7.03–8.7.06
 - purpose of patent 8.7.52–8.7.54
 - time 8.7.42–8.7.50
 - two-part claims 8.7.09, 8.7.10
 - types of claims 8.7.02
 - types of patents 8.7.01
 - use claims 8.7.08
- drafting pharmaceutical patents
 - medical use claims 9.7.02–9.7.06
- due date in EPC 16.7.06
- due diligence
 - audit 98.7.05–98.7.11
 - overview 98.7.01–98.7.04
 - transactions involving IP assets 98.7.12–98.7.14
- enablement 24.7.01
- entitlement to the invention 31.7.01
- examination 11.7.01–11.7.08
- exhaustion of rights 54.7.01–54.7.28
- experimental use 51.7.01
- extensions of term 17.7.01–17.7.03
- fraud 30.7.01
- full description 25.7.01–25.7.30
- generic company filing strategies 71.7.01
- genetic modified organisms 72.7.11–72.7.28
- government use or acquisition of licences 100.7.01
- grace periods
 - evident abuse 22.7.03
 - generally 22.7.01
 - international exhibition 22.7.04
 - time limit 22.7.02
- indefiniteness 27.7.01–27.7.18
- indirect infringement 45.7.01, 45.7.02
- industrial applicability 26.7.01–26.7.03
- inequitable conduct 30.7.01
- infringement proceedings 46.7.01–46.7.03
- infringing acts 43.7.01–43.7.04
- innovator company strategies 70.7.01
- internal fair basis 24.7.01
- interpretation of patent claims/specifications
 - art 69 protocol 4.7.05–4.7.08
 - art 69(1) EPC 4.7.05–4.7.08
 - art 84 EPC 4.7.09, 4.7.10, 4.7.11
 - clarity requirement 4.7.10, 4.7.11
 - disclaimers 4.7.16–4.7.18
 - inconsistencies 4.7.12
 - overview 4.7.01–4.7.04
 - product-by-process claims 4.7.19–4.7.26
 - relative terms 4.7.13
 - unclear expressions 4.7.14, 4.7.15
- inventive step
 - age of documents 23.7.59
 - analogous use 23.7.39
 - analogy process 23.7.52
 - bonus effect 23.7.64
 - chemical inventions 23.7.40–23.7.43
 - closest prior art 23.7.05–23.7.12
 - combination inventions 23.7.35–23.7.37
 - commercial success 23.7.61, 23.7.62
 - comparative tests 23.7.65
 - could-would approach 23.7.24–23.7.28
 - denial of inventive step,
 - examples of 23.7.53–23.7.55
 - disclaimer 23.7.48
 - equivalents 23.7.44
 - expectation of success 23.7.29–23.7.32
 - generally 23.7.01, 23.7.02
 - most promising springboard 23.7.11, 23.7.12
 - new use of known measure 23.7.47
 - optimization of parameters 23.7.49
 - prejudice in the art 23.7.57, 23.7.58

Europe (*cont.*)inventive step (*cont.*)

- problem inventions 23.7.45, 23.7.46
- problem-solution approach 23.7.03, 23.7.04
- proof 23.7.24–23.7.55
- same purpose/effect 23.7.06
- satisfaction of long-felt need 23.7.60
- secondary indications 23.7.56–23.7.65
- similar technical problem 23.7.08–23.7.10
- simple solution 23.7.63
- small improvement 23.7.51
- surprising effect 23.7.64
- technical disclosure 23.7.34
- technical problem 23.7.13–23.7.23
- time factor 23.7.59

inventorship

- definition of inventor 5.7.01–5.7.04

lapse of patent applications 16.7.09–16.7.13

licences 85.7.01, 85.7.02

licensing

- competition law 96.7.02, 96.7.03
- overview 96.7.01

litigation 57.7.01

- practicalities 62.7.01

loss of patent rights 16.7.09–16.7.13

medical device regulatory approval

- CE marking 68.7.34–68.7.40
- classification of medical devices 68.7.25–68.7.29
- clinical investigations 68.7.43–68.7.50
- competent authorities 68.7.06
- conformity assessment
 - procedures 68.7.34–68.7.40
- essential requirements 68.7.30–68.7.33
- impact of Commission review 68.7.55–68.7.71
- process of approval 68.7.07–68.7.50
- registration of manufacturers 68.7.41, 68.7.42
- relevant legislation 68.7.01–68.7.05
- vigilance obligations 68.7.51–68.7.54

misrepresentation 30.7.01

multi-jurisdictional strategy 61.7.01

non-infringement declarations 53.7.01

non-literal infringement 44.7.01

novelty

- ascertaining differences 21.7.39–21.7.46
- availability to the public 21.7.12–21.7.17
- chemical compounds 21.7.49–21.7.56
- chemical inventions 21.7.47–21.7.62
- content of relevant prior art 21.7.19–21.7.38
- distinguishing features 21.7.43–21.7.46
- European prior rights 21.7.05
- excluded prior national rights 21.7.07
- generally 21.7.01
- non-prejudicial disclosures 21.7.08–21.7.11
- parameter range selection 21.7.57–21.7.62
- PCT applications as prior art 21.7.06
- prior art, definition of 21.7.02–21.7.18
- proof 21.7.18
- publication dates 21.7.03, 21.7.04
- selection inventions 21.7.47–21.7.62
- use, novelty of 21.7.63–21.7.71

nullification proceedings 40.7.01

opposition proceedings

- amendments 38.7.29–38.7.34
- continued proceedings 38.7.11
- cost 38.7.05
- decision of opposition division 38.7.35, 38.7.36
- designation of opponent 38.7.14
- formal requirements 38.7.12–38.7.28
- generally 38.7.01–38.7.11
- independent procedure 38.7.04
- interest of the opponent 38.7.15–38.7.18
- legal framework of opposition 38.7.24–38.7.28
- legal transfer 38.7.07–38.7.11
- national patent remains granted 38.7.03
- public prior use 38.7.23
- right to be heard 38.7.06
- substantiation of the grounds of
 - opposition 38.7.12–38.7.19

ownership

- applicant 6.7.01–6.7.03
- enforcement of right to patent 6.7.04–6.7.08
- formal requirements 6.7.09–6.7.13

PACE request 11.7.03–11.7.05

parallel importing 54.7.01–54.7.28

patent term 16.7.01

patentable subject matter

- biological inventions 19.7.42–19.7.51
- business methods 19.7.11, 19.7.12
- computer-implemented
 - inventions 19.7.13–19.7.14

discoveries 19.7.06

exceptions under art.53(c)

- EPC 19.7.16–19.7.19

exclusion under art.52(2)(a)

- EPC 19.7.06–19.7.08

exclusion under art.52(2)(b) EPC 19.7.09

exclusion under art.52(2)(c)

- EPC 19.7.10–19.7.14

exclusion under art.52(2)(d) 19.7.15

lack of technical character 19.7.05

mathematical methods 19.7.08

medical methods 19.7.16–19.7.19

microbiological processes 19.7.52–19.7.55

multi-step methods 19.7.20–19.7.35

overview 19.7.01, 19.7.02

plant varieties 19.7.40

plants 19.7.39–19.7.41

public order, inventions

- contrary to 19.7.36–19.7.38

technical nature of invention 19.7.03, 19.7.04

pharmaceutical regulatory approval

applications under Art.10 of

- Directive 2001/83 66.7.17–66.7.28

arbitration procedure 66.7.09, 66.7.10

centralized procedure 66.7.11–66.7.15

decentralized

- procedure 66.7.03, 66.7.06–66.7.08

mutual recognition procedure 66.7.03–66.7.05

national route 66.7.02

new combinations 66.7.29–66.7.32

overview 66.7.01

particulars for marketing authorization 66.7.16

- plant breeders' rights
 - common catalogue requirements 91.7.16
 - Community Plant Variety
 - Rights 91.7.02–91.7.06
 - exemptions 91.7.07
 - national systems 91.7.08–91.7.15
 - patents 91.7.01
- practicalities of litigation 62.7.01
- preliminary injunctions 58.7.01
- prior secret use 50.7.01
- priority dates
 - copy of previous application 20.7.12, 20.7.13
 - declaration of priority 20.7.11
 - first application in Paris Convention
 - country 20.7.32, 20.7.33
 - formal requirements 20.7.03–20.7.14
 - loss of priority right 20.7.34, 20.7.35
 - multiple priorities 20.7.06–20.7.10
 - Paris Convention 20.7.01, 20.7.02
 - partial priorities 20.7.06–20.7.10
 - previous application 20.7.03–20.7.05
 - translation 20.7.14
 - validity of priority right 20.7.15–20.7.31
- procedure from filing to grant 10.7.01–10.7.09
- prosecution strategies 12.7.01–12.7.07
- re-establishment of rights
 - further processing 16.7.14–16.7.16
 - restitutio in integrum* 16.7.17–16.7.29
- re-examination 39.7.01
- regulatory bodies 65.7.08, 65.7.09, 65.7.13, 65.7.18, 65.7.19
- regulatory legislation
 - agricultural chemicals 65.7.14–65.7.17
 - Community Code 65.7.01–65.7.04
 - medical devices 65.7.10–65.7.12
 - Regulation 726/2004 65.7.05, 65.7.06
 - Regulation 1394/2007 65.7.07
- remedies for infringement 47.7.01
- restrictions 48.7.01
- renewal fees 16.7.02–16.7.05, 16.7.07, 16.7.08
- renunciation of rights 16.7.30–16.7.40
- research and development collaboration
 - competition law 94.7.18–94.7.21
 - confidentiality 94.7.12–94.7.15
 - overview 94.7.01–94.7.04
 - ownership of intellectual
 - property 94.7.05–94.7.09
 - payment 94.7.16
 - right to use intellectual
 - property 94.7.10, 94.7.11
 - termination 94.7.17
- restitutio in integrum* 16.7.17–16.7.29
- revocation 40.7.01
- secret use 28.7.01
- settlement of litigation 63.7.01
- skilled addressee
 - background 3.7.01
 - biotechnology/genetic engineering
 - field 3.7.06–3.7.09
 - characteristics 3.7.02–3.7.05
 - common general knowledge 3.7.14–3.7.16
 - neighbouring technical fields 3.7.10–3.7.13
 - state of the art 3.7.14–3.7.16
- slow down prosecution 12.7.04–12.7.07
- split trials 59.7.01
- state of the art 3.7.14–3.7.16
- sufficiency 25.7.01–25.7.30
- summary judgments 60.7.01
- supplementary protection certificates 17.7.04, 17.8.01–17.8.26
 - challenging certificate 17.8.20
 - duration 17.8.14, 17.8.15
 - formal requirements 17.8.04–17.8.12
 - paediatric extensions 17.8.21–17.8.26
 - scope of protection 17.8.16–17.8.19
 - timing 17.8.13
- technology transfer
 - arrangements 83.7.01–83.7.26
- third party interventions 37.7.01–37.7.09
- tie-in/tie-out clauses 84.7.01–84.7.10
- timing of amendment 33.7.01–33.7.06
- trade marks
 - absolute grounds of refusal 92.7.09–92.7.19
 - colours 92.7.15, 92.7.16
 - customary in current language or in
 - bona fide established practices of trade 92.7.18
 - defences to infringement 92.7.55, 92.7.56
 - devoid of any distinctive character 92.7.12, 92.7.13
 - harmonization of law 92.7.04
 - indication, descriptive 92.7.17
 - infringement 92.7.50–92.7.54
 - invalidity 92.7.44–92.7.47
 - overview 92.7.01–92.7.03
 - parallel imports 92.7.57–92.7.78
 - registrability 92.7.05–92.7.08
 - revocation 92.7.48, 92.7.49
 - shapes 92.7.20–92.7.43
 - three-dimensional shape-of-product
 - marks 92.7.14
 - use, distinctive character acquired
 - through 92.7.19
- types of examination 11.7.01–11.7.08
- unfair competition
 - comparative advertising 92.7.89, 92.7.91, 92.7.92
 - misleading advertising 92.7.89, 92.7.90
 - overview 92.7.79
 - unfair business-to-consumer commercial
 - practices 92.7.80–92.7.88
- unjustified infringement
 - proceedings 87.7.01–87.7.07
- utility 26.7.01–26.7.03
- written description 25.7.01–25.7.30
- evidence**
 - see also* discovery; expert evidence
 - Australia 46.1.09, 46.1.10
 - France 57.8.12, 57.8.13
 - Italy 46.10.03
 - Japan 57.5.07–57.5.09
 - Netherlands 57.11.01–57.11.06

examination

- Australia 11.1.01–11.1.18
- Canada 11.2.01–11.2.10
- China 11.3.01–11.3.10
- Europe 11.7.01–11.7.08
- France 11.8.01–11.8.12
- Germany 11.9.01–11.9.09
- India 11.4.01
- Italy 11.10.01
- Japan 11.5.01–11.5.13
- Netherlands 11.11.01
- overview 7.14–7.18
- United Kingdom 11.12.01, 11.12.02
- United States 11.6.01–11.6.09

exhaustion of rights

- Australia 54.1.01–54.1.09
- Canada 54.2.01–54.2.11
- China 54.3.01
- Europe 54.7.01–54.7.28
- France 54.8.01–54.8.13
- Germany 54.9.01–54.9.07
- India 54.4.01, 54.4.02
- Italy 54.10.01
- Japan 54.5.01–54.5.11
- Netherlands 54.11.01, 54.11.02
- overview 49.06
- United Kingdom 54.12.01–54.12.07
- United States 54.6.01–54.6.11

experimental use

- Australia 51.1.01–51.1.05
- Canada 51.2.01–51.2.06
- China 51.3.01
- Europe 51.7.01
- France 51.8.01–51.8.18
- Germany 51.9.01–51.9.06
- India 51.4.01, 51.04.02
- Italy
 - clinical trials 51.10.06, 51.10.07
 - extemporaneous preparation of pharmaceuticals 51.10.04, 51.10.05
 - overview 51.10.01
 - private use 51.10.02, 51.10.03
- Japan
 - clinical trials 51.5.06–51.5.08
 - generic drugs 51.5.03, 51.5.04
 - Herbicide* case 51.5.02
 - overview 51.5.01
 - Pancreatic Diseases; Medicament* case 51.5.05
- Netherlands
 - acts done in seeking marketing authorisation 51.11.05–51.11.07
 - clinical trials 51.11.08
 - exemption 51.11.02–51.11.04
 - overview 51.11.01
- overview 49.03
- United Kingdom
 - clinical trials 51.12.12
 - exemptions 51.12.01
 - pharmacy use 51.12.13
 - private use 51.12.02
 - scope of protection 51.12.03–51.12.11
- United States 51.6.01–51.6.03

expert evidence

- Australia
 - interpretation of patent claims/specifications 4.1.05–4.1.08
- Canada 3.2.06
 - interpretation of patent claims/specifications 4.2.05
- interpretation of patent claims/specifications
 - Australia 4.1.05–4.1.08
 - Canada 4.2.05
 - United Kingdom 57.12.29–57.12.31
 - United States 57.6.08

expiry of patent

- Canada 16.2.14
- Japan 71.5.02–71.5.10

extensions of term

- Australia
 - application requirements 17.1.25–17.1.28
 - calculation of term 17.1.22, 17.1.23
 - disclosed in complete specification 17.1.08–17.1.10
 - five years from first regulatory approval date 17.1.21
 - grant of extension 17.1.22, 17.1.23
 - per se, pharmaceutical substance 17.1.13–17.1.18
 - pharmaceutical substance 17.1.03–17.1.07
 - recombinant DNA technology 17.1.19
 - register of therapeutic goods 17.1.20
 - rights of patentee during extension 17.1.24
 - scope of claim 17.1.11, 17.1.12
 - standard pharmaceutical patent 17.1.01, 17.1.02
 - timing 17.1.25–17.1.28
- Canada 17.2.01–17.2.03
- China 17.3.01, 17.3.02
- Europe 17.7.01–17.7.03
- France 17.9.01
- Germany 17.10.01
- India 17.4.01
- Japan 17.5.02–17.5.20
- Netherlands 17.12.01–17.12.11
- overview 15.07–15.10
- United Kingdom 17.13.01
- United States
 - agencies responsible 17.6.19–17.6.20
 - calculation of extension period 17.6.17, 17.6.18
 - delays 17.6.24–17.6.28
 - determination of term from face of patent 17.6.29
 - disclosure duty 17.6.21–17.6.23
 - first permitted commercial marketing or use limitation 17.6.11–17.6.14
 - one extension per patent 17.6.15
 - one extension per regulatory review period 17.6.16
 - regulatory review 17.6.02
 - requirements for extension 17.6.03, 17.06.04
 - scope of extension 17.6.08–17.6.10
 - types of patents that may be extended 17.6.05–17.6.07

fees *see* renewal fees**file wrapper estoppel**

- Germany 4.9.15, 4.9.16
- United Kingdom 4.12.17, 4.12.18

- filing strategies** *see* **generic company filing strategies;**
innovator company strategies
- forum**
- Australia 46.1.01, 46.1.02
 - Canada 46.2.02–46.2.09
 - France 46.8.04
 - Japan 46.5.01, 46.5.02
- France**
- agricultural chemicals regulatory approval
 - basic principles 69.8.01–69.8.04
 - provisional authorizations 69.8.05
 - allowable amendments 34.8.01, 34.8.02
 - amended specifications 35.8.01, 35.8.02
 - amendment
 - allowable amendments 34.8.01, 34.8.02
 - amended specifications 35.8.01, 35.8.02
 - pre-grant amendments 33.8.02–33.8.06
 - principle 33.8.01
 - appeals 56.8.02–56.8.04
 - applications 13.8.01–13.8.14
 - approval of generic drugs 77.8.01
 - assignments
 - duties 97.8.06–97.8.13
 - nullity 97.8.14
 - overview 97.8.01–97.8.04
 - publicity 97.8.05
 - registration 97.8.05
 - biological regulatory approval
 - basic principles 67.8.01, 67.8.02
 - labile blood products 67.8.03
 - Bolar exemption 52.8.01–52.8.05
 - case management 57.8.11
 - certificates of addition 13.8.11–13.8.13
 - certified patents 77.8.01
 - clarity 27.8.01–27.8.03
 - commercialization strategies 95.8.01, 95.8.02
 - competition law
 - disclosure to standard setting
 - organizations 86.8.01–86.8.07
 - intellectual property rights as
 - exception 82.8.01–82.8.19
 - licences 85.8.01–85.8.05
 - settlement of litigation 88.8.01–88.8.07
 - technology transfer
 - arrangements 83.8.01–83.8.05
 - tie-in/tie-out clauses 84.8.01–84.8.07
 - unjustified infringement
 - proceedings 87.8.01–87.8.10
 - compulsory licensing
 - dependency licences 99.8.07, 99.8.08
 - generally 99.8.01
 - non-use 99.8.02–99.8.08
 - confidential information
 - know-how 90.8.01–90.8.04
 - manufacturing trade secrets 90.8.05–90.8.07
 - court hierarchies
 - choice of forum 56.8.07
 - competent courts 56.8.01–56.8.06
 - data exclusivity
 - comparison with other rights 74.8.0.1
 - generic companies 79.8.01
 - innovator companies 78.8.01
 - medical devices 80.8.01
 - new chemical entity 75.8.01
 - non-pharmaceuticals 80.8.01
 - other periods 76.8.01
 - data exclusivity strategies for generic
 - companies 79.8.01
 - data exclusivity strategies for innovator
 - companies 78.8.01, 79.8.01
 - declarations of validity 41.8.01, 41.8.01–41.8.07
 - declaratory judgments 60.8.06
 - defences to infringement
 - Bolar exemption 52.8.01–52.8.05
 - exhaustion of rights 54.8.01–54.8.13
 - experimental use 51.8.01–51.8.18
 - non-infringement
 - declarations 53.8.01–53.8.16
 - parallel importing 54.8.01–54.8.13
 - prior secret use 50.8.01–50.8.14
 - deferred search 11.8.09–11.8.12
 - disclosure of information to patent
 - offices 14.8.01, 14.8.02
 - disclosure to standard setting
 - organizations 86.8.01–86.8.07
 - discovery 57.8.01–57.8.04
 - divisional applications 13.8.05–13.8.10
 - drafting bioscience patents
 - amendments 8.8.06
 - divisional applications 8.8.07
 - drafting strategies 8.8.05–8.8.12
 - filing strategies 8.8.13–8.8.20
 - format of claim 8.8.08
 - language for filing 8.8.19
 - living matter deposit 8.8.09–8.8.11
 - priority right 8.8.16
 - routes for filing 8.8.17, 8.8.18
 - sequence listings 8.8.12
 - types of claims 8.8.03, 8.8.04
 - types of patents 8.8.01, 8.8.02
 - unity of invention 8.8.07
 - drafting pharmaceutical patents 9.8.01
 - due diligence 98.8.01–98.8.22
 - enablement 24.8.01
 - entitlement to the invention 31.8.01, 31.8.02
 - equivalents doctrine
 - background 44.8.01
 - examples of infringement 44.8.10–44.8.14
 - function must be essential
 - element 44.8.06–44.8.08
 - importance of the function 44.8.02–44.8.05
 - obviousness of equivalence 44.8.09
 - evidence 57.8.12, 57.8.13
 - examination 11.8.01–11.8.12
 - exhaustion of rights 54.8.01–54.8.13
 - experimental use 51.8.01–51.8.18
 - extensions of term 17.9.01
 - forum 46.8.04
 - fraud 30.8.01, 30.8.02
 - generic company filing strategies 71.8.01, 71.8.02
 - genetic modified organisms 72.8.01, 72.8.02
 - government use or acquisition of
 - licences 100.8.11
 - grace periods 22.8.01

France (*cont.*)

- indefiniteness 27.8.01–27.8.03
- indirect infringement
 - background 45.8.01
 - contributory infringement 45.8.02–45.8.05
 - elements of contributory infringement 45.8.06–45.8.13
 - exceptions to contributory infringement 45.8.14, 45.8.15
- inequitable conduct 30.8.01, 30.8.02
- infringement proceedings
 - bailiffs 46.8.08
 - carrying out seizure order 46.8.13–46.8.16
 - choice of place of seizure 46.8.12
 - evidence 46.8.05–46.8.12, 46.8.17–46.8.19
 - expert reports 46.8.17–46.8.19
 - experts 46.8.09, 46.8.10
 - facts 46.8.05, 46.8.06
 - forum 46.8.04
 - jurisdiction 46.8.07
 - law enforcement authorities 46.8.11
 - standing 46.8.01–46.8.03
- infringing acts 43.8.01
- innocent infringement 48.8.01
- innovator company strategies 70.8.01, 70.8.02
- interlocutory applications 57.8.06–57.8.10
- internal fair basis 24.8.01
- interpretation of patent claims/specifications
 - basic principles 4.8.01–4.8.05
 - biotech inventions 4.8.06–4.8.08
 - doctrine of equivalence 4.8.04, 4.8.05
 - general means, theory of 4.8.04, 4.8.05
- inventive step
 - assessment 23.8.04–23.8.06
 - basic principle 23.8.01
 - person skilled in the art 23.8.03
 - state of the art 23.8.02
- inventorship
 - basic principles 5.8.01, 5.8.02
 - moral rights 5.8.03, 5.8.04
- lapse of patent applications 16.8.12–16.8.16
- licences 85.8.01–85.8.05
- licensing
 - duties 96.8.09–96.8.17
 - enforceability 96.8.06–96.8.08
 - generally 96.8.01
 - nullity 96.8.19
 - requirements 96.8.02–96.8.05
 - termination 96.8.18
- literal infringement 43.8.02–43.8.08
- litigation
 - case management 57.8.11
 - discovery 57.8.01–57.8.04
 - evidence 57.8.12, 57.8.13
 - interlocutory applications 57.8.06–57.8.10
 - practicalities 62.8.01, 62.8.02
 - subpoenas 57.8.05
 - trial 57.8.14
- medical device regulatory
 - approval 68.8.01–68.8.03
- misrepresentation 30.8.01, 30.8.02
- multi-jurisdictional strategy 61.8.01–61.8.17
- national procedure 72.8.06–72.8.09
- non-infringement declarations 53.8.01–53.8.16
 - amicable step 53.8.08–53.8.12
 - judicial step 53.8.13–53.8.15
 - overview 53.8.01
 - proof 53.8.02–56.8.05
 - requirements 53.8.07, 56.8.06
 - strategy 53.8.16
- non-literal infringement 44.8.01–44.8.14
- novelty
 - basic principles 21.8.01–21.8.05
 - first medical use 21.8.06–21.8.08
 - non-prejudicial disclosures 21.8.03–21.8.05
 - second medical use 21.8.06–21.8.08
- nullification proceedings 40.8.01–40.8.18
- opposition proceedings 38.8.01
- ownership
 - basic principles 6.8.01–6.8.03
 - co-ownership 6.8.04, 6.8.05
 - employee inventions 6.8.06–6.8.09
- parallel importing 54.8.01–54.8.13
- patent term 16.8.01
- patentable subject matter
 - biotech inventions 19.8.13–19.8.19
 - business methods 19.8.04
 - computer programs 19.8.03
 - diagnostic methods 19.8.05–19.8.08
 - intellectual creations 19.8.02–19.8.04
 - plant and animal varieties 19.8.09–19.8.12
 - statutory exclusions 19.8.01
 - treatment methods 19.8.05–19.8.08
- pharmaceutical regulatory approval
 - basic principles 66.8.01–66.8.03
 - homeopathic drugs 66.8.07
 - national procedure 66.8.04–66.8.06
 - temporary authorizations 66.8.08
- plant breeders' rights
 - basic principles 91.8.01–91.8.03
 - infringement action 91.8.09–91.8.13
 - national plant varieties
 - certificates 91.8.04–91.8.08
- practicalities of litigation 62.8.01, 62.8.02
- preliminary injunctions 58.8.01–58.8.14
- prior art search 11.8.03–11.8.08
- prior secret use
 - background 50.8.01, 50.8.02
 - evidence of the prior possession 50.8.10
 - good faith 50.8.06, 50.8.07
 - location of the prior possession 50.8.09
 - possession 50.8.03–50.8.05
 - scope of prior possession right 50.8.11–50.8.14
 - secrecy of the prior possession 50.8.08
- priority dates
 - foreign priority 20.8.02, 20.8.03
 - internal priority 20.8.04, 20.8.05
 - types of priority 20.8.01
- procedure from filing to grant
 - filing 10.8.01–10.8.04
 - formality examination 10.8.07–10.8.09
 - grant 10.8.19, 10.8.20
 - national defence 10.8.05, 10.8.06
 - publication 10.8.16–10.8.18

- search report 10.8.10–10.8.15
 - utility certificates 10.8.21
 - prosecution strategies 12.8.01–12.8.05
 - re-examination 39.8.01
 - regulatory bodies 65.8.01, 65.8.05
 - regulatory legislation 65.8.03, 65.8.04
 - remedies for infringement
 - attorneys' fees 47.8.19–47.8.21
 - damages 47.8.03–47.8.17
 - generally 47.8.01, 47.8.02
 - good faith 48.8.02–48.8.13
 - innocent infringement 48.8.01
 - restrictions 48.8.01–48.8.13
 - wilful infringement 47.8.18
 - renewal fees 16.8.02–16.8.05
 - research and development collaboration
 - overview 94.8.01, 94.8.02
 - research programme 94.8.03
 - usual clauses 94.8.04–94.8.10
 - revocation
 - alternative procedures 40.8.12, 40.8.13
 - effects of invalidation 40.8.14–40.8.18
 - generally 40.8.01–40.8.06
 - standing 40.8.07–40.8.11
 - secret use 28.8.01, 28.8.02
 - settlement of litigation
 - agreement 63.8.01
 - licence agreement 63.8.02
 - withdrawal of case 63.8.03–63.8.07
 - skilled addressee
 - disclosure 3.8.12
 - inventive step 3.8.12
 - level of skill 3.8.11
 - overview 3.8.01–3.8.03
 - technical field 3.8.04–3.8.10
 - split trials
 - infringement/validity splits 59.8.03
 - liability/quantum splits 59.8.02
 - Markman hearings 59.8.01
 - subpoenas 57.8.05
 - sufficiency 25.8.01–25.8.06
 - summary judgments 60.8.01–60.8.05
 - supplementary protection certificates 13.8.14
 - former legislation 17.9.05–17.9.07
 - practice 17.9.08–17.9.16
 - types of SPC 17.9.02–17.9.04
 - technology transfer arrangements 83.8.01–83.8.05
 - third party interventions 37.8.01, 37.8.02
 - tie-in/tie-out clauses 84.8.01–84.8.07
 - timing of amendment 33.08.01–33.8.11
 - trade marks
 - absolute grounds examination 92.8.05–92.8.08
 - confusion, risk of 92.8.09–92.8.16
 - generic drugs 92.8.17–92.8.27
 - overview 92.8.01–92.8.04
 - pharmaceutical trade mark marketing
 - authorization 92.8.28–92.8.30
 - shapes 92.8.06–92.8.08
 - word and figurative marks 92.8.05
 - trial 57.8.14
 - unity of invention
 - appreciation 29.8.04
 - principle 29.8.01–29.8.03
 - unjustified infringement
 - proceedings 87.8.01–87.8.10
 - utility
 - case law 26.8.03
 - principle 26.8.01, 26.8.02
 - treatment methods 26.8.04
 - veterinary medicinal products 72.8.03–72.8.05
 - withdrawal of patent applications 16.8.06–16.8.11
 - written description 25.8.01–25.8.06
- fraud**
- Australia 30.1.01–30.1.04
 - Canada 30.2.01–30.2.14
 - China 30.3.01–30.3.06
 - Europe 30.7.01
 - France 30.8.01, 30.8.02
 - Germany 30.9.01–30.9.03
 - India 30.4.01–30.4.03
 - Italy 30.10.01
 - Japan 30.5.01–30.5.03
 - Netherlands 30.11.01
 - overview 18.41–18.44
 - United Kingdom 30.12.01
 - United States 30.6.01–30.6.21
- free trade agreements**
- international agreements 2.33
- full description**
- Australia 25.1.01, 25.02
 - Canada 25.2.01–25.2.15
 - China 25.3.01–25.3.08
 - Europe 25.7.01–25.7.30
 - Germany 25.9.01–25.9.14
 - India 25.4.01–25.4.05
 - Italy 25.10.01–25.10.13
 - Netherlands 25.11.01–25.11.17
 - requirement 18.28–18.33
 - United Kingdom 25.12.01–25.12.26
 - United States 25.6.01–25.6.23
- generic company filing strategies**
- Australia 71.1.01–71.1.04
 - Canada 71.2.01–71.2.19
 - China 71.3.01
 - Europe 71.7.01
 - France 71.8.01, 71.8.02
 - Germany 71.9.01
 - India 71.4.01
 - Italy 71.10.01–71.10.05
 - Japan
 - biosimilars 71.5.14–71.5.16
 - expiry of patents on corresponding brand
 - drug 71.5.02–71.5.10
 - expiry of PMS term 71.5.11, 71.5.12
 - follow-on biologics 71.5.14–71.5.16
 - indications carve-out 71.5.13
 - procedures 71.5.01
 - Netherlands 71.11.01
 - United Kingdom 71.12.01
 - United States
 - biowaivers 71.6.02–71.6.04
 - inactive ingredient changes 71.6.05–71.6.12
 - overview 71.6.01

- generic drugs
see also approval of generic drugs
 Germany
 pharmaceutical regulatory approval 66.9.07
 Japan
 experimental use 51.5.03, 51.5.04
 pharmaceutical regulatory approval
 Germany 66.9.07
 United States 66.6.14–66.6.24
 United States
 pharmaceutical regulatory
 approval 66.6.14–66.6.24
- genetic modified organisms
 Australia 72.1.01–72.1.16
 China 72.3.01
 Europe 72.7.11–72.7.28
 France 72.8.01, 72.8.02
 Germany 72.9.01, 72.9.02
 India 72.4.01–72.4.05
 Italy 72.10.01–72.10.29
 Japan 72.5.01, 72.5.02
 Netherlands 72.11.02–72.11.04
 United Kingdom 72.12.02, 72.12.03
- Germany
 accelerated examination 11.9.08
 agricultural chemicals regulatory
 approval 69.9.01, 69.9.02
 allowable amendments 34.9.01–34.9.20
 amended specifications 35.9.01
 amendment
 allowable amendments 34.9.01–34.9.20
 amended specifications 35.9.01
 applications 33.9.03–33.9.07
 conflict between new matter and extension
 of scope of protection 34.9.18–34.9.20
 correction of obvious errors 33.9.02
 extension of scope of
 protection 34.9.12–34.9.17
 generally 33.9.01
 new matter 34.9.02–34.9.11
 patents 33.9.08–33.9.11
 reissue applications 35.9.02
 restriction applications 35.9.03–35.9.05
 amendments
 opposition proceedings 38.9.32–38.9.35
 appeals 56.9.09–56.9.11, 56.9.17, 56.9.18
 applications
 divisional applications 13.9.02
 generally 13.9.01
 supplementary patents 13.9.03–13.9.05
 supplementary protection
 certificates 13.9.06–13.9.15
 types 13.9.01–13.9.15
 approval of generic drugs 77.9.01
 art
 skilled addressee 3.9.07, 3.9.08
 assignments
 invalidity of assigned patent 97.9.09, 97.9.10
 overview 97.9.01–97.9.03
 right deriving from patent 97.9.08
 right to grant of patent 97.9.07
 right to patent 97.9.04–97.9.06
 biological regulatory approval 67.9.01
 Bolar exemption 52.9.01, 52.9.02
 cease and desist order 47.9.01
 certified patents 77.9.01
 clarity 27.9.01
 commercialization strategies 95.9.01, 95.9.02
 competition law
 disclosure to standard setting
 organizations 86.9.01–86.9.13
 intellectual property rights as
 exception 82.9.01–82.9.03
 licences 85.9.01, 85.9.02
 settlement of litigation 88.9.01–88.9.03
 technology transfer arrangements 83.9.01
 tie-in/tie-out clauses 84.9.01–84.9.03
 unjustified infringement
 proceedings 87.9.01–87.9.10
 compulsory licensing
 antitrust law 99.9.09–99.9.12
 dependent inventions 99.9.06
 generally 99.9.01, 99.9.02
 manufacturing of medicinal product for export
 to developing country 99.9.08
 procedure 99.9.07
 public interest 99.9.03–99.9.05
 confidential information
 Act Against Unfair Practices 90.9.08–90.9.14
 civil law protection 90.9.15–90.9.24
 criminal law protection 90.9.25, 90.9.26
 definition 90.9.02–90.9.07
 overview 90.9.01
 costs 62.9.06–62.9.12
 court hierarchies
 appeals 56.9.09–56.9.11
 complaint against opposition
 decision 56.9.15, 56.9.16
 infringement actions 56.9.05–56.9.08
 invalidity proceedings 56.9.19–56.9.25
 opposition proceedings 56.9.12–56.9.14
 separation of infringement and invalidity
 proceedings 56.9.01–56.9.04
 damages 47.9.02–47.9.06
 data exclusivity
 agricultural chemicals 80.9.01
 comparison with other rights 74.9.01
 generic companies 79.9.01
 new chemical entity 75.9.01
 non-pharmaceuticals 80.9.01
 other periods 76.9.01
 data exclusivity strategies for generic
 companies 79.9.01
 data exclusivity strategies for innovator
 companies 78.9.01
 declarations of validity 41.9.01
 declaratory judgments 60.9.07–60.9.11
 defences to infringement
 Bolar exemption 52.9.01, 52.9.02
 exhaustion of rights 54.9.01–54.9.07
 experimental use 51.9.01–51.9.06
 non-infringement declarations 53.9.01–53.9.11
 parallel importing 54.9.01–54.9.07
 prior secret use 50.9.01–50.9.06

- disclosure of information to patent offices 14.9.01
- disclosure to standard setting
 - organizations 86.9.01–86.9.13
- doctrine of equivalence 4.9.11–4.9.14
- drafting bioscience patents
 - biological patents 8.9.16, 8.9.17
 - embryo protection 8.9.14, 8.9.15
 - European Directive 8.9.01
 - human genes, restrictions on
 - patents for 8.9.09–8.9.13
 - strategies 8.9.06–8.9.08
 - types of claims 8.9.02–8.9.05
 - types of patents 8.9.02–8.9.05
- drafting pharmaceutical patents
 - basic principles 9.9.01–9.9.03
 - claims 9.9.35–9.9.37
 - dependent claims 9.9.37
 - description 9.9.38
 - filing strategies 9.9.39–9.9.48
 - independent claims 9.9.36
 - intermediate products 9.9.10
 - one part claims 9.9.35
 - patents 9.9.28
 - process claims 9.9.18
 - product claims 9.9.05–9.9.08
 - product-by-process claims 9.9.09
 - selection inventions 9.9.11–9.9.17
 - two part claims 9.9.35
 - types of claims 9.9.04–9.9.25
 - types of IP rights 9.9.26–9.9.34
 - use claims 9.9.19–9.9.25
 - utility models 9.9.29–9.9.34
- due diligence
 - collecting information 98.9.05, 98.9.06
 - economic information 98.9.13–98.9.18
 - encumbrance of ownership 98.9.07, 98.9.08
 - instruments for invalidation 98.9.09–98.9.12
 - overview 98.9.01–98.9.04
 - restriction of use 98.9.07, 98.9.08
- enablement 24.9.01
- entitlement to the invention 31.9.01, 31.9.02
- equivalents doctrine
 - background 44.9.01–44.9.03
 - rationale 44.9.01–44.9.03
 - Schneidmesser questions 44.9.04–44.9.10
 - statements of ranges and numbers 44.9.11
- examination 11.9.01–11.9.09
- exhaustion of rights 54.9.01–54.9.07
- experimental use 51.9.01–51.9.06
- extensions of term 17.10.01
- file wrapper estoppel 4.9.15, 4.9.16
- fraud 30.9.01–30.9.03
- full description 25.9.01–25.9.14
- generic company filing strategies 71.9.01
- genetic modified organisms 72.9.01, 72.9.02
- government use or acquisition of
 - licences 100.9.01–100.9.03
- grace periods
 - abusive publication 22.9.02–22.9.04
 - generally 22.9.01
 - international exhibition 22.9.05–22.9.07
 - utility model 22.9.08–22.9.12
- indefiniteness 27.9.01
- indirect infringement
 - conditions 45.9.03–45.9.05
 - double territorial requirement 45.9.07
 - exclusions 45.9.03–45.9.05
 - knowledge 45.9.08
 - means relating to essential element
 - of invention 45.9.06
 - products generally available in the
 - trade 45.9.09
 - statutory provisions 45.9.01, 45.9.02
- inequitable conduct 30.9.01–30.9.03
- infringement actions 57.9.01–57.9.18
- infringement proceedings
 - information 46.9.11–46.9.13
 - pre-trial proceedings 46.9.14–46.9.17
 - proceedings 46.9.01–46.9.10
- infringing acts 43.9.01–43.9.04
- innovator company strategies 70.9.01
- internal fair basis 24.9.01
- interpretation of patent claims/specifications
 - claims, interpretation of 4.9.05–4.9.10
 - doctrine of equivalence 4.9.11–4.9.14
 - file wrapper estoppel 4.9.15, 4.9.16
 - overview 4.9.01–4.9.04
 - technical teaching 4.9.05, 4.9.06
- invalidity proceedings 62.9.13–62.9.19
- inventive step
 - assessment 23.9.02–23.9.05
 - chemical inventions 23.9.06–23.9.09
 - generally 23.9.01
 - problem-solution approach 23.9.02–23.9.05
- inventorship
 - assignment of rights to grant of patent 5.9.10, 5.9.11
 - categories of inventors 5.9.02
 - European patent applications 5.9.12
 - inventor principle 5.9.01
 - joint inventors 5.9.03–5.9.05
 - naming inventor 5.9.06
 - unjustified patent application 5.9.07, 5.9.08
 - unjustified registration of utility model 5.9.09
- joint inventors
 - inventorship 5.9.03–5.9.05
- licences 85.9.01, 85.9.02
- licensing
 - antitrust law 96.9.07–96.9.09
 - infringement 96.9.05, 96.9.06
 - insolvency 96.9.10–96.9.12
 - licences 96.9.04
 - overview 96.9.01–96.9.03
- limitation period 48.9.01–48.9.04
- literal infringement 43.9.05–43.9.08
- litigation
 - costs 62.9.06–62.9.12
 - infringement actions 57.9.01–57.9.18
 - practicalities 62.9.01–62.9.19
 - revocation actions 57.9.19–57.9.23
- medical device regulatory
 - approval 68.9.01, 68.9.02
- misrepresentation 30.9.01–30.9.03
- multi-jurisdictional strategy 61.9.01–61.9.06

Germany (*cont.*)

- non-infringement declarations
 - formalities 53.9.01–53.9.04
 - international strategy 53.9.09–53.9.11
 - procedure 53.9.05
 - strategy 53.9.06–53.9.08
- novelty
 - ascertaining the difference 21.9.19, 21.9.20
 - chemical inventions 21.9.21–21.9.27
 - content of prior art 21.9.14–21.9.18
 - disclosure 21.9.14–21.9.18
 - generally 21.9.01
 - prior art 21.9.02–21.9.13
 - selection inventions 21.9.21–21.9.27
 - use, novelty of 21.9.28–21.9.34
- nullification proceedings
 - amendments 40.9.13, 40.9.14
 - appeals 40.9.21–40.9.23
 - applicable grounds 40.9.17, 40.9.18
 - formal requirements 40.9.09–40.9.12
 - generally 40.9.01–40.9.05
 - grounds for nullification 40.9.08
 - parties 40.9.06, 40.9.07
 - scope of proceedings 40.9.15, 40.9.16
 - termination of proceedings 40.9.19, 40.9.20
- opposition proceedings
 - amendments 38.9.32–38.9.35
 - appeal 38.9.42–38.9.46
 - fee 38.9.28
 - formal requirements 38.9.27–38.9.31
 - generally 38.9.01–38.9.04
 - grounds for opposition 38.9.12–38.9.26
 - grounds of opposition 38.9.39, 38.9.40
 - identification of opponent 38.9.29
 - legal status of parties 38.9.03, 38.9.04
 - opponent 38.9.05–38.9.11
 - scope of proceedings 38.9.36–38.9.38
 - substantiation of the grounds
 - of opposition 38.9.30, 38.9.31
 - termination of proceedings 38.9.41
 - time limit 38.9.28
- ownership
 - basic principles 6.9.01–6.9.03
 - co-ownership 6.9.04–6.9.06
 - employee inventions 6.9.07–6.9.15
- parallel importing 54.9.01–54.9.07
- passing off 92.9.16–92.9.32
- patent term 16.9.01–16.9.03
- patentable subject matter
 - aesthetic creations 19.9.11
 - business methods 19.9.13
 - computer-implemented
 - inventions 19.9.14–19.9.15
 - definition of invention 19.9.04–19.9.06
 - discoveries 19.9.08
 - game rules 19.9.12
 - human body and elements 19.9.17–19.9.28
 - mathematical methods 19.9.10
 - medical methods 19.9.35–19.9.41
 - mental activity rules and schemes 19.9.12
 - morality 19.9.23–19.9.28
 - non-statutory subject matter 19.9.07–19.9.16
 - overview 19.9.01–19.9.03
 - plant and animal varieties 19.9.29–19.9.34
 - presentation of information 19.9.16
 - public order 19.9.23–19.9.28
 - scientific theories 19.9.09
- pharmaceutical regulatory approval
 - biologicals 66.9.08
 - biosimilar approvals 66.9.07
 - decentralized procedure 66.9.06
 - generic drugs 66.9.07
 - mutual recognition procedure 66.9.06
 - national approval 66.9.01–66.9.05
- plant breeders' rights 91.9.01–91.9.10
- practicalities of litigation 62.9.01–62.9.19
- preliminary injunctions 58.9.01–58.9.15
- prior secret use
 - dual court system 50.9.04
 - existence of prior user right 50.9.01, 50.9.02
 - illegal usurpation 50.9.05, 50.9.06
 - third parties 50.9.03
- priority dates
 - domestic priority, claiming 20.9.07–20.9.14
 - foreign priority, claiming 20.9.15–20.9.19
 - generally 20.9.01
 - international priority 20.9.15–20.9.19
 - material aspects 20.9.02–20.9.06
 - multiple priorities 20.9.05, 20.9.06
 - partial priority 20.9.05, 20.9.06
 - validity of priority claim 20.9.03–20.9.06
- procedure from filing to grant
 - documents 10.9.03–10.9.26
 - filing of patent applications 10.9.01
 - grant of patent 10.9.32
 - language requirements 10.9.02
 - obvious bars to patenting 10.9.28–10.9.30
 - procedure after filing 10.9.27
 - substantive patent examination 10.9.31
- prosecution strategies 12.9.01–12.9.10
- re-examination 39.9.01
- regulatory bodies 65.9.01, 65.9.03
 - medical devices 65.9.05, 65.9.06
- regulatory legislation
 - agricultural chemicals 65.9.07
 - medicinal products 65.9.02
- reissue applications 35.9.02
- remedies for infringement
 - account of profits 47.9.09
 - cease and desist order 47.9.01
 - compensation for enrichment 47.9.07
 - confiscation by customs 47.9.11
 - criminal law 47.9.12
 - damages 47.9.02–47.9.06
 - destruction 47.9.10
 - disclosure of third party involvement 47.9.08
 - limitation period 48.9.01–48.9.04
 - restrictions 48.9.01–48.9.04
- renewal fees 16.9.04–16.9.07
- request for examination 11.9.01–11.9.04
- research and development collaboration
 - confidentiality 94.9.15
 - content of rights 94.9.09
 - costs 94.9.10–94.9.14

- generally 94.9.01
- ownership 94.9.02–94.9.08
- revenues 94.9.10–94.9.14
- revocation 40.9.01–40.9.23, 57.9.19–57.9.23
- search request 11.9.05–11.9.07
- secret use 28.9.01
- settlement of litigation 63.9.01–63.9.04
- skilled addressee
 - art 3.9.07, 3.9.08
 - importance 3.9.01–3.9.03
 - neighbouring fields of art 3.9.07, 3.9.08
 - statutory provisions 3.9.04–3.9.06
- slowing down prosecution 12.9.05–12.9.10
- split trials 59.9.01–59.9.04
- sufficiency 25.9.01–25.9.14
- summary judgments 60.9.02–60.9.06
- supplementary protection
 - certificates 13.9.06–13.9.15, 17.10.02–17.10.08
- technology transfer arrangements 83.9.01
- third party interventions 37.9.01–37.9.07
- tie-in/tie-out clauses 84.9.01–84.9.03
- timing of amendment 33.9.01–33.9.11
- trade marks
 - assignment 92.9.15
 - exclusive rights 92.9.14
 - overview 92.9.01, 92.9.02
 - preconditions for protection 92.9.03–92.9.06
 - relative grounds for refusal of protection 92.9.11–92.9.13
- unfair competition 92.9.16–92.9.32
- unity of invention
 - definition of unity 29.9.02
 - generally 29.9.01
 - intermediate products 29.9.06
 - overcoming objection 29.9.07–29.9.09
 - plurality of claims 29.9.03–29.9.05
- unjustified infringement
 - proceedings 87.9.01–87.9.10
- utility 26.9.01, 26.9.02
- utility models 9.9.29–9.9.34, 11.9.09
- withdrawal of patent applications 16.9.08–16.9.11
- written description 25.9.01–25.9.14
- GMOs** *see* **genetic modified organisms**
- government use or acquisition of licences**
 - Australia 100.1.01–100.1.03
 - Canada 100.2.01–100.2.07
 - China 100.3.01
 - Europe 100.7.01
 - France 100.8.11
 - Germany 100.9.01–100.9.03
 - India 100.4.01–100.4.08
 - Italy 100.10.01–100.10.3
 - Japan 100.5.01–100.5.09
 - Netherlands 100.11.01
 - United Kingdom 100.12.01–100.12.08
 - United States 100.6.01–100.6.03
- grace periods**
 - Australia 22.1.01, 22.1.02
 - Canada 22.2.01–22.2.07
 - China 22.3.01–22.3.12
 - academic/technological meetings 22.3.08, 22.3.09
 - disclosed by another person without applicant's consent 22.3.10–22.3.12
 - international exhibitions 22.3.06, 22.3.07
- Europe
 - evident abuse 22.7.03
 - generally 22.7.01
 - international exhibition 22.7.04
 - time limit 22.7.02
- France 22.8.01
- Germany
 - abusive publication 22.9.02–22.9.04
 - generally 22.9.01
 - international exhibition 22.9.05–22.9.07
 - utility model 22.9.08–22.9.12
- India 22.4.01, 22.4.02
- Italy 22.10.01–22.10.06
- Japan
 - benefit of grace period 22.5.04
 - generally 22.5.01
 - important issues 22.5.05–22.5.08
 - inventions which can obtain benefit of grace period 22.5.02
 - necessary procedures to obtain grace period 22.5.03
- Netherlands 22.11.01–22.11.04
- overview 18.18, 18.19
- United Kingdom 22.12.01
- United States 22.6.01–22.6.04
- grey importing** *see* **parallel importing**
- hearsay evidence**
 - Japan 57.5.07–57.5.09
- horticultural methods**
 - India 19.4.08
- human beings**
 - Canada
 - drafting bioscience patents 8.2.12
 - drafting bioscience patents
 - Australia 8.1.02
 - Canada 8.2.12
- human gene therapy**
 - United States 72.6.21–72.6.24
- indefiniteness**
 - Australia 27.1.01–27.1.04
 - Canada 27.2.01–27.2.11
 - China 27.3.01–27.3.05
 - Europe 27.7.01–27.7.18
 - France 27.8.01–27.8.03
 - Germany 27.9.01
 - India 27.4.01–27.4.03
 - Italy 27.10.01
 - Japan 27.5.01–27.5.07
 - Netherlands 27.11.01–27.11.05
 - overview 18.36, 18.37
 - United Kingdom 27.12.01–27.12.03
 - United States 4.6.25, 27.6.01–27.6.08
- India**
 - account of profits 47.4.11, 47.4.12
 - agricultural chemicals regulatory approval 69.4.01–69.4.03
 - agricultural methods 19.4.08
 - allowable amendments 34.4.01–34.4.05

India (cont.)

- amended specifications 35.4.01, 35.4.02
- amendment
 - allowable amendments 34.4.01–34.4.05
 - amended specifications 35.4.01, 35.4.02
 - certificates of correction 35.4.04
 - reissue applications 35.4.03
 - timing 33.4.01–33.4.06
- appeals 56.4.11
- applications
 - addition, patents of 13.4.15–13.4.19
 - appropriate office 13.4.09
 - controller's power to make orders respecting division 13.4.20, 13.4.21
 - Convention application 13.4.04–13.4.07
 - designating and/or electing
 - India 13.4.11, 13.4.12
 - filing of priority document 13.4.13
 - ordinary applications 13.4.03
 - PCT international application 13.4.08
 - PCT national phase application 13.4.14
 - procedure 13.4.10
 - terms of patent of addition 13.4.16, 13.4.17
 - types 13.4.01
 - validity of patents of addition 13.4.18, 13.4.19
 - who can apply 13.4.02
- approval of generic drugs 77.4.01
- assignments 97.4.01–97.4.04
- biodiversity 72.4.06
- biological regulatory approval 67.4.01–67.4.03
- Bolar exemption 52.4.01
- certificates of correction 35.4.04
- certified patents 77.4.01
- clarity 27.4.01–27.4.03
- colourable variation 44.4.06, 44.4.07
- commercialization strategies 95.4.01–95.4.06
- competition law
 - disclosure to standard setting organizations 86.4.01
 - intellectual property rights as
 - exception 82.4.01–82.4.04
 - licences 85.4.01
 - technology transfer arrangements 83.4.01, 83.4.02
 - tie-in/tie-out clauses 84.4.01, 84.4.02
 - unjustified infringement proceedings 87.4.01
- compulsory licensing
 - applications 99.4.03–99.4.05
 - conditions 99.4.08, 99.4.09
 - generally 99.4.01, 99.4.02
 - grant of licence 99.4.06
 - non-working patents 99.4.07
 - procedure for application 99.4.07
 - terms of licence 99.4.08, 99.4.09
- confidential information
 - legislation 90.4.05, 90.4.06
 - overview 90.4.01
 - trade secrets 90.4.02–90.4.04
- contributory infringement 45.4.02–45.5.04
- costs 47.4.14
- court hierarchies 56.4.01–56.4.14
- damages 47.4.09, 47.4.10
- data exclusivity
 - comparison with other rights 74.4.01–74.4.03
 - generic companies 79.4.01
 - innovator companies 78.4.01
 - medical devices 80.4.01
 - new chemical entity 75.4.01
 - other periods 76.4.01
- data exclusivity strategies for generic companies 79.4.01
- data exclusivity strategies for innovator companies 78.4.01
- declarations of validity 41.4.01
- declaratory judgments 60.4.01–60.4.07
- defences to infringement
 - Bolar exemption 52.4.01
 - exhaustion of rights 54.4.01, 54.4.02
 - experimental use 51.4.01, 51.04.02
 - non-infringement declarations 53.4.01–53.4.08
 - parallel importing 54.4.01, 54.4.02
 - prior secret use 50.4.01–50.4.06
- disclosure of information to patent offices 14.4.01–14.4.03
- disclosure to standard setting organizations 86.4.01
- discovery 57.4.01–57.4.15
- drafting bioscience patents
 - microorganisms 8.4.02
 - second medical use claims 8.4.04
 - sequence listings 8.4.03
- drafting pharmaceutical patents 9.4.01–9.4.04
- due diligence 98.4.01–98.4.05
- enablement 24.4.01
- entitlement to the invention 31.4.01–31.4.04
- equivalents doctrine 44.4.03–44.4.05
- examination 11.4.01
- exhaustion of rights 54.4.01, 54.4.02
- experimental use 51.4.01, 51.04.02
- extensions of term 17.4.01
- fees 62.4.01–62.4.04
- fraud 30.4.01–30.4.03
- full description 25.4.01–25.4.05
- generic company filing strategies 71.4.01
- genetic modified organisms 72.4.01–72.4.05
- government use or acquisition of
 - licences 100.4.01–100.4.08
- grace periods 22.4.01, 22.4.02
- horticultural methods 19.4.08
- indefiniteness 27.4.01–27.4.03
- indirect infringement 45.4.01–45.4.05
- inducement to infringe 45.4.05
- inequitable conduct 30.4.01–30.4.03
- infringement proceedings
 - burden of proof 46.4.06, 46.4.07
 - defendants 46.4.05
 - generally 46.4.01
 - jurisdiction 46.4.02, 46.4.03
 - parties 46.4.04
- infringing acts 43.4.01–43.4.12
- injunctions 47.4.03, 47.4.04
- innovator company strategies 70.4.01
- internal fair basis 24.4.01
- interpretation of patent claims/specifications
 - abstract 4.4.17–4.4.21

- advantages of the invention 4.4.04
- background 4.4.01, 4.4.02
- clarity of claims 4.4.03
- field of invention 4.4.15
- patent specification 4.4.08–4.4.21
- principles of construction 4.4.22–4.4.30
- provisional specifications 4.4.02
- statement of invention 4.4.16
- structure of claims 4.4.05–4.4.07
- title of specification 4.4.14
- inventive step 23.4.01–23.4.06
- inventorship 5.4.01–5.4.13
- lapse of patent applications 16.4.05–16.4.09
- licences 85.4.01
- licensing 96.4.01–96.4.06
 - assignment 96.4.05
 - exclusive licences 96.4.01
 - implied licence 96.4.03
 - infringement proceedings 96.4.02
 - limitations 96.4.04
 - royalties 96.4.06
 - sole licences 96.4.01
- literal infringement 43.4.11, 43.4.12
- litigation 57.4.01–57.4.15
- living organisms 19.4.02
- medical device data exclusivity 80.4.01
- medical device regulatory approval 68.4.01
- misrepresentation 30.4.01–30.4.03
- multi-jurisdictional strategy 61.4.01–61.4.08
- non-infringement declarations 53.4.01–53.4.08
- non-literal infringement 44.4.01–44.4.12
- novelty 21.4.01–21.4.05
- opposition proceedings
 - generally 38.4.01–38.4.04
 - post-grant opposition 38.4.06, 38.4.08–38.4.17
 - pre-grant representation 38.4.05, 38.4.07
- ownership 6.4.01–6.4.05
- parallel importing 54.4.01, 54.4.02
- passing off 92.4.08–92.4.14
- patent term 16.4.01
- patentable subject matter
 - agricultural methods 19.4.08
 - biological processes 19.4.03
 - examples 19.4.07
 - horticultural methods 19.4.08
 - living organisms 19.4.02
 - overview 19.4.01
 - selection patents 19.4.09
 - therapy 19.4.06
 - treatment methods 19.4.04, 19.4.05
- pharmaceutical regulatory
 - approval 66.4.01–66.4.09
- pith and marrow doctrine 44.4.11, 44.4.12
- plant breeders' rights
 - benefit sharing 91.4.08
 - compulsory licensing 91.4.10
 - criminal offence 91.4.09
 - infringement 91.4.05–91.4.07
 - legislation 91.4.03
 - overview 91.4.01, 91.4.02
 - term of protection 91.4.04
- preliminary injunctions 58.4.01, 58.4.02
- prior secret use 50.4.01–50.4.06
- priority dates 20.4.01–20.4.03
- procedure from filing to grant
 - examination of application 10.4.04
 - filing of application 10.4.01
 - grant of patent 10.4.07
 - placing application in order for grant 10.4.05, 10.4.06
 - publication of application 10.4.02
 - request for examination 10.4.03
- prosecution strategies 12.4.01–12.4.05
- re-examination 39.4.01
- regulatory bodies 65.4.01
- reissue applications 35.4.03
- remedies for infringement
 - account of profits 47.4.11, 47.4.12
 - background 47.4.01, 47.4.02
 - costs 47.4.14
 - damages 47.4.09, 47.4.10
 - injunctions 47.4.03, 47.4.04
 - prima facie case 47.4.06–47.4.08
 - restrictions 48.4.01–48.4.03
 - temporary injunctions 47.4.05
 - willful infringement 47.4.13
- renewal fees 16.4.02
- research and development
 - collaboration 94.4.01–94.4.04
- revocation
 - atomic energy cases 40.4.04
 - counterclaim 40.4.06
 - generally 40.4.01
 - non-working patent 40.4.05
 - petition of central government 40.4.02
 - procedure 40.4.07–40.4.11
 - public interest 40.4.03
- secret use 28.4.01
- selection patents 19.4.09
- settlement of litigation 63.4.01
- skilled addressee 3.4.01
- split trials 59.4.01
- sufficiency 25.4.01–25.4.05
- summary judgments 60.4.01–60.4.07
- supplementary protection certificates 17.4.02
- surrender of patent 16.4.04
- technology transfer arrangements 83.4.01, 83.4.02
- third party interventions 37.4.01
- tie-in/tie-out clauses 84.4.01, 84.4.02
- timing of amendment 33.4.01–33.4.06
- trade marks
 - criminal offences 92.4.07
 - overview 92.4.01
 - registered trade marks 92.4.02–92.4.05
 - term of trade mark 92.4.06
 - unregistered trade marks 92.4.08–92.4.10
- unfair competition 92.4.15–92.4.22
- unity of invention 29.4.01–29.4.04
- unjustified infringement proceedings 87.4.01
- utility 26.4.01, 26.4.02
- withdrawal of patent applications 16.4.03
- written description 25.4.01–25.4.07

indirect infringement

- Australia 45.1.01–45.1.11
- Canada 45.2.01–45.2.03
- China 45.3.01, 45.3.02
- Europe 45.7.01, 45.7.02
- France
 - background 45.8.01
 - contributory infringement 45.8.02–45.8.05
 - elements of contributory infringement 45.8.06–45.8.13
 - exceptions to contributory infringement 45.8.14, 45.8.15
- Germany
 - conditions 45.9.03–45.9.05
 - double territorial requirement 45.9.07
 - exclusions 45.9.03–45.9.05
 - knowledge 45.9.08
 - means relating to essential element of invention 45.9.06
 - products generally available in the trade 45.9.09
 - statutory provisions 45.9.01, 45.9.02
- India 45.4.01–45.4.05
- Italy
 - liability for contributory infringement 45.10.02, 45.10.03
 - prerequisites to establish contributory infringement 45.10.01
- Japan
 - exceptions 45.5.02–45.5.05
 - generally 45.5.01
 - inducement 45.5.06
- Netherlands
 - background 45.11.01
 - cross-border implications 45.11.02
 - means concerning essential part of invention 45.11.03, 45.11.04
 - pharmaceutical patents 45.11.05
- overview 42.07–42.11
- United Kingdom
 - claims limited by use 45.12.14
 - inducements to infringe 45.12.15
 - joint tortfeasors 45.12.16
 - staple commercial product 45.12.10–45.12.13
 - statutory provisions 45.12.01–45.12.09
- United States
 - acts in foreign countries 45.6.05
 - contributory infringement 45.6.04
 - inducement 45.6.01–45.6.03

inequitable conduct

- Australia 30.1.01–30.1.04
- Canada 30.2.01–30.2.14
- China 30.3.01–30.3.06
- Europe 30.7.01
- France 30.8.01, 30.8.02
- Germany 30.9.01–30.9.03
- India 30.4.01–30.4.03
- Italy 30.10.01
- Japan 30.5.01–30.5.03
- Netherlands 30.11.01
- overview 18.41–18.44
- United Kingdom 30.12.01
- United States 30.6.01–30.6.21

infringement

- see also* defences to infringement; literal infringement; equivalents doctrine; indirect infringement; infringing acts; infringement proceedings; non-literal infringement; remedies for infringement
- overview 42.01–42.1.19
- infringement proceedings** 42.12–42.17
 - Australia
 - case management 46.1.08
 - evidence 46.1.09, 46.1.10
 - facts 46.1.09, 46.1.10
 - forum 46.1.01, 46.1.02
 - onus of proof 46.1.13
 - plaintiff 46.1.03, 46.1.04
 - pleadings 46.1.05–46.1.07
 - trial 46.1.11, 46.1.12
 - Canada
 - defendants 46.2.15, 46.2.16
 - forum 46.2.02–46.2.09
 - generally 46.2.01
 - geographic jurisdiction 46.2.10, 46.2.11
 - onus of proof 46.2.17, 46.2.18
 - plaintiffs 46.2.12–46.2.14
 - selection of venue 46.2.02–46.2.09
 - China 46.3.01–46.3.05
 - Europe 46.7.01–46.7.03
 - France
 - bailiffs 46.8.08
 - carrying out seizure order 46.8.13–46.8.16
 - choice of place of seizure 46.8.12
 - evidence 46.8.05, 46.8.06, 46.8.17–46.8.19
 - expert reports 46.8.17–46.8.19
 - experts 46.8.09, 46.8.10
 - facts 46.8.05, 46.8.06
 - forum 46.8.04
 - jurisdiction 46.8.07
 - law enforcement authorities 46.8.11
 - standing 46.8.01–46.8.03
 - Germany
 - information 46.9.11–46.9.13
 - pre-trial proceedings 46.9.14–46.9.17
 - proceedings 46.9.01–46.9.10
 - India
 - burden of proof 46.4.06, 46.4.07
 - defendants 46.4.05
 - generally 46.4.01
 - jurisdiction 46.4.02, 46.4.03
 - parties 46.4.04
 - Italy
 - evidence 46.10.03
 - Italian torpedo 46.10.07–46.10.10
 - standing 46.10.01, 46.10.02
 - strategy 46.10.04–46.10.06
 - Japan
 - courts 46.5.01, 46.5.02
 - filing briefs 46.5.04, 46.5.05
 - filing complaint 46.5.03
 - forum 46.5.01, 46.5.02
 - presumption of infringement 46.5.13
 - production of documents 46.5.08, 46.5.09

- separation of issues 46.5.10–46.5.12
- witnesses 46.5.06, 46.5.07
- Netherlands
 - accelerated proceedings 46.11.05
 - appeals 46.11.06
 - costs 46.11.07
 - generally 46.11.01
 - preliminary relief proceedings 46.11.02–46.11.04
 - proceedings on the merits 46.11.05
- United Kingdom
 - burden of proof 46.12.06–46.12.09
 - defendants 46.12.15–46.12.21
 - entitlement to bring
 - proceedings 46.12.10–46.12.14
 - forum 46.12.01–46.12.03
 - split hearings 46.12.04, 46.12.05
- United States
 - abbreviated new drug
 - applications 46.6.21–46.6.27
 - appeals 46.6.33–46.6.35
 - District Court proceedings 46.6.01–46.6.09
 - international trade commission 46.6.28–46.6.32
 - multi-district litigation 46.6.20
 - stages in litigation 46.6.10–46.6.19
- infringing acts**
 - Australia 43.1.01–43.1.05
 - Canada 43.2.01–43.2.05
 - China 43.3.01
 - Europe 43.7.01–43.7.04
 - France 43.8.01
 - Germany 43.9.01–43.9.04
 - India 43.4.01–43.4.12
 - Italy 43.10.01–43.10.04
 - Japan 43.5.01–43.5.03
 - Netherlands 43.11.01–43.11.07
 - overview 42.01–42.03
 - United Kingdom 43.12.01–43.12.10
 - United States 43.6.01–43.6.20
- injunctions**
 - see also preliminary injunctions*
 - Australia 47.1.02
 - Canada 47.2.01, 47.2.02
 - India 47.4.03, 47.4.04
 - Italy 47.10.02–47.10.05
 - Netherlands 47.11.01
 - United Kingdom 47.12.02–47.12.05
- innocent infringement**
 - Australia 48.1.04, 48.1.05
 - Canada 48.2.03–48.2.05
 - France 48.8.01
 - Italy 48.10.01, 48.10.02
 - United Kingdom 48.12.03–48.12.06
 - United States 48.6.04–48.6.08
- innovation patents**
 - Australia 8.1.03
 - drafting bioscience patents
 - Australia 8.1.03
- innovator company strategies**
 - see also data exclusivity strategies for innovator companies*
 - Australia 70.1.01–70.1.05
 - Canada 70.2.01–70.2.14
 - China 70.3.01–70.3.03
 - Europe 70.7.01
 - France 70.8.01, 70.8.02
 - Germany 70.9.01
 - India 70.4.01
 - Italy 70.10.01–70.10.07
 - Japan
 - combos 70.5.07, 70.5.08
 - indication carve-out 70.5.11
 - overview 70.5.01
 - paediatric indications 70.5.09
 - patent term extension 70.5.02–70.5.06
 - salts/esters 70.5.10
 - Netherlands 70.11.01
 - United Kingdom 70.12.01
 - United States
 - overview 70.6.01
 - regulated accelerated approval 70.6.02–70.6.04
 - statutory accelerated approval 70.6.05–70.6.10
 - subpart E status 70.6.11–70.6.14
- inspection**
 - Australia 47.1.08
- interest**
 - Canada 47.2.15, 47.2.16
- interlocutory applications**
 - France 57.8.06–57.8.10
- internal fair basis**
 - Australia 24.1.01–24.1.04
 - Canada 24.2.01–24.2.15
 - China 24.3.01–24.3.02
 - Europe 24.7.01
 - France 24.8.01
 - Germany 24.9.01
 - India 24.4.01
 - Italy 24.10.01
 - Japan 24.5.01–24.5.07
 - Netherlands 24.11.01
 - overview 18.26, 18.27
 - United Kingdom 24.12.01
 - United States 24.6.01–24.6.19
- international agreements**
 - Berne Convention 2.30–2.32
 - free trade agreements 2.33
 - Madrid Agreement 2.22–2.26
 - meaning 1.02, 2.01
 - modification of national laws 2.01
 - Nice Agreement 2.28
 - overview 1.03, 2.33
 - Paris Convention for the Protection of
 - Industrial Property 2.10, 2.11
 - Patent Cooperation Treaty (PCT) 2.12–2.14
 - Patent Law Treaty (PLT) 2.20, 2.21
 - Plant Varieties Convention 2.29
 - regional agreements 2.33
 - scope 2.02
 - Strasbourg Agreement concerning the International
 - Patent Classification 1971 2.15, 2.16
 - Trademark Law Treaty (TLT) 2.27
 - TRIPS 2.03–2.09
 - World Trade Organization Agreement on
 - Trade-Related Aspects of Intellectual Property Rights (TRIPS) 2.03–2.09

- interpretation of patent claims/specifications**
- Australia
 - construction 4.1.01–4.1.05
 - expert witnesses 4.1.05–4.1.08
 - principles 4.1.01–4.1.05
 - purposive construction 4.1.09, 4.1.10
 - Canada
 - construction 4.2.01–4.2.09
 - expert evidence 4.2.05
 - purposive construction 4.2.06–4.2.09
 - China
 - eclectic interpretation 4.3.08–4.3.10
 - legislative background 4.3.01–4.3.20
 - dictionaries
 - United States 4.6.21
 - disclaimers
 - Europe 4.7.16–4.7.18
 - Netherlands 4.11.06
 - doctrine of equivalence
 - France 4.8.04, 4.8.05
 - Germany 4.9.11–4.9.14
 - United Kingdom 4.12.10
 - Europe
 - art 69 protocol 4.7.05–4.7.08
 - art 69(1) EPC 4.7.05–4.7.08
 - art 84 EPC 4.7.09, 4.7.10, 4.7.11
 - clarity requirement 4.7.10, 4.7.11
 - disclaimers 4.7.16–4.7.18
 - inconsistencies 4.7.12
 - overview 4.7.01–4.7.04
 - product-by-process claims 4.7.19–4.7.26
 - relative terms 4.7.13
 - unclear expressions 4.7.14, 4.7.15
 - expert evidence
 - Australia 4.1.05–4.1.08
 - Canada 4.2.05
 - file wrapper estoppel
 - Germany 4.9.15, 4.9.16
 - United Kingdom 4.12.17, 4.12.18
 - France
 - basic principles 4.8.01–4.8.05
 - biotech inventions 4.8.06–4.8.08
 - doctrine of equivalence 4.8.04, 4.8.05
 - general means, theory of 4.8.04, 4.8.05
 - generally 1.09–1.11
 - Germany
 - claims, interpretation of 4.9.05–4.9.10
 - doctrine of equivalence 4.9.11–4.9.14
 - file wrapper estoppel 4.9.15, 4.9.16
 - overview 4.9.01–4.9.04
 - technical teaching 4.9.05, 4.9.06
 - India
 - abstract 4.4.17–4.4.21
 - advantages of the invention 4.4.04
 - background 4.4.01, 4.4.02
 - clarity of claims 4.4.03
 - field of invention 4.4.15
 - patent specification 4.4.08–4.4.21
 - principles of construction 4.4.22–4.4.30
 - provisional specifications 4.4.02
 - statement of invention 4.4.16
 - structure of claims 4.4.05–4.4.07
 - title of specification 4.4.14
 - Italy
 - characterizing elements 4.10.05–4.10.08
 - preamble 4.10.03, 4.10.04
 - role of claims 4.10.01, 4.10.02
 - specification 4.10.09, 4.10.10
 - transition 4.10.04
 - Japan
 - claims 4.5.02–4.5.12
 - functional claims 4.5.26, 4.5.27
 - generally 4.5.01
 - Lipase case 4.5.21, 4.5.22
 - ordinary meaning 4.5.20
 - prior art 4.5.25
 - product-by-process claims 4.5.26, 4.5.27
 - prosecution history 4.5.23, 4.5.24
 - specification 4.5.13–4.5.16
 - technical scope of patented invention 4.5.17–4.5.19
 - Netherlands
 - Art 25 Dutch Patent Act 1995 4.11.03–4.11.05
 - Art 69 EPC and protocol 4.11.12–4.11.16
 - biotechnological inventions 4.11.20
 - chemical patents 4.11.19
 - clarity of claims 4.11.03–4.11.05
 - disclaimers 4.11.06
 - essence of the invention 4.11.12–4.11.16
 - functional definition 4.11.09, 4.11.10
 - general inventive concept 4.11.17, 4.11.18
 - literal infringement 4.11.12–4.11.16
 - relative terms 4.11.10
 - overview 4.11.01, 4.11.02
 - pharmaceutical patents 4.11.19
 - positive wording of claims 4.11.06
 - product-by-process claims 4.11.08
 - references to claims to description 4.11.07
 - relative terms 4.11.10
 - trade marks 4.11.11
 - vague terms 4.11.10
 - preamble
 - Italy 4.10.03, 4.10.04
 - United States 4.6.05, 4.6.06
 - product-by-process claims
 - Europe 4.7.19–4.7.26
 - Japan 4.5.26, 4.5.27
 - United States 4.6.28–4.6.30
 - prosecution history
 - Japan 4.5.23, 4.5.24
 - United States 4.6.11
 - purposive construction
 - Australia 4.1.09, 4.1.10
 - Canada 4.2.06
 - United Kingdom 4.12.09–4.12.14
 - United Kingdom
 - ambiguous patent 4.12.19–4.12.22
 - case law 4.12.08
 - combinations 4.12.25
 - conduct of patentee 4.12.17, 4.12.18
 - date of construction 4.12.15
 - definition of terms used in patent 4.12.16

- doctrine of equivalence 4.12.10
- dosing regimes 4.12.26
- file wrapper estoppel 4.12.17, 4.12.18
- improver questions 4.12.11, 4.12.12
- numerical ranges 4.12.23, 4.12.24
- overview 4.12.01–4.12.03
- protocol questions 4.12.11, 4.12.12
- purposive construction 4.12.09–4.12.14
- relevant legislation 4.12.04–4.12.07
- Swiss form medical use claims 4.12.26
- variants 4.12.11, 4.12.12
- United States
 - claim construction 4.6.01
 - claim differentiation 4.6.14–4.6.16
 - conventional transitional phases 4.6.22, 4.6.23
 - court's determination 4.6.19, 4.6.20
 - date of filing or invention 4.6.18
 - dictionaries 4.6.21
 - extrinsic evidence 4.6.20
 - indefinite articles 4.6.25
 - intrinsic evidence 4.6.02
 - limitations by preamble of claim 4.6.05, 4.6.06
 - meaning in the context of claim 4.6.05, 4.6.06
 - non-conventional transitional language 4.6.24
 - preferred embodiments 4.6.09, 4.6.10
 - product-by-process claims 4.6.28–4.6.30
 - prosecution history 4.6.11
 - public policy 4.6.17
 - specification 4.6.07, 4.6.08
 - upholding validity of claims 4.6.26, 4.6.27
 - words of the claim 4.6.03
- invalidity proceedings
 - see also* declarations of validity; nullification proceedings; opposition proceedings; re-examination; revocation; third party interventions
 - overview 36.01–36.17
- inventive step
 - Australia 23.1.01–23.1.14
 - Canada 23.2.01–23.2.26
 - China 23.3.01–23.3.14
 - Europe
 - age of documents 23.7.59
 - analogous use 23.7.39
 - analogy process 23.7.52
 - bonus effect 23.7.64
 - chemical inventions 23.7.40–23.7.43
 - closest prior art 23.7.05–23.7.12
 - combination inventions 23.7.35–23.7.37
 - commercial success 23.7.61, 23.7.62
 - comparative tests 23.7.65
 - could-would approach 23.7.24–23.7.28
 - denial of inventive step, examples
 - of 23.7.53–23.7.55
 - disclaimer 23.7.48
 - equivalents 23.7.44
 - expectation of success 23.7.29–23.7.32
 - generally 23.7.01, 23.7.02
 - most promising springboard 23.7.11, 23.7.12
 - new use of known measure 23.7.47
 - optimization of parameters 23.7.49
 - prejudice in the art 23.7.57, 23.7.58
 - problem inventions 23.7.45, 23.7.46
 - problem-solution approach 23.7.03, 23.7.04
 - proof 23.7.24–23.7.55
 - same purpose/effect 23.7.06
 - satisfaction of long-felt need 23.7.60
 - secondary indications 23.7.56–23.7.65
 - similar technical problem 23.7.08–23.7.10
 - simple solution 23.7.63
 - small improvement 23.7.51
 - surprising effect 23.7.64
 - technical disclosure 23.7.34
 - technical problem 23.7.13–23.7.23
 - time factor 23.7.59
 - France
 - assessment 23.8.04–23.8.06
 - basic principle 23.8.01
 - person skilled in the art 23.8.03
 - state of the art 23.8.02
 - Germany
 - assessment 23.9.02–23.9.05
 - chemical inventions 23.9.06–23.9.09
 - generally 23.9.01
 - problem-solution approach 23.9.02–23.9.05
 - India 23.4.01–23.4.06
 - Italy 23.10.01–23.10.06
 - Japan
 - determination 23.5.04–23.5.23
 - fused cells 23.5.13
 - generally 23.5.01
 - genes 23.5.06–23.5.09
 - microorganisms 23.5.15–23.5.19
 - monoclonal antibodies 23.5.14
 - pharmaceutical inventions 23.5.20–23.5.23
 - recombinant vectors 23.5.10
 - transformants 23.5.11, 23.5.12
 - Netherlands 23.11.01–23.11.07
 - overview 18.20–18.25
 - United Kingdom
 - background 23.12.03–23.12.07
 - commercial success 23.12.18, 23.12.19
 - mindset of skilled man 23.12.15, 23.12.16
 - obviousness 23.12.08–23.12.19
 - selection patents 23.12.17
 - statutory provisions 23.12.01, 23.12.02
 - technical vs commercial obviousness 23.12.14
 - unforeseen benefits 23.12.13
 - Windsurfing* test 23.12.08–23.12.19
 - United States
 - biotechnological processes 23.6.15–23.6.21
 - collaboration 23.6.22, 23.6.23
 - common ownership 23.6.22, 23.6.23
 - Graham v John Deere* 23.6.02
 - KSR Int'l Co v Teleflex, Inc* 23.6.03–23.6.06
 - level of ordinary skill in the art 23.6.10
 - non-obviousness 23.6.01
 - prior art 23.6.09
 - reasonable expectation of
 - success 23.6.07, 23.6.08
 - secondary considerations of non-obviousness 23.6.11–23.6.14

- inventorship**
- Australia
 - basic principles 5.1.01–5.1.05
 - definition of inventor 5.1.03
 - entitlement 5.1.06–5.1.13
 - persons 5.1.02
 - Canada
 - conflict proceedings 5.2.06–5.2.13
 - definition of inventor 5.2.01–5.2.03
 - interference proceedings 5.2.04, 5.2.05
 - China 5.3.01–5.3.08
 - definition of inventor
 - Australia 5.1.03
 - Canada 5.2.01–5.2.03
 - China 5.3.02
 - Europe 5.7.01–5.7.04
 - Japan 5.5.09, 5.5.10
 - Europe
 - definition of inventor 5.7.01–5.7.04
 - France
 - basic principles 5.8.01, 5.8.02
 - moral rights 5.8.03, 5.8.04
 - generally 1.12–1.14
 - Germany
 - assignment of rights to grant of patent 5.9.10, 5.9.11
 - categories of inventors 5.9.02
 - European patent applications 5.9.12
 - inventor principle 5.9.01
 - joint inventors 5.9.03–5.9.05
 - naming inventor 5.9.06
 - unjustified patent application 5.9.07, 5.9.08
 - unjustified registration of utility model 5.9.09
 - importance 1.12
 - India 5.4.01–5.4.13
 - Italy
 - bad faith application 5.10.04–5.10.07
 - basic principles 5.10.01, 5.10.02
 - moral rights 5.10.03
 - Japan
 - definition of inventor 5.5.09, 5.5.10
 - first-to-file system 5.5.01
 - moral right 5.5.04
 - name and address of inventor 5.5.02, 5.5.03
 - right to obtain patent 5.5.05–5.5.08
 - joint inventors
 - Germany 5.9.03–5.9.05
 - United States 5.6.11, 5.6.12
 - moral rights
 - France 5.8.03, 5.8.04
 - Italy 5.10.03
 - Japan 5.5.04
 - Netherlands
 - basic principles 5.11.01
 - claiming entitlement to patent 5.11.04
 - exceptions 5.11.03
 - first applicant 5.11.02
 - invalidation of patent 5.11.04
 - right to be mentioned as inventor 5.11.05
 - United Kingdom
 - entitlement disputes 5.12.04–5.12.15
 - procedure 5.12.16–5.12.21
 - who may apply for patent 5.12.01–5.12.03
 - United States
 - basic principles 5.6.01
 - burden of proof 5.6.26
 - conception 5.6.03
 - correcting inventorship 5.6.15, 5.6.17
 - corroboration 5.6.17–5.6.20
 - declaration of an interference 5.6.23, 5.6.24
 - determination 5.6.09, 5.6.10
 - District Court, interference proceedings in 5.6.37, 5.6.38
 - elements of invention 5.6.02–5.6.08
 - interference proceedings 5.6.30–5.6.38
 - interfering subject matter 5.6.25
 - joint inventorship 5.6.11, 5.6.12
 - presumption of correct inventorship 5.6.13, 5.6.14
 - priority of invention 5.6.21–5.6.29
 - proof 5.6.27–5.6.29
 - reasonable diligence 5.6.28
 - reduction to practice 5.6.04
 - simultaneous conception and reduction to practice 5.6.05–5.6.08
 - USPTO, interference proceedings at 5.6.30–5.6.36
 - Italy
 - agricultural chemicals regulatory approval plant protection products 69.10.13–69.10.21
 - REACH Regulation 69.10.01–69.10.12
 - allowable amendments 34.10.01, 34.10.02
 - amended specifications 35.10.01, 35.10.02
 - amendment
 - allowable amendments 34.10.01, 34.10.02
 - amended specifications 35.10.01, 35.10.02
 - timing 33.10.01–33.10.3
 - appeals 56.10.02, 56.10.03
 - applications 13.10.01
 - approval of generic drugs 77.10.01–77.10.05
 - assignments 97.10.01–97.10.03
 - biological regulatory approval 67.10.01–67.10.19
 - Bolar exemption 52.10.01–52.10.06
 - certified patents 77.10.01–77.10.05
 - clarity 27.10.01
 - commercialization strategies 95.10.01–95.10.07
 - competition law
 - disclosure to standard setting organizations 86.10.01–86.10.04
 - intellectual property rights as exception 82.10.01–82.10.03
 - licences 85.10.01–85.10.03
 - settlement of litigation 88.10.01–88.10.18
 - technology transfer
 - arrangements 83.10.01–83.10.03
 - tie-in/tie-out clauses 84.10.01–84.10.06
 - unjustified infringement
 - proceedings 87.10.01–87.10.04
 - compulsory licensing 99.10.01–99.10.06
 - confidential information 90.10.01–90.10.11
 - court hierarchies
 - choice of forum 56.10.06–56.10.08

- Court of Appeal 56.10.02, 56.10.03
- Court of Cassation 56.10.04, 56.10.05
 - generally 56.10.01
- damages 47.10.07–47.10.10
- data exclusivity
 - comparison with other rights 74.10.01–74.10.19
 - generic companies 79.10.01–79.10.08
 - innovator companies 78.10.01–78.10.11
 - medicinal products 74.10.02–74.10.13
 - new chemical entity 75.10.01–75.10.07
 - new indication 75.10.02, 75.10.03
 - non-pharmaceuticals 80.10.01
 - other periods 76.10.01
 - reference medicinal product 75.10.01
 - switching from prescription medicine to non-prescription medicine 75.10.04–75.10.07
- data exclusivity strategies for generic companies 79.10.01–79.10.08
- data exclusivity strategies for innovator companies 78.10.01–78.10.11
- declarations of validity 41.10.01
- declaratory judgments 60.10.01, 60.10.02
- defences to infringement
 - Bolar exemption 52.10.01–52.10.06
 - exhaustion of rights 54.10.01
 - experimental use 51.10.01–51.10.07
 - non-infringement
 - declarations 53.10.01–53.10.07
 - parallel importing 54.10.01
 - prior secret use 50.10.01–50.10.07
- disclosure of information to patent offices 14.10.01
- disclosure to standard setting
 - organizations 86.10.01–86.10.04
- drafting bioscience patents
 - basic principles 8.10.01
 - claims 8.10.02, 8.10.03
 - deposit requirements 8.10.04–8.10.06
 - microorganisms 8.10.04–8.10.06
- drafting pharmaceutical patents
 - claims 9.10.02, 9.10.03
 - filing strategies 9.10.04
 - generally 9.10.01
- due diligence 98.10.01–98.10.06
- enablement 24.10.01
- entitlement to the invention 31.10.01–31.10.06
- equivalents doctrine
 - background 44.10.01
 - chemical equivalents 44.10.03, 44.10.04
 - inventive idea 44.10.02
 - mechanical equivalents 44.10.05–44.10.07
 - partial infringement 44.10.02
 - rationale 44.10.01
- evidence 46.10.03
- examination 11.10.01
- exhaustion of rights 54.10.01
- experimental use
 - clinical trials 51.10.06, 51.10.07
 - extemporaneous preparation of pharmaceuticals 51.10.04, 51.51.05
 - overview 51.10.01
 - private use 51.10.02, 51.10.03
- fraud 30.10.01
- full description 25.10.01–25.10.13
- generic company filing
 - strategies 71.10.01–71.10.05
- genetic modified organisms 72.10.01, 72.10.01–72.10.29
- indefiniteness 27.10.01
- indirect infringement
 - liability for contributory infringement 45.10.02, 45.10.03
- inequitable conduct 30.10.01
- infringement proceedings
 - evidence 46.10.03
 - Italian torpedo 46.10.07–46.10.10
 - standing 46.10.01, 46.10.02
 - strategy 46.10.04–46.10.06
- infringing acts 43.10.01–43.10.04
- injunctions 47.10.02–47.10.05
- innocent infringement 48.10.01, 48.10.02
- innovator company strategies 70.10.01–70.10.07
- internal fair basis 24.10.01
- interpretation of patent claims/specifications
 - characterizing elements 4.10.05–4.10.08
 - role of claims 4.10.01, 4.10.02
 - specification 4.10.09, 4.10.10
 - transition 4.10.04
- inventive step 23.10.01–23.10.06
- inventorship
 - bad faith application 5.10.04–5.10.07
 - basic principles 5.10.01, 5.10.02
 - moral rights 5.10.03
- lapse of patent applications 16.10.10–16.10.13
- licences 85.10.01–85.10.03
- licensing 96.10.01–96.10.08
- literal infringement 43.10.05, 43.10.06
- litigation 57.10.01–57.10.09
 - practicalities 62.10.01, 62.10.02
- medical device regulatory approval
 - clinical investigations 68.10.15
 - manufacturer registration process 68.10.09
 - overview 68.10.01–68.10.06
 - process of approval 68.10.07, 68.10.08
 - vigilance 68.10.10–68.10.14
- misrepresentation 30.10.01
- moral rights
 - inventorship 5.10.03
- multi-jurisdictional strategy 61.10.01, 61.10.02
- non-infringement declarations
 - jurisdiction 53.10.03–53.10.05
 - procedure 53.10.01–53.10.02
 - strategy 53.10.06, 53.10.07
 - venue 53.10.03–53.10.05
- novelty 21.10.01–21.10.10
- nullification proceedings 40.10.01–40.10.11
- opposition proceedings 38.10.01
- ownership
 - basic rule 6.10.01
 - employee inventions 6.10.02–6.10.09
- parallel importing 54.10.01
- passing off 92.10.27–92.10.29
- patent term 16.10.01

Italy (*cont.*)

patentable subject matter 19.10.01–19.10.09
 pharmaceutical regulatory
 approval 66.10.01–66.10.14
 plant breeders' rights 91.10.01–91.10.17
 practicalities of litigation 62.10.01, 62.10.02
 preliminary injunctions 58.10.01–58.10.07
 prior secret use
 limitations 50.10.07
 overview 50.10.01–50.10.03
 timing 50.10.06
 use of invention 50.10.04
 within its own business 50.10.05
 priority dates 20.10.01–20.10.07
 procedure from filing to grant
 appeals 10.10.07–10.10.09
 opposition 10.10.06
 overview 10.10.01–10.10.04
 public availability of application 10.10.05
 prosecution strategies 12.10.01
 re-examination 39.10.01
 regulatory bodies 65.10.14
 regulatory legislation 65.10.01–65.10.13, 65.10.15
 remedies for infringement
 damages 47.10.07–47.10.10
 destruction 47.10.06
 expiration date close 48.10.03
 generally 47.10.01
 injunctions 47.10.02–47.10.05
 innocent infringement 48.10.01, 48.10.02
 publication of the decision 47.10.11
 restrictions 48.10.01–48.10.03
 renewal fees 16.10.02
 research and development
 collaboration 94.10.1–94.10.09
 revocation 40.10.01–40.10.11
 settlement of litigation 63.10.01, 63.10.02
 skilled addressee
 attributes 3.10.05–3.10.07
 overview 3.10.01–3.10.04
 split trials 59.10.01–59.10.04
 sufficiency 25.10.01–25.10.13
 summary judgments 60.10.01, 60.10.2
 supplementary protection
 certificates 17.11.01–17.11.09
 technology transfer
 arrangements 83.10.01–83.10.03
 tie-in/tie-out clauses 84.10.01–84.10.06
 timing of amendment 33.10.01–33.10.03
 trade marks
 absolute grounds for refusal 92.10.07
 acquiescence 92.10.23
 distinctiveness 92.10.05, 92.10.06
 enforcement 92.10.24–92.10.26
 infringement 92.10.12–92.10.18
 loss of rights 92.10.19, 92.10.20
 non-use 92.10.21, 92.10.22
 overview 92.10.01, 92.10.02
 registrability 92.10.03, 92.10.04
 relative grounds for refusal 92.10.10, 92.10.11
 remedies 92.10.24–92.10.26
 shapes 92.10.08, 92.10.09

unfair competition 92.10.27–92.10.29
 unity of invention 29.10.01–29.10.06
 unjustified infringement
 proceedings 87.10.01–87.10.04
 withdrawal of patent
 applications 16.10.03–16.10.09
 written description 25.10.01–25.10.13

Japan

accelerated examination 11.5.08–11.5.10
 agricultural chemicals regulatory approval
 agricultural chemicals 69.5.04–69.5.15
 veterinary medicines 69.5.01–69.5.03
 allowable amendments 34.5.01–34.5.11
 amended specifications 35.5.01
 amendment
 allowable amendments 34.5.01–34.5.11
 amended specifications 35.5.01
 appeal 33.5.05
 appeal against final rejection 33.5.04
 final notice of refusal 33.5.03, 34.5.03–34.5.06
 notice of grant 33.5.06–33.5.09,
 34.5.08–34.5.11
 pendency of application 33.5.01, 33.5.02,
 34.5.01, 34.5.02
 appeals 56.5.10, 56.5.11
 applications
 divisional application 13.5.02–13.5.08
 ordinary application 13.5.01
 approval of generic drugs 77.5.01–77.5.07
 assignments
 assign-back 97.5.10
 employee inventions 97.5.11
 exclusive licences 97.5.01–97.5.03
 grant-back 97.5.10
 joint ownership 97.5.08, 97.5.09
 non-exclusive licences 97.5.04–97.5.06
 right to obtain patents 97.5.07
 transfer of patent rights 97.5.01–97.5.03
 biodiversity 72.5.03
 bioinformatics 19.5.07, 19.5.08
 biological regulatory approval 67.5.01–67.5.11
 biological products 67.5.04, 67.5.05, 67.5.11
 cell/tissue based products 67.5.10
 specified biological products 67.5.06–67.5.09
 Bolar exemption 52.5.01
 certified patents 77.5.01–77.5.07
 clarity 27.5.01–27.5.07
 commercialization strategies 95.5.01
 competition law
 disclosure to standard setting
 organizations 86.5.01–86.5.07
 intellectual property rights as
 exception 82.5.01–82.5.06
 licences 85.5.01–85.5.03
 technology transfer
 arrangements 83.5.01–83.5.10
 tie-in/tie-out clauses 84.5.01–84.5.03
 unjustified infringement
 proceedings 87.5.01–87.5.04
 compulsory licensing
 dependent invention 99.5.13

- generally 99.5.01
- licences of right 99.5.22–99.5.26
- non-working patents 99.5.02, 99.5.03, 99.5.02–99.5.05
- public interest 99.5.06–99.5.12
- related to patented inventions 99.5.21
- working own patented invention 99.5.14–99.5.20
- confidential information
 - access restraint 90.5.07
 - contracts 90.5.01
 - protective orders 90.5.05, 90.5.06
 - tort 90.5.02
 - trade secrets 90.5.03, 90.5.04
- costs 62.5.05
- court hierarchies
 - expertise of judges 56.5.07, 56.5.08
 - Intellectual Property High Court 56.5.04–56.5.06
 - Osaka District Court 56.5.01
 - Supreme Court 56.5.10, 56.5.11
 - suspension of enforcement of District Court decisions 56.5.09
 - Tokyo District Court 56.5.01
 - venue 56.5.02, 56.5.03
- damages 47.5.05–47.5.11
- data exclusivity
 - comparison with other rights 74.5.01–74.5.15
 - generic companies 79.5.01, 79.5.02
 - innovator companies 78.5.01
 - new chemical entity 75.5.01
 - non-pharmaceuticals 80.5.01–80.5.04
 - other periods 76.5.01
 - patent term extension 74.5.08–74.5.15
- data exclusivity strategies for generic companies 79.5.01, 79.5.02
- data exclusivity strategies for innovator companies 78.5.01
- declarations of validity 41.5.01
- declaratory judgments 60.5.02, 60.5.03
- defences to infringement
 - Bolar exemption 52.5.01
 - exhaustion of rights 54.5.01–54.5.11
 - experimental use 51.5.01–51.5.08
 - non-infringement declarations 53.5.01–53.5.11
 - parallel importing 54.5.01–54.5.11
 - prior secret use 50.5.01–50.5.07
- destruction of infringing articles 47.5.02–47.5.04
- disclosure of information to patent offices 14.5.01–14.5.07
- disclosure to standard setting organizations 86.5.01–86.5.07
- discovery 57.5.10, 57.5.11
- drafting bioscience patents 8.5.01–8.5.18
 - genes 8.5.03, 8.5.04
 - proteins 8.5.05–8.5.18
 - types of patents and claims 8.5.01, 8.5.02
- drafting pharmaceutical patents 9.5.01–9.5.20
 - basic rules 9.5.01, 9.5.02
 - description requirements 9.5.13–9.5.16
 - human being, method of treating or diagnosing 9.5.17
 - novel crystal forms of known compounds 9.5.19, 9.5.20
 - prodrugs 9.5.18
 - types of pharmaceutical inventions 9.5.03–9.5.12
- due diligence 98.5.01
- enablement 24.5.01–24.5.07
- entitlement to the invention 31.5.01–31.5.03
- equivalents doctrine 44.5.01–44.5.09
- examination 11.5.01–11.5.13
- exhaustion of rights 54.5.01–54.5.11
- experimental use
 - clinical trials 51.5.06–51.5.08
 - generic drugs 51.5.03, 51.5.04
 - Herbicide* case 51.5.02
 - overview 51.5.01
 - Pancreatic Diseases Medicament* case 51.5.05, 51.5.06
- extensions of term 17.5.02–17.5.20
- failure to work patented invention 48.5.06–48.5.08
- forum 46.5.01, 46.5.02
- fraud 30.5.01–30.5.03
- generic company filing strategies
 - biosimilars 71.5.14–71.5.16
 - expiry of patents on corresponding brand drug 71.5.02–71.5.10
 - expiry of PMS term 71.5.11, 71.5.12
 - follow-on biologics 71.5.14–71.5.16
 - indications carve-out 71.5.13
 - procedures 71.5.01
- genetic modified organisms 72.5.01, 72.5.02
- government use or acquisition of licences 100.5.01–100.5.09
- grace periods
 - benefit of grace period 22.5.04
 - generally 22.5.01
 - important issues 22.5.05–22.5.08
 - inventions which can obtain benefit of grace period 22.5.02
 - necessary procedures to obtain grace period 22.5.03
- hearsay evidence 57.5.07–57.5.09
- indefiniteness 27.5.01–27.5.07
- indirect infringement
 - exceptions 45.5.02–45.5.05
 - generally 45.5.01
 - inducement 45.5.06
- inequitable conduct 30.5.01–30.5.03
- infringement proceedings 57.5.01–57.5.03
 - courts 46.5.01, 46.5.02
 - filing briefs 46.5.04, 46.5.05
 - filing complaint 46.5.03
 - forum 46.5.01, 46.5.02
 - presumption of infringement 46.5.13
 - production of documents 46.5.08, 46.5.09
 - separation of issues 46.5.10–46.5.12
 - witnesses 46.5.06, 46.5.07
- infringing acts 43.5.01–43.5.03
- injunctions 47.5.01
- innovator company strategies
 - combos 70.5.07, 70.5.08
 - indication carve-out 70.5.11
 - overview 70.5.01
 - paediatric indications 70.5.09
 - patent term extension 70.5.02–70.5.06
 - salts/esters 70.5.10

- Japan (*cont.*)
- internal fair basis 24.5.01–24.5.07
 - interpretation of patent claims/specifications
 - claims 4.5.02–4.5.12
 - functional claims 4.5.26, 4.5.27
 - generally 4.5.01
 - Lipase case 4.5.21, 4.5.22
 - ordinary meaning 4.5.20
 - prior art 4.5.25
 - product-by-process claims 4.5.26, 4.5.27
 - prosecution history 4.5.23, 4.5.24
 - specification 4.5.13–4.5.16
 - technical scope of patented invention 4.5.17–4.5.19
 - inventive step
 - determination 23.5.04–23.5.23
 - fused cells 23.5.13
 - generally 23.5.01–23.5.03
 - genes 23.5.06–23.5.09
 - microorganisms 23.5.15–23.5.19
 - monoclonal antibodies 23.5.14
 - pharmaceutical inventions 23.5.20–23.5.23
 - recombinant vectors 23.5.10
 - transformants 23.5.11, 23.5.12
 - inventorship
 - definition of inventor 5.5.09, 5.5.10
 - first-to-file system 5.5.01
 - moral right 5.5.04
 - name and address of inventor 5.5.02, 5.5.03
 - right to obtain patent 5.5.05–5.5.08
 - lapse of patent applications 16.5.05–16.5.07
 - licences 85.5.01–85.5.03
 - licensing 96.5.01–96.5.05
 - assignor estoppels 96.5.05
 - exclusive licence 96.5.01
 - indemnity, patent 96.5.03
 - non-exclusive licence 96.5.02
 - registration of patents 96.5.04
 - limitation period 48.5.01
 - literal infringement 43.5.04–43.5.06
 - litigation
 - access restraining 57.5.14
 - attorney's fees 62.5.08
 - briefs 62.5.06, 62.5.07
 - costs 62.5.05, 62.5.10
 - discovery 57.5.10, 57.5.11
 - expedited proceedings 57.5.17, 62.5.01, 62.5.02
 - hearsay evidence 57.5.07–57.5.09
 - infringement proceedings 57.5.01–57.5.03
 - judges 57.5.04–57.5.06
 - practicalities 62.5.01–62.5.10
 - protective orders 57.5.12, 57.5.13
 - separation of damage from infringement
 - issues 57.5.15, 57.5.16
 - stamp tax 62.5.08
 - trial 57.5.04–57.5.06
 - medical device data exclusivity 80.5.01–80.5.04
 - medical device regulatory approval 68.5.01, 68.5.02
 - misrepresentation 30.5.01–30.5.03
 - moral right
 - inventorship 5.5.04
 - multi-jurisdictional strategy 61.5.01–61.5.06
 - non-infringement declarations 53.5.01–53.5.11
 - burden of proof 53.5.06, 53.5.07
 - declaratory judgment action 53.5.01–53.5.03
 - form of declaration 53.5.04, 53.5.05
 - non-infringement strategy 53.5.10, 53.5.11
 - patentee's counterclaim 53.5.08, 53.5.09
 - non-literal infringement 44.5.01–44.5.09
 - novelty
 - another application 21.5.14–21.5.16
 - generally 21.5.01–21.5.03
 - invention described in another
 - application 21.5.17–21.5.21
 - invention described in a
 - publication 21.5.10–21.5.13
 - prior to filing of patent
 - application 21.5.04–21.5.09
 - publicly known invention 21.5.06, 21.5.07
 - publicly worked invention 21.5.08, 21.5.09
 - nullification proceedings 40.5.01–40.5.11
 - opposition proceedings 38.5.01
 - ownership
 - applicant and patentee 6.5.01–6.5.06
 - co-ownership 6.5.10–6.5.13
 - employee inventions 6.5.07–6.5.09
 - parallel importing 54.5.01–54.5.11
 - passing off 92.5.11
 - patent prosecution highway (PPH) 11.5.11–11.5.13
 - patent term 16.5.01
 - patentable subject matter
 - bioinformatics 19.5.07, 19.5.08
 - diagnostic methods 19.5.02–19.5.05
 - generally 19.5.01
 - human beings 19.5.02–19.5.05
 - selection patents 19.5.06
 - treatment methods 19.5.02–19.5.05
 - pharmaceutical regulatory approval
 - generally 66.5.01
 - licence for manufacturing
 - business 66.5.11–66.5.15
 - licence for manufacturing-marketing
 - business 66.5.05–66.5.10
 - manufacturing-marketing
 - approval 66.5.16–66.5.26
 - master file 66.5.27, 66.5.28
 - necessary procedures 66.5.02–66.5.04
 - priority review system 66.5.29, 66.5.30
 - plant breeders' rights
 - duration of rights 91.5.08–91.5.11
 - examination of application 91.5.07
 - exception of breeders' rights 91.5.12
 - overview 91.5.01
 - person who can obtain protection 91.5.03, 91.5.04
 - protected plants 91.5.02
 - provisional protection 91.5.05, 91.5.06
 - publication of application 91.5.05, 91.5.06
 - registration fee 91.5.13
 - practicalities of litigation 62.5.01–62.5.10
 - preliminary injunctions 58.5.01–58.5.12
 - prior art
 - interpretation of patent claims/specifications 4.5.25
 - prior secret use 50.5.01–50.5.07
 - overview 50.5.01, 50.5.02
 - proof of prior user right 50.5.04, 50.5.05

- purpose of prior user right 50.5.03
- scope of protection 50.5.06
- third party use 50.5.07
- priority dates 20.5.01–20.5.06
 - application filed in contracting nation of WTO 20.5.03
 - cases 20.5.04–20.5.06
 - Paris Convention 20.5.01
 - PCT application 20.5.02
- procedure from filing to grant
 - appeal against final rejection/decision of refusal 10.5.11–10.5.14
 - application 10.5.01, 10.5.02
 - decision of refusal 10.5.10
 - decision to grant patent 10.5.08
 - final notice of refusal 10.5.09
 - final rejection 10.5.10
 - formality examination 10.5.03
 - notification of reasons for refusal 10.5.07
 - payment of patent fee 10.5.15
 - publication of unexamined application 10.5.04
 - registration 10.5.15
 - request for examination 10.5.05, 10.5.06
 - second office action 10.5.09
- prosecution strategies 12.5.01–12.5.10
- re-examination 39.5.01–39.5.11
- regulatory bodies
 - Ministry of Health, Labour and Welfare 65.5.01–65.5.04
 - Pharmaceutical Affairs and Food Sanitation Council 65.5.06, 65.5.07
 - Pharmaceuticals and Medical Devices Agency 65.5.05
- remedies for infringement
 - damages 47.5.05–47.5.11
 - destruction of infringing articles 47.5.02–47.5.04
 - equitable remedies 48.5.02
 - failure to work patented invention 48.5.06–48.5.08
 - injunctions 47.5.01
 - limitation period 48.5.01
 - measures for recovery of reputation 47.5.12
 - presumption of negligence 48.5.03
 - rebuttal of presumption of damage 48.5.04, 48.5.05
 - restrictions 48.5.01–48.5.08
- renewal fees 16.5.02–16.5.03
- research and development collaboration
 - alliances 94.5.16–94.5.20
 - assign-back 94.5.07
 - employee invention 94.5.11–94.5.15
 - estoppels 94.5.08
 - foreign filing licence 94.5.09
 - grant-back 94.5.07
 - joint ownership 94.5.02–94.5.06
 - no contest provisions 94.5.08
 - remuneration for employee's invention 94.5.10
- revocation 40.5.01–40.5.11
- secret use 28.5.01–28.5.03
- selection patents 19.5.06
- settlement of litigation 63.5.01–63.5.06
- skilled addressee
 - definition 3.5.01–3.5.03
 - patent practice 3.5.04–3.5.06
- split trials 59.5.01–59.5.03
- summary judgments 60.5.01
- supplementary protection certificates 17.5.01
- technology transfer
 - arrangements 83.5.01–83.5.10
- third party interventions 37.5.01–37.5.06
- tie-in/tie-out clauses 84.5.01–84.5.03
- timing of amendment 33.5.01–33.5.09
- trade marks
 - famous trade mark protection 92.5.09, 92.5.10
 - protection of registered trade marks 92.5.01, 92.5.02
 - well-known trade mark protection 92.5.06–92.5.08
- trial 57.5.04–57.5.06
- unity of invention 29.5.01, 29.5.02
- unjustified infringement proceedings 87.5.01–87.5.04
- utility
 - gene, vector
 - protein, transformant, cell, antibody etc 26.5.03
 - generally 26.5.01, 26.5.02
 - treatment methods 26.5.04, 26.5.05
- withdrawal of patent applications 16.5.04
- joint inventors
 - Germany
 - inventorship 5.9.03–5.9.05
 - United States
 - inventorship 5.6.11, 5.6.12
- lack of entitlement to invention *see* **entitlement to the invention**
- lapse of patent applications
 - Australia 16.1.10–16.1.15
 - Canada 16.2.13
 - China 16.3.05–16.3.08
 - Europe 16.7.09–16.7.13
 - France 16.8.12–16.8.16
 - India 16.4.05–16.4.09
 - Italy 16.10.10–16.10.13
 - Japan 16.5.05–16.5.07
 - Netherlands 16.11.12
 - United States 16.6.03
- licences
 - see also* **compulsory licensing; government use or acquisition of licences; licensing**
 - Australia 85.1.01–85.1.04
 - Canada 85.2.01–85.2.09
 - China 85.3.01
 - Europe 85.7.01, 85.7.02
 - France 85.8.01–85.8.05
 - Germany 85.9.01, 85.9.02
 - India 85.4.01
 - Italy 85.10.01–85.10.03
 - Japan 85.5.01–85.5.03
 - Netherlands 85.11.01, 85.11.02
 - overview 81.11, 81.12
 - United Kingdom 85.12.01
 - United States 85.6.01–85.6.04

- licensing**
 Australia 96.1.01–96.1.11
 Canada 96.2.01–96.2.14
 China 96.3.01–96.3.06
 Europe
 competition law 96.7.02, 96.7.03
 overview 96.7.01
 France
 duties 96.8.09–96.8.17
 enforceability 96.8.06–96.8.08
 generally 96.8.01
 nullity 96.8.19
 requirements 96.8.02–96.8.05
 termination 96.8.18
 Germany
 antitrust law 96.9.07–96.9.09
 infringement 96.9.05, 96.9.06
 insolvency 96.9.10–96.9.12
 licences 96.9.04
 overview 96.9.01–96.9.03
 India 96.4.01–96.4.06
 assignment 96.4.05
 exclusive licences 96.4.01
 implied licence 96.4.03
 infringement proceedings 96.4.02
 limitations 96.4.04
 royalties 96.4.06
 sole licences 96.4.01
 Italy 96.10.01–96.10.08
 Japan 96.5.01–96.5.05
 assignor estoppels 96.5.05
 exclusive licence 96.5.01
 indemnity, patent 96.5.03
 non-exclusive licence 96.5.02
 registration of patents 96.5.04
 Netherlands 96.11.01–96.11.04
 overview 93.12–93.14
 United Kingdom
 assignment of licences 96.12.19
 competition law 96.12.20
 estoppel 96.12.11
 exclusive licences 96.12.02–96.12.05
 exhaustion 96.12.17, 96.12.18
 formalities 96.12.06–96.12.08
 know-how 96.12.12
 non-exclusive licences 96.12.02–96.12.05
 overview 96.12.01
 registration 96.12.09, 96.12.10
 royalties 96.12.13, 96.12.14
 sole licences 96.12.02–96.12.05
 termination 96.12.15, 96.12.16
 United States 96.6.01–96.6.18
 Bayh-Dole Act 96.6.15
 competition law 96.6.18
 contesting validity 96.6.16, 96.6.17
 default rules 96.6.05
 overview 96.6.01–96.6.03
 points to specify in licence 96.6.06–96.6.14
 state contract law 96.6.04
- limitation period**
 Australia 48.1.01, 48.1.02
 Canada 48.2.01
 Germany 48.9.01–48.9.04
 Japan 48.5.01
 United Kingdom 48.12.01, 48.12.02
 United States 48.6.01
- listed patents** *see* **certified patents**
- literal infringement**
 Australia 43.1.06, 43.1.07
 Canada 43.2.06–43.2.10
 China 43.3.02
 France 43.8.02–43.8.08
 Germany 43.9.05–43.9.08
 India 43.4.11, 43.4.12
 Italy 43.10.05, 43.10.06
 Japan 43.5.04–43.5.06
 Netherlands 43.11.06, 43.11.07
 overview 42.01–42.03
- litigation**
see also **settlement of litigation**; **split trials**
 applications
 Canada 57.2.45–57.2.48
 Australia 57.1.01–57.1.09
 practicalities 62.1.01–62.1.09
 Canada
 appeals 57.2.49–57.2.56
 applications 57.2.45–57.2.48
 case management 57.2.57–57.2.64
 costs 57.2.65–57.2.71
 discovery 57.2.14–57.2.34
 generally 57.2.01–57.2.04
 pleadings 57.2.05–57.2.13
 practicalities 62.2.01–62.2.29
 pre-trial procedure 57.2.35–57.2.37
 trial 57.2.38–57.2.44
 case management
 Canada 57.2.57–57.2.64
 France 57.8.11
 United Kingdom 57.12.14–57.12.18
 United States 57.6.02–57.6.06
 China 57.3.01–57.3.08
 practicalities 62.3.01–62.3.06
 confidentiality
 United States 57.6.07
 costs
 Canada 57.2.65–57.2.71
 disclosure
 United Kingdom 57.12.19–57.12.22
 discovery
 Canada 57.2.14–57.2.34
 France 57.8.01–57.8.04
 India 57.4.01–57.4.15
 Japan 57.5.10, 57.5.11
 United States 57.6.02–57.6.06
 Europe 57.7.01
 practicalities 62.7.01
 expert evidence
 United States 57.6.08
 France
 case management 57.8.11
 discovery 57.8.01–57.8.04
 evidence 57.8.12, 57.8.13

- interlocutory applications 57.8.06–57.8.10
- practicalities 62.8.01, 62.8.02
- subpoenas 57.8.05
- trial 57.8.14
- Germany
 - costs 62.9.06–62.9.12
 - infringement actions 57.9.01–57.9.18
 - practicalities 62.9.01–62.9.19
 - revocation actions 57.9.19–57.9.23
- hearsay evidence
 - Japan 57.5.07–57.5.09
- India 57.4.01–57.4.15
 - fees 62.4.01–62.4.04
 - practicalities 62.4.01–62.4.04
- Italy 57.10.01–57.10.09
 - practicalities 62.10.01, 62.10.02
- Japan
 - access 57.5.14
 - attorney's fees 62.5.08
 - briefs 62.5.06, 62.5.07
 - costs 62.5.05, 62.5.10
 - discovery 57.5.10, 57.5.11
 - expedited proceedings 57.5.17, 62.5.01, 62.5.02
 - hearsay evidence 57.5.07–57.5.09
 - infringement proceedings 57.5.01–57.5.03
 - judges 57.5.04–57.5.06
 - practicalities 62.5.01–62.5.10
 - protective orders 57.5.12, 57.5.13
 - separation of damage from infringement issues 57.5.15, 57.5.16
 - stamp tax 62.5.09
 - trial 57.5.04–57.5.06
- Netherlands
 - discovery 57.11.02–57.11.09
 - evidence 57.11.01
 - practicalities 62.11.01, 62.11.02
- overview 55.05–55.17
- practicalities
 - Australia 62.1.01–62.1.09
 - Canada 62.2.01–62.2.29
 - China 62.3.01–62.3.06
 - Europe 62.7.01
 - France 62.8.01, 62.8.02
 - Germany 62.9.01–62.9.19
 - India 62.4.01–62.4.04
 - Italy 62.10.01, 62.10.02
 - Japan 62.5.01–62.5.10
 - Netherlands 62.11.01, 62.11.02
 - overview 55.38–55.40
 - United Kingdom 62.12.01–62.12.09
 - United States 62.6.01–62.6.18
- pre-trial procedure
 - Canada 57.2.35–57.2.37
- privilege
 - United States 57.6.09, 57.6.10
- subpoenas
 - France 57.8.05
- trial
 - Canada 57.2.38–57.2.44
 - Japan 57.5.04–57.5.06
 - United Kingdom 57.12.32–57.12.35
 - United States 57.6.01, 57.6.11–57.6.13
- United Kingdom 57.12.32–57.12.35
- United States 57.6.01, 57.6.11–57.6.13
- United Kingdom
 - case management 57.12.14–57.12.18
 - commencement of claims 57.12.08–57.12.10
 - counterclaims 57.12.11–57.12.13
 - defence 57.12.11–57.12.13
 - disclosure 57.12.19–57.12.22
 - experiments 57.12.23–57.12.26
 - expert evidence 57.12.29–57.12.31
 - generally 57.12.01–57.12.05
 - interim applications 57.12.27, 57.12.28
 - practicalities 62.12.01–62.12.09
 - timescales 57.12.06, 57.12.07
 - trial 57.12.32–57.12.35
- United States
 - case management 57.6.02–57.6.06
 - confidentiality 57.6.07
 - discovery 57.6.02–57.6.06
 - expert evidence 57.6.08
 - practicalities 62.6.01–62.6.18
 - privilege 57.6.09, 57.6.10
 - trial 57.6.01, 57.6.11–57.6.13
 - waiver 57.6.09, 57.6.10
- living matter
 - Canada 19.2.17–19.2.19
 - India 19.4.02
 - United States 19.6.06
- Madrid Agreement 2.22–2.26
- medical device regulatory approval
 - Australia 68.1.01–68.1.10
 - Canada 68.2.01–68.2.20
 - China 68.3.01–68.3.05
 - Europe
 - CE marking 68.7.34–68.7.40
 - classification of medical devices 68.7.25–68.7.29
 - clinical investigations 68.7.43–68.7.50
 - competent authorities 68.7.06
 - conformity assessment procedures 68.7.34–68.7.40
 - essential requirements 68.7.30–68.7.33
 - impact of Commission review 68.7.55–68.7.71
 - process of approval 68.7.07–68.7.50
 - registration of manufacturers 68.7.41, 68.7.42
 - relevant legislation 68.7.01–68.7.05
 - vigilance obligations 68.7.51–68.7.54
 - France 68.8.01–68.8.03
 - Germany 68.9.01, 68.9.02
 - India 68.4.01
 - Italy
 - clinical investigations 68.10.15
 - manufacturer registration process 68.10.09
 - overview 68.10.01–68.10.06
 - process of approval 68.10.07, 68.10.08
 - vigilance 68.10.10–68.10.14
 - Japan 68.5.01, 68.5.02
 - Netherlands 68.11.01–68.11.03

- medical device regulatory approval** (*cont.*)
- United Kingdom
 - competent authorities 68.12.03
 - legislation 68.12.01, 68.12.02
 - process of approval 68.12.04
 - United States
 - classification of medical devices 68.6.02–68.6.06
 - investigational device
 - exemptions 68.6.07, 68.6.08
 - overview 68.6.01
 - PMA route to market 68.6.09–68.6.13
 - pre-market notification route 68.6.14–68.6.18
- medical devices**
- data exclusivity
 - Australia 80.1.01–80.1.05
 - Canada 80.2.01, 80.2.02
 - China 80.3.01–80.3.04
 - Europe 80.7.01
 - France 80.8.01
 - India 80.4.01
 - Italy 81.10.01
 - Japan 80.5.01–80.5.04
 - Netherlands 80.11.01
 - overview 73.16
 - United Kingdom 80.12.01
 - United States 80.6.01–80.6.03
- microorganisms**
- drafting bioscience patents
 - Australia 8.1.05–8.1.07
 - Canada 8.2.06
 - China 8.3.09–8.3.11
 - India 8.4.02
 - Italy 8.10.04–8.10.06
- misrepresentation**
- Australia 30.1.01–30.1.04
 - Canada 30.2.01–30.2.14
 - China 30.3.01–30.3.06
 - Europe 30.7.01
 - France 30.8.01, 30.8.02
 - Germany 30.9.01–30.9.03
 - India 30.4.01–30.4.03
 - Italy 30.10.01
 - Japan 30.5.01–30.5.03
 - Netherlands 30.11.01
 - overview 18.41–18.44
 - United Kingdom 30.12.01
 - United States 30.6.01–30.6.21
- moral rights**
- inventorship
 - Italy 5.10.03
 - Japan 5.5.04
- multi-jurisdictional strategy**
- Australia 61.1.01–61.1.03
 - Canada 61.2.01–61.2.19
 - China 61.3.01, 61.3.02
 - Europe 61.7.01
 - France 61.8.01–61.8.17
 - Germany 61.9.01–61.9.06
 - India 61.4.01–61.4.08
 - Italy 61.10.01, 61.10.02
 - Japan 61.5.01–61.5.06
 - Netherlands 61.11.01–61.11.08
 - overview 55.35–55.37
 - United Kingdom 61.12.01–61.21.21
 - United States 61.6.01–61.6.04
- nanotechnology**
- United States 72.6.08–72.6.12
- National Treatment**
- TRIPS 2.05
- Netherlands**
- account of profits 47.11.07, 47.11.08
 - agricultural chemicals regulatory
 - approval 69.11.01–69.11.04
 - allowable amendments 34.11.01–34.11.08
 - amended specifications 35.11.01, 35.11.02
 - amendments
 - allowable amendments 34.11.01–34.11.08
 - amended specifications 35.11.01, 35.11.02
 - certificates of correction 35.11.01
 - timing 33.11.01–33.11.06
 - applications
 - Aruba 13.11.08
 - concurrence 13.11.06, 13.11.07
 - divisional applications 13.11.04
 - enforcement of patents 13.11.09, 13.11.10
 - Netherlands Antilles 13.11.08
 - non pre-examined patent 13.11.05
 - territorial scope 13.11.08
 - types 13.11.01–13.11.10
 - approval of generic drugs 77.11.01
 - assignments
 - content of agreement 97.11.02, 97.11.03
 - effect of invalidity 97.11.06
 - form of agreement 97.11.02, 97.11.03
 - overview 97.11.01
 - registration 97.11.04, 97.11.05
 - biodiversity 72.11.01–72.11.04
 - biological regulatory approval 67.11.01
 - Bolar exemption 52.11.01, 52.11.02
 - certificates of correction 35.11.01
 - certified patents 77.11.01
 - clarity 27.11.01–27.11.05
 - commercialization strategies 95.11.01
 - competition law
 - disclosure to standard setting
 - organizations 86.11.01
 - intellectual property rights as
 - exception 82.11.01–82.11.03
 - licences 85.11.01, 85.11.02
 - technology transfer
 - arrangements 83.11.01–83.11.05
 - tie-in/tie-out clauses 84.11.01–84.11.02
 - unjustified infringement proceedings 87.11.01
 - compulsory licensing
 - defence related patents 99.11.10
 - Doha declaration 99.11.06
 - EURATOM Treaty 99.11.11
 - generally 99.11.01
 - legal effects 99.11.14
 - non-use 99.11.04
 - plant breeders' rights 99.11.07, 99.11.08
 - procedure 99.11.12, 99.11.13
 - public interest 99.11.02, 99.11.03

- semiconductor technology 99.11.09
- younger patent, enabling use of 99.11.05
- confidential information 90.11.01–90.11.05
- costs 56.11.06
- court hierarchies 56.11.01–56.11.06
- damages 47.11.07, 47.11.08
- data exclusivity
 - comparison with other rights 74.11.01–74.11.06
 - generic companies 79.11.01–79.11.04
 - innovator companies 78.11.01
 - medical devices 80.11.01
 - new chemical entity 75.11.01–75.11.04
 - other periods 76.11.01–76.11.03
- data exclusivity strategies for generic companies 79.11.01–79.11.04
- data exclusivity strategies for innovator companies 78.11.01
- declarations of validity 41.11.01
- declaratory judgments 60.11.01, 60.11.02
- defences to infringement
 - Bolar exemption 52.11.01, 52.11.02
 - experimental use 51.11.01–51.11.08
 - non-infringement
 - declarations 53.11.01–53.11.10
 - parallel importing 54.11.01, 54.11.02
 - prior secret use 50.11.01–50.11.06
- disclosure of information to patent offices 14.11.01
- disclosure to standard setting organizations 86.11.01
- discovery 57.11.02–57.11.09
- drafting bioscience patents
 - basic principles 8.11.01
 - regulations 8.11.04–8.11.07
 - rules 8.11.04–8.11.07
 - strategies 8.11.09–8.11.11
 - types of claims 8.11.08
 - types of patents 8.11.02, 8.11.03
- drafting pharmaceutical patents
 - filing strategies 9.11.01
 - generally 9.11.01
 - strategies 9.11.07–9.11.09
 - types of claims 9.11.04–9.11.06
 - types of patents 9.11.02, 9.11.03
- due diligence 98.11.01
- enablement 24.11.01
- equivalents doctrine
 - function, method, result test 44.11.01–44.11.03
 - non pre-examined patents 44.11.04–44.11.06
 - pre-examined patents 44.11.04–44.11.06
- evidence 57.11.01
- examination 11.11.01
- experimental use
 - acts done in seeking marketing
 - authorisation 51.11.05–51.11.07
 - clinical trials 51.11.08
 - exemption 51.11.02–51.11.04
 - overview 51.11.01
- extensions of term 17.12.01–17.12.11
- fraud 30.11.01
- full description 25.11.01–25.11.17
- generic company filing strategies 71.11.01
- genetic modified organisms 72.11.02–72.11.04
- government use or acquisition of licences 100.11.01
- grace periods 22.11.01–22.11.04
- indefiniteness 27.11.01–27.11.05
- indirect infringement
 - background 45.11.01
 - cross-border implications 45.11.02
 - means concerning essential part
 - of invention 45.11.03, 45.11.04
 - pharmaceutical patents 45.11.05
- inequitable conduct 30.11.01
- infringement proceedings
 - accelerated proceedings 46.11.05
 - appeals 46.11.06
 - costs 46.11.07
 - generally 46.11.01
 - preliminary relief proceedings 46.11.02–46.11.04
 - proceedings on the merits 46.11.05
- infringing acts 43.11.01–43.11.05
- injunctions 47.11.01
- innovator company strategies 70.11.01
- internal fair basis 24.11.01
- interpretation of patent claims/specifications
 - Art 25 Dutch Patent Act 1995 4.11.03–4.11.05
 - Art 69 EPC and protocol 4.11.12–4.11.16
 - biotechnological inventions 4.11.20
 - chemical patents 4.11.19
 - clarity of claims 4.11.03–4.11.05
 - disclaimers 4.11.06
 - essence of the invention 4.11.12–4.11.16
 - functional definition 4.11.09, 4.11.10
 - general inventive concept 4.11.17, 4.11.18
 - literal infringement 4.11.12–4.11.16
 - numeric terms 4.11.10
 - overview 4.11.01, 4.11.02
 - pharmaceutical patents 4.11.19
 - positive wording of claims 4.11.06
 - product-by-process claims 4.11.08
 - references to claims to description 4.11.07
 - relative terms 4.11.10
 - trade marks 4.11.11
 - vague terms 4.11.10
- inventive step 23.11.01–23.11.07
- inventorship
 - basic principles 5.11.01
 - claiming entitlement to patent 5.11.04
 - exceptions 5.11.03
 - first applicant 5.11.02
 - invalidation of patent 5.11.04
 - right to be mentioned as inventor 5.11.05
- lapse of patent applications 16.11.12
- licences 85.11.01, 85.11.02
- licensing 96.11.01–96.11.04
- literal infringement 43.11.06, 43.11.07
- litigation
 - discovery 57.11.02–57.11.09
 - evidence 57.11.01
 - practicalities 62.11.01, 62.11.02
- medical device regulatory
 - approval 68.11.01–68.11.03
- misrepresentation 30.11.01
- multi-jurisdictional strategy 61.11.01–61.11.08
- non-infringement declarations 53.11.01–53.11.10
- novelty 21.11.01–21.11.13

Netherlands (cont.)

opposition proceedings 38.11.01
 orphan drugs 76.11.06, 76.11.07
 ownership
 basic rule 6.11.01
 claiming entitlement to patent 6.11.12–6.11.15
 co-ownership 6.11.09
 employee inventions 6.11.05
 exception to first-to-file system 6.11.02–6.11.09
 invalidation of patent 6.11.10, 6.11.11
 remuneration for lack of patent 6.11.08
 researcher inventions 6.11.06, 6.11.07
 trainee inventions 6.11.06, 6.11.07
 parallel importing 54.11.01, 54.11.02
 passing off 92.11.03
 patent term 16.11.01, 16.11.02
 patentable subject matter
 biotechnological inventions 19.11.03–19.11.06,
 19.11.34–19.11.38
 case law 19.11.20, 19.11.21
 diagnostic methods 19.11.12–19.11.19
 essentially biological processes 19.11.32, 19.11.33
 exceptions 19.11.07
 exclusions even though inventions 19.11.22
 human body 19.11.28
 human embryonic stem cells 19.11.27
 items not regarded as
 inventions 19.11.08–19.11.10
 items not susceptible of industrial
 application 19.11.11
 morality 19.11.23–19.11.25
 opinion G 1/04 19.11.12–19.11.19
 overview 19.11.01, 19.11.02
 plant or animal varieties 19.11.29–19.11.31
 public order 19.11.23–19.11.25
 pharmaceutical regulatory
 approval 66.11.01–66.11.03
 plant breeders' rights
 exhaustion 91.11.19–91.11.24
 interaction between
 legislation 91.11.03–91.11.18
 legislation 91.11.02
 licensing 91.11.25, 91.11.26
 overview 91.11.01
 practicalities of litigation 62.11.01, 62.11.02
 preliminary injunctions 58.11.01–58.11.09
 prior secret use
 burden of proof 50.11.04, 50.11.05
 limitations on defence 50.11.06
 overview 50.11.01
 provisions 50.11.02, 50.11.03
 priority dates
 effects of priority 20.11.11–20.11.13
 formal requirements 20.11.02–20.11.05
 generally 20.11.01
 internal priority 20.11.10
 multiple rights 20.11.06–20.11.09
 procedure from filing to grant
 formal requirements 10.11.03–10.11.18
 generally 10.11.01, 10.11.02
 prosecution strategies 12.11.01–12.11.03
 re-examination 39.11.01

regulatory bodies 65.11.04, 65.11.06, 65.11.08
 regulatory legislation 65.11.01–65.11.03,
 65.11.05, 65.11.07,
 remedies for infringement
 account of profits 47.11.07, 47.11.08
 additional remedies 47.11.10
 attorney's fees 47.11.09
 cross-border injunctions 47.11.02–47.11.06
 damages 47.11.07, 47.11.08
 injunctions 47.11.01
 restrictions 48.11.01
 wilful infringement 47.11.06
 research and development
 collaboration 94.11.01–94.11.05
 revocation
 accelerated proceedings 40.11.01, 40.11.02
 advisory report 40.11.06, 40.11.07
 counterclaims 40.11.03
 Dutch patents 40.11.04, 40.11.05
 preliminary relief
 proceedings 40.11.08–40.11.10
 secret use 28.11.01, 28.11.02
 settlement of litigation 63.11.01
 skilled addressee
 attributes 3.11.05–3.11.07
 overview 3.11.01–3.11.04
 scope of protection 3.11.08–3.11.10
 split trials 59.11.01, 59.11.02
 sufficiency 25.11.01–25.11.17
 summary judgments 60.11.01, 60.11.02
 technology transfer
 arrangements 83.11.01–83.11.05
 third party interventions 37.11.01
 timing of amendment 33.11.01–33.11.06
 trade marks 92.11.01–92.11.05
 unity of invention 29.11.01–29.11.06
 unjustified infringement proceedings 87.11.01
 utility 26.11.01–26.11.04
 withdrawal of patent
 applications 16.11.05–16.11.12
 written description 25.11.01–25.11.17
Nice Agreement 2.28
non-infringement declarations
 Australia 53.1.01–53.1.08
 Canada 53.2.01–53.2.08
 China 53.3.01–53.3.03
 Europe 53.7.01
 France
 amicable step 53.8.08–53.8.12
 judicial step 53.8.13–53.8.15
 overview 53.8.01
 proof 53.8.02–56.8.05
 requirements 53.8.07, 56.8.06
 strategy 53.8.16
 Germany
 formalities 53.9.01–53.9.04
 international strategy 53.9.09–53.9.11
 procedure 53.9.05
 strategy 53.9.06–53.9.08
 India 53.4.01–53.4.02
 Italy 53.10.01–53.10.07
 jurisdiction 53.10.03–53.10.05

- strategy 53.10.06, 53.10.07
- venue 53.10.03–53.10.05
- Japan
 - burden of proof 53.5.06, 53.5.07
 - declaratory judgment
 - action 53.5.01–53.5.03
 - form of declaration 53.5.04, 53.5.05
 - non-infringement strategy 53.5.10, 53.5.11
 - patentee's counterclaim 53.5.08, 53.5.09
- Netherlands 53.11.01–53.11.10
- overview 49.05
- United Kingdom 53.12.01–53.12.12
 - act or product 53.12.03, 53.12.04
 - applicability 53.12.07, 53.12.08
 - full written particulars 53.12.05, 53.12.06
 - generally 53.12.01
 - legislation 53.12.02
 - licensees 53.12.09
 - strategy 53.12.12
 - streamlined procedure 53.12.11
 - validity 53.12.10
- United States 53.6.01
- non-literal infringement**
 - Australia 44.1.01–44.1.05
 - Canada 44.2.01–44.2.12
 - China 44.3.01, 44.3.02
 - Europe 44.7.01
 - France 44.8.01–44.8.14
 - India 44.4.01–44.4.12
 - Japan 44.5.01–44.5.09
 - Netherlands 44.11.01–44.11.03
 - overview 42.04–42.06
- non-pharmaceuticals**
 - data exclusivity
 - United States 80.6.01–80.6.03
 - United States
 - data exclusivity 80.6.01–80.6.03
- novelty**
 - Australia 21.1.01–21.1.06
 - Canada 21.2.01–21.2.19
 - China 21.3.01–21.3.08
 - Europe
 - ascertaining differences 21.7.39–21.7.46
 - availability to the public 21.7.12–21.7.17
 - chemical compounds 21.7.49–21.7.56
 - chemical inventions 21.7.47–21.7.62
 - content of relevant prior art 21.7.19–21.7.38
 - distinguishing features 21.7.43–21.7.46
 - European prior rights 21.7.05
 - excluded prior national rights 21.7.07
 - generally 21.7.01
 - non-prejudicial disclosures 21.7.08–21.7.11
 - parameter range selection 21.7.57–21.7.62
 - PCT applications as prior art 21.7.06
 - prior art, definition of 21.7.02–21.7.18
 - proof 21.7.18
 - publication dates 21.7.03, 21.7.04
 - selection inventions 21.7.47–21.7.62
 - use, novelty of 21.7.63–21.7.71
 - France
 - basic principles 21.8.01–21.8.05
 - first medical use 21.8.06–21.8.08
 - non-prejudicial disclosures 21.8.03–21.8.05
 - second medical use 21.8.06–21.8.08
 - Germany
 - ascertaining the difference 21.9.19, 21.9.20
 - chemical inventions 21.9.21–21.9.27
 - content of prior art 21.9.14–21.9.18
 - disclosure 21.9.14–21.9.18
 - generally 21.9.01
 - prior art 21.9.02–21.9.13
 - selection inventions 21.9.21–21.9.27
 - use, novelty of 21.9.28–21.9.34
 - India 21.4.01–21.4.05
 - Italy 21.10.01–21.10.10
 - Japan
 - another application 21.5.14–21.5.16
 - generally 21.5.01–21.5.03
 - invention described in another application 21.5.17–21.5.21
 - invention described in a publication 21.5.10–21.5.13
 - prior to filing of patent application 21.5.04–21.5.09
 - publicly known invention 21.5.06, 21.5.07
 - publicly worked invention 21.5.08, 21.5.09
 - Netherlands 21.11.01–21.11.13
 - overview 18.12–18.17
 - United Kingdom
 - definition of novelty 21.12.01, 21.12.02
 - disclosure 21.12.12–21.12.14
 - enablement 21.12.15–21.12.18
 - made available to the public 21.12.07–21.12.11
 - prior publication 21.12.08, 21.12.09
 - prior use 21.12.10, 21.12.11
 - state of the art 21.12.03–21.12.06
 - United States
 - accidental anticipation 21.6.07
 - anticipation 21.6.02
 - enablement standard for anticipation 21.6.05
 - generally 21.6.01
 - incorporation by reference 21.6.04
 - inherent anticipation 21.6.06
 - single reference's significance 21.6.03
 - species-genus relationships 21.6.08
 - types of prior art 21.6.09
- nullification proceedings**
 - Australia 40.1.01–40.1.03
 - Canada 40.2.01–40.2.22
 - China 40.3.01–40.3.15
 - Europe 40.7.01
 - France 40.8.01–40.8.18
 - Germany
 - amendments 40.9.13, 40.9.14
 - appeals 40.9.21–40.9.23
 - applicable grounds 40.9.17, 40.9.18
 - formal requirements 40.9.09–40.9.12
 - generally 40.9.01–40.9.05
 - grounds for nullification 40.9.08
 - parties 40.9.06, 40.9.07
 - scope of proceedings 40.9.15, 40.9.16
 - termination of proceedings 40.9.19, 40.9.20
 - India 40.4.01–40.4.11
 - Italy 40.10.01–40.10.11

nullification proceedings (*cont.*)

- Japan 40.5.01–40.5.11
- Netherlands 40.11.01–40.11.10
- overview 36.12–36.15
- United States 40.6.01

obtaining patent rights

- see also* applications; disclosure of information to patent offices; drafting bioscience patents; drafting pharmaceutical patents; examination; procedure from filing to grant; prosecution strategies
- overview 7.01–7.25

opposition proceedings

- Australia 38.1.01–38.1.27
- Canada 38.2.01–38.2.03
- China 38.3.01
- Europe
 - amendments 38.7.29–38.7.34
 - continued proceedings 38.7.11
 - cost 38.7.05
 - decision of opposition
 - division 38.7.35, 38.7.36
 - designation of opponent 38.7.14
 - generally 38.7.01–38.7.11
 - independent procedure 38.7.04
 - interest of the opponent 38.7.15–38.7.18
 - legal framework of opposition 38.7.24–38.7.28
 - legal transfer 38.7.07–38.7.11
 - national patent remains granted 38.7.03
 - public prior use 38.7.23
 - right to be heard 38.7.06
 - substantiation of the grounds
 - of opposition 38.7.19–38.7.22

France 38.8.01

Germany

- amendments 38.9.32–38.9.35
- appeal 38.9.42–38.9.46
- fee 38.9.28
- formal requirements 38.9.27–38.9.31
- generally 38.9.01–38.9.04
- grounds for opposition 38.9.12–38.9.26
- grounds of opposition 38.9.39, 38.9.40
- identification of opponent 38.9.29
- legal status of parties 38.9.03, 38.9.04
- opponent 38.9.05–38.9.11
- scope of proceedings 38.9.36–38.9.38
- substantiation of the grounds
 - of opposition 38.9.30, 38.9.31
- termination of proceedings 38.9.41
- time limit 38.9.28

India

- generally 38.4.01–38.4.04
- post-grant opposition 38.4.06, 38.4.08–38.4.17
- pre-grant representation 38.4.05, 38.4.07

Italy 38.10.01

Japan 38.5.01

Netherlands 38.11.01

overview 36.04–36.06

United Kingdom 38.12.01

United States 38.6.01

orphan drugs

- Europe 76.7.14–76.7.17
- Netherlands 76.11.06, 76.11.07
- United States
 - approval 76.6.20–76.6.26
 - benefits 76.6.27–76.6.35
 - designation 76.6.11–76.6.19
 - exclusivity 76.6.10

ownership

- Australia 6.1.01–6.1.09
 - employer-employee relationship 6.1.06–6.1.09
- Canada 6.2.01–6.2.12
 - inventorship disputes 6.2.13–6.2.22
- China 6.3.01–6.3.06

co-ownership

- France 6.8.04, 6.8.05
- Netherlands 6.11.09
- United Kingdom 6.12.20–6.12.25

employer-employee relationship

- Australia 6.1.06–6.1.09
- Canada 6.2.13–6.2.22
- France 6.8.06–6.8.09
- Germany 6.9.07–6.9.15
- Italy 6.10.01–6.10.09
- Japan 6.5.07–6.5.09
- Netherlands 6.11.05
- United Kingdom 6.12.04–6.12.19
- United States 6.6.08

Europe

- applicant 6.7.01–6.7.03
- enforcement of right to patent 6.7.04–6.7.08
- formal requirements 6.7.09–6.7.13

France

- basic principles 6.8.01–6.8.03
- co-ownership 6.8.04, 6.8.05
- employee inventions 6.8.06–6.8.09
- generally 1.15–1.17

Germany

- basic principles 6.9.01–6.9.03
- co-ownership 6.9.04–6.9.06
- employee inventions 6.9.07–6.9.15

India 6.4.01–6.4.05

Italy

- basic rule 6.10.01
- employee inventions 6.10.02–6.10.09

Japan

- applicant and patentee 6.5.01–6.5.06
- co-ownership 6.5.10–6.5.13
- employee inventions 6.5.07–6.5.09

Netherlands

- basic rule 6.11.01
- claiming entitlement to patent 6.11.12–6.11.15
- co-ownership 6.11.09
- employee inventions 6.11.05
- exception to first-to-file system 6.11.02–6.11.09
- invalidation of patent 6.11.10, 6.11.11
- remuneration for lack of patent 6.11.08
- researcher inventions 6.11.06, 6.11.07
- trainee inventions 6.11.06, 6.11.07

United Kingdom

- assignment 6.12.03

- bypassing employee compensation scheme 6.12.17–6.12.19
- co-ownership 6.12.20–6.12.25
- compensation of employees 6.12.09–6.12.14
- employee inventions 6.12.04–6.12.19
- licences 6.12.03
- normal duties 6.12.06, 6.12.08
- proprietor 6.12.01, 6.12.02
- special obligation 6.12.08
- United States
 - assignment 6.6.05–6.6.07
 - employee inventions 6.6.08
 - hire-to-invent doctrine 6.6.09–6.6.11
 - inventorship 6.6.01, 6.6.02
 - joint ownership 6.6.03, 6.6.04
 - shop-right doctrine 6.6.12, 6.6.13
 - transfer 6.6.05–6.6.07
- parallel importing**
 - Australia 54.1.01–54.1.09
 - Canada 54.2.01–54.2.11
 - China 54.3.01
 - Europe 54.7.01–54.7.28
 - France 54.8.01–54.8.13
 - Germany 54.9.01–54.9.07
 - India 54.4.01, 54.4.02
 - Italy 54.10.01
 - Japan 54.5.01–54.5.11
 - Netherlands 54.11.01, 54.11.02
 - overview 49.06
 - United Kingdom 54.12.01–54.12.07
 - United States 54.6.01–54.6.11
- Paris Convention for the Protection of Industrial Property**
 - provisions 2.10, 2.11
- passing off**
 - Australia 92.1.23–92.1.26
 - Canada 92.2.48–92.2.51
 - Germany 92.9.16–92.9.32
 - India 92.4.08–92.4.14
 - Italy 92.10.27–92.10.29
 - Japan 92.5.11
 - Netherlands 92.11.03
 - overview 89.11–89.16
 - United Kingdom 92.12.08–92.12.11
- Patent Cooperation Treaty (PCT)**
 - provisions 2.12–2.14
- Patent Law Treaty (PLT)**
 - provisions 2.20, 2.21
- patent offices**
 - disclosure *see* disclosure of information to patent offices
- patent specifications**
 - construction *see* interpretation of patent claims/specifications
- patent term**
 - see also* extensions of term; supplementary protection certificates
 - Australia 16.1.01–16.1.07
 - calculation 15.02
 - Canada 16.2.01, 16.2.02
 - China 16.3.01–16.3.04
 - Europe 16.7.01
 - France 16.8.01
 - Germany 16.9.01–16.9.03
 - India 16.4.01
 - Italy 16.10.01
 - Japan 16.5.01
 - Netherlands 16.11.01, 16.11.02
 - standard term 15.01
 - TRIPS 15.01
 - two-tiered systems 15.03
 - United Kingdom 16.12.01
 - United States 16.6.01, 16.6.02
- patentable subject matter**
 - Australia 19.1.01–19.1.12
 - Canada
 - art 19.2.05–19.2.08
 - business methods 19.2.26, 19.2.27
 - composition of matter 19.2.12–19.2.16
 - computer inventions 19.2.28–19.2.31
 - definition of invention 19.2.02–19.2.04
 - games 19.2.32
 - generally 19.2.01–19.2.04
 - living matter 19.2.17–19.2.19
 - machine 19.2.10
 - manufacture 19.2.11
 - process 19.2.09
 - scientific principles 19.2.20
 - selection patents 19.2.21–19.2.25
 - China 19.3.01–19.3.05
 - Europe
 - biological inventions 19.7.42–19.7.51
 - business methods 19.7.11, 19.7.12
 - computer-implemented inventions 19.7.13–19.7.14
 - discoveries 19.7.06
 - exceptions under art.53(c) EPC 19.7.16–19.7.19
 - exclusion under art.52(2)(a) EPC 19.7.06–19.7.08
 - exclusion under art.52(2)(b) EPC 19.7.09
 - exclusion under art.52(2)(c) EPC 19.7.10–19.7.14
 - exclusion under art.52(2)(d) 19.7.15
 - lack of technical character 19.7.05
 - mathematical methods 19.7.08
 - medical methods 19.7.16–19.7.19
 - microbiological processes 19.7.52–19.7.55
 - multi-step methods 19.7.20–19.7.35
 - overview 19.7.01, 19.7.02
 - plant varieties 19.7.40
 - plants 19.7.39–19.7.41
 - public order, inventions
 - contrary to 19.7.36–19.7.38
 - technical nature of invention 19.7.03, 19.7.04
 - France
 - biotech inventions 19.8.13–19.8.19
 - business methods 19.8.04
 - computer programs 19.8.03
 - diagnostic methods 19.8.05–19.8.08
 - intellectual creations 19.8.02–19.8.04
 - plant and animal varieties 19.8.09–19.8.12
 - statutory exclusions 19.8.01
 - treatment methods 19.8.05–19.8.08

patentable subject matter (*cont.*)

Germany

- aesthetic creations 19.9.11
- biotechnological inventions 19.9.17–19.9.28
- business methods 19.9.13
- computer-implemented inventions 19.9.14–19.9.15
- definition of invention 19.9.04–19.9.06
- discoveries 19.9.08
- game rules 19.9.12
- human body and elements 19.9.17–19.9.28
- mathematical methods 19.9.10
- medical methods 19.9.35–19.9.41
- mental activity rules and schemes 19.9.12
- morality 19.9.23–19.9.28
- non-statutory subject matter 19.9.07–19.9.16
- overview 19.9.01–19.9.03
- plant and animal varieties 19.9.29–19.9.34
- presentation of information 19.9.16
- public order 19.9.23–19.9.28
- scientific theories 19.9.09

India

- agricultural methods 19.4.08
- biological processes 19.4.03
- examples 19.4.07
- horticultural methods 19.4.08
- living organisms 19.4.02
- overview 19.4.01
- selection patents 19.4.09
- therapy 19.4.06
- treatment methods 19.4.04, 19.4.05

Italy 19.10.01–19.10.09

Japan

- bioinformatics 19.5.07, 19.5.08
- diagnostic methods 19.5.02–19.5.05
- generally 19.5.01
- human beings 19.5.02–19.5.05
- selection patents 19.5.06
- treatment methods 19.5.02–19.5.05

Netherlands

- biotechnological inventions 19.11.03–19.11.06, 19.11.34–19.11.38
- case law 19.11.20, 19.11.21
- diagnostic methods 19.11.12–19.11.19
- essentially biological processes 19.11.32, 19.11.33
- exceptions 19.11.07
- exclusions even though inventions 19.11.22
- human body 19.11.28
- human embryonic stem cells 19.11.27
- items not regarded as inventions 19.11.08–19.11.10
- items not susceptible of industrial application 19.11.11
- morality 19.11.23–19.11.25
- opinion G 1/04 19.11.12–19.11.19
- overview 19.11.01, 19.11.02
- plant or animal varieties 19.11.29–19.11.31
- public order 19.11.23–19.11.25

overview 18.02–18.06

United Kingdom

- aesthetic works 19.12.05
- biotechnological inventions 19.12.17, 19.12.18

- business methods 19.12.06–19.12.09
- computer programs 19.12.06–19.12.09
- discoveries 19.12.04
- excluded inventions 19.12.03
- immoral inventions 19.12.11–19.12.13
- medical use 19.12.14–19.12.16
- presentation of information 19.12.10–19.12.13
- requirement of patentability 19.12.01, 19.12.02
- scientific theories 19.12.04
- treatment methods 19.12.14–19.12.16

United States

- abstract ideas 19.6.15–19.6.17
- bioinformatics 19.6.23–19.6.25
- business methods 19.6.15–19.6.17
- cloning 19.6.07, 19.6.08
- ethics based limitations 19.6.06
- human beings 19.6.10–19.6.13
- living matter 19.6.06
- made by man 19.6.04, 19.6.05
- manufacturing methods 19.6.07, 19.06.08
- medical diagnostics 19.6.14
- natural phenomena 19.6.15–19.6.22
- nature, laws of 19.6.15–19.6.17
- non-human animals 19.6.09
- overview 19.6.01, 19.6.02
- scope 19.6.03
- stem cells 19.6.07, 19.6.08

PCT *see* Patent Cooperation Treaty (PCT)**pharmaceutical data exclusivity** *see* data exclusivity strategies for pharmaceuticals**pharmaceutical regulatory approval**

Australia

- manufacturing approval process 66.1.04–66.1.11
- marketing approval process 66.1.12–66.1.19
- overview 66.1.01–66.1.03

Canada 66.2.01–66.2.27

China 66.3.01

Europe

- applications under Art.10 of Directive 2001/83 66.7.17–66.7.28
- arbitration procedure 66.7.09, 66.7.10
- centralized procedure 66.7.11–66.7.15
- decentralized procedure 66.7.03, 66.7.06–66.7.08
- mutual recognition procedure 66.7.03–66.7.05
- national route 66.7.02
- new combinations 66.7.29–66.7.32
- overview 66.7.01
- particulars for marketing authorization 66.7.16

France

- basic principles 66.8.01–66.8.03
- homeopathic drugs 66.8.07
- national procedure 66.8.04–66.8.06
- temporary authorizations 66.8.08

Germany

- biologicals 66.9.08
- biosimilar approvals 66.9.07
- decentralized procedure 66.9.06
- generic drugs 66.9.07
- mutual recognition procedure 66.9.06
- national approval 66.9.01–66.9.05

India 66.4.01–66.4.09

- Italy 66.10.01–66.10.14
- Japan
generally 66.5.01
licence for manufacturing business 66.5.11–66.5.15
licence for manufacturing-marketing
business 66.5.05–66.5.10
manufacturing-marketing
approval 66.5.16–66.5.26
master file 66.5.26, 66.5.27
necessary procedures 66.5.02–66.5.04
priority review system 66.5.29, 66.5.30
- Netherlands 66.11.01–66.11.03
- United Kingdom 66.12.01–66.12.12
- United States
generic drugs 66.6.14–66.6.24
innovator new drug development and
approval 66.6.02–66.6.13
marketing unapproved drugs 66.6.31–66.6.39
OTC drug monographs 66.6.25–66.6.30
overview 66.6.01
- pharmacogenomics**
United States 72.6.02–72.6.07
- plant breeders' rights**
Australia
exclusive rights 91.1.09–91.1.14
overview 91.1.01
PBR Act 91.1.02–91.1.08
Canada 91.2.01–91.2.28
China 91.3.01–91.3.03
Europe
common catalogue requirements 91.7.16
Community Plant Variety
Rights 91.7.02–91.7.06
exemptions 91.7.07
national systems 91.7.08–91.7.15
patents 91.7.01
France
basic principles 91.8.01–91.8.03
infringement action 91.8.09–91.8.13
national plant varieties
certificates 91.8.04–91.8.08
Germany 91.9.01–91.9.10
India
benefit sharing 91.4.08
compulsory licensing 91.4.10
criminal offence 91.4.09
infringement 91.4.05–91.4.07
legislation 91.4.03
overview 91.4.01, 91.4.02
term of protection 91.4.04
Italy 91.10.01–91.10.17
Japan
duration of rights 91.5.08–91.5.11
examination of application 91.5.07
exception of breeders' rights 91.5.12
overview 91.5.01
person who can obtain
protection 91.5.03, 91.5.04
protected plants 91.5.02
provisional protection 91.5.05, 91.5.06
publication of application 91.5.05, 91.5.06
registration fee 91.5.13
- Netherlands
exhaustion 91.11.19–91.11.24
interaction between
legislation 91.11.03–91.11.18
legislation 91.11.02
licensing 91.11.25, 91.11.26
overview 91.11.01
overview 89.09, 89.10
- United Kingdom
compulsory licences 91.12.12
exceptions 91.12.11
infringement 91.12.09, 91.12.10
obtaining rights 91.12.02
overview 91.12.01
priority 91.12.06
qualification for protection 91.12.03–91.12.05
rights conferred 91.12.07, 91.12.08
- United States
certificates 91.6.14–91.6.17
infringement of certificates 91.6.18–91.6.21
infringement legislation 91.6.10, 91.6.11
new plant protection 91.6.01, 91.6.02
overview of legislation 91.6.03–91.6.05
Plant Variety Protection Act
of 1970 91.6.12, 91.6.13
requirements of legislation 91.6.06–91.6.09
utility patents 91.6.22–91.6.26
- Plant Varieties Convention**
provisions 2.29
- pleadings**
Australia 46.1.05–46.1.07
Canada 57.2.05–57.2.13
- PLT** *see* **Patent Law Treaty (PLT)**
- preliminary injunctions**
Australia 58.1.01–58.1.07
Canada 58.2.01–58.2.22
China 58.3.01–58.3.07
Europe 58.7.01
France 58.8.01–58.8.14
Germany 58.9.01–58.9.15
India 58.4.01, 58.4.02
Italy 58.10.01–58.10.07
Japan 58.5.01–58.5.12
Netherlands 58.11.01–58.11.09
overview 55.18–55.22
United Kingdom 58.12.01–58.12.13
United States 58.6.01–58.6.13, 59.6.22
- prior art**
Canada 12.2.06
France 11.8.03–11.8.08
Japan
interpretation of patent claims/specifications 4.5.25
- prior secret use**
Australia 50.1.01–50.1.10
Gillette defence 50.1.09, 50.1.10
Canada 50.2.01–50.2.12
first to file 50.2.05–50.2.08
first to invent 50.2.09–50.2.11
Gillette defence 50.2.12
immunity for prior acquisition 50.2.01–50.2.04
China 50.3.01
Europe 50.7.01

prior secret use (*cont.*)

France

- background 50.8.01, 50.8.02
- evidence of the prior possession 50.8.10
- good faith 50.8.06, 50.8.07
- location of the prior possession 50.8.09
- possession 50.8.03–50.8.05
- scope of prior possession right 50.8.11–50.8.14
- secrecy of the prior possession 50.8.08

Germany

- dual court system 50.9.04
- existence of prior user right 50.9.01, 50.9.02
- illegal usurpation 50.9.05, 50.9.06
- third parties 50.9.03

Gillette defence

- Australia 50.1.09, 50.1.10
- Canada 50.2.12

India 50.4.01–50.4.06

Italy

- limitations 50.10.07
- overview 50.10.01–50.10.03
- timing 50.10.06
- use of invention 50.10.04
- within its own business 50.10.05

Japan

- overview 50.5.01, 50.5.02
- proof of prior user right 50.5.04, 50.5.05
- purpose of prior user right 50.5.03
- scope of protection 50.5.06
- third party use 50.5.07

Netherlands

- burden of proof 50.11.04, 50.11.05
- limitations on defence 50.11.06
- overview 50.11.01
- provisions 50.11.02, 50.11.03

overview 49.02

United Kingdom 50.12.01–50.12.12

United States 50.6.01–50.6.04

- background 50.6.01
- earlier inventor defence 50.6.02
- earlier inventor must abandon, suppress or conceal 50.6.03, 50.6.04

priority dates

Australia 20.1.01–20.1.03

Canada 20.2.01–20.2.07

China 20.3.01–20.3.10

Europe

- copy of previous application 20.7.12, 20.7.13
- declaration of priority 20.7.11
- first application in Paris Convention country 20.7.32, 20.7.33
- formal requirements 20.7.03–20.7.14
- loss of priority right 20.7.34, 20.7.35
- multiple priorities 20.7.06–20.7.10
- Paris Convention 20.7.01, 20.7.02
- partial priorities 20.7.06–20.7.10
- previous application 20.7.03–20.7.05
- translation 20.7.14
- validity of priority right 20.7.15–20.7.31

France

- foreign priority 20.8.02, 20.8.03

internal priority 20.8.04, 20.8.05

types of priority 20.8.01

Germany

- domestic priority, claiming 20.9.07–20.9.14
- foreign priority, claiming 20.9.15–20.9.19
- generally 20.9.01
- international priority 20.9.15–20.9.19
- material aspects 20.9.02–20.9.06
- multiple priorities 20.9.05, 20.9.06
- partial priority 20.9.05, 20.9.06
- validity of priority claim 20.9.03–20.9.06

India 20.4.01–20.4.03, 20.10.01–20.10.07

Italy 20.10.01–20.10.07

Japan 20.5.01–20.5.06

application filed in contracting nation of WTO 20.5.03

cases 20.5.04–20.5.06

Paris Convention 20.5.01

PCT application 20.5.02

Netherlands

- effects of priority 20.11.11–20.11.13
- formal requirements 20.11.02–20.11.05
- generally 20.11.01
- internal priority 20.11.10
- multiple rights 20.11.06–20.11.09

overview 18.07–18.11

United Kingdom 20.12.01–20.12.04

United States 20.6.01–20.6.08

application filed in foreign country 20.6.03

chains, priority 20.6.06, 20.6.07

exceptions 20.6.08

formalities 20.6.08

international application 20.6.05

non-provisional application filed in US 20.6.04

provisional application filed in US 20.6.02 rules 20.6.08

privilege

United States 57.6.09, 57.6.10

procedure from filing to grant

Australia 10.1.01–10.1.08

Canada 10.2.01–10.2.26

China 10.3.01, Fig 10.1

Europe

overview 10.7.01–10.7.09

France

filing 10.8.01–10.8.03

formality examination 10.8.07–10.8.09

grant 10.8.19, 10.8.20

national defence 10.8.05, 10.8.06

publication 10.8.16–10.8.18

search report 10.8.10–10.8.15

utility certificates 10.8.21

Germany

documents 10.9.03–10.9.26

filing of patent applications 10.9.01

grant of patent 10.9.32

language requirements 10.9.02

obvious bars to patenting 10.9.28–10.9.30

procedure after filing 10.9.27

substantive patent examination 10.9.31

- India
 examination of application 10.4.04
 filing of application 10.4.01
 grant of patent 10.4.07
 placing application in order for
 grant 10.4.05, 10.4.06
 publication of application 10.4.02
 request for examination 10.4.03
- Italy
 appeals 10.10.07–10.10.09
 opposition 10.10.06
 overview 10.10.01–10.10.04
 public availability of application 10.10.05
- Japan
 appeal against final rejection/decision
 of refusal 10.5.11–10.5.14
 application 10.5.01, 10.5.02
 decision of refusal 10.5.10
 decision to grant patent 10.5.08
 final notice of refusal 10.5.09
 final rejection 10.5.10
 formality examination 10.5.03
 notification of reasons for refusal 10.5.07
 payment of patent fee 10.5.15
 publication of unexamined application 10.5.04
 registration 10.5.15
 request for examination 10.5.05, 10.5.06
 second office action 10.5.09
- Netherlands
 formal requirements 10.11.03–10.11.18
 generally 10.11.01, 10.11.02
 overview 7.12, 7.13
- United Kingdom
 filing application 10.12.01–10.12.05
 preliminary examination 10.12.06, 10.12.07
 publication 10.12.13, 10.12.14
 searches 10.12.08–10.12.12
 substantive examination 10.12.15–10.12.21
- United States
 allowance 10.6.34
 appeals 10.6.32, 10.6.33
 declaration 10.6.06
 drawings 10.6.05
 examination of application 10.6.11–10.6.31
 fee for filing 10.6.07
 oath 10.6.06
 overview 10.6.01, 10.6.02
 process after filing 10.6.08–10.6.10
 provisional patent application 10.6.35
 required elements 10.6.03–10.6.07
 specification 10.6.04
- prosecution strategies**
 Australia 12.1.01–12.1.10
 Canada 12.2.01–12.2.11
 China 12.3.01
 Europe 12.7.01–12.7.07
 France 12.8.01–12.8.05
 Germany 12.9.01–12.9.10
 India 12.4.01–12.4.05
 Italy 12.10.01
 Japan 12.5.01–12.5.10
 Netherlands 12.11.01–12.11.03
 overview 7.19, 7.20
 United Kingdom 12.12.01–12.12.13
 United States 12.6.01–12.6.22
- purposive construction**
 Australia 4.1.09, 4.1.10
 Canada 4.2.06
 United Kingdom 4.12.09–4.12.14
- re-examination**
 Australia 39.1.01–39.1.09
 Canada 39.2.01–39.2.17
 China 39.3.01–39.3.07
 Europe 39.7.01
 France 39.8.01
 Germany 39.9.01
 India 39.4.01
 Italy 39.10.01
 Japan 39.5.01–39.5.11
 Netherlands 39.11.01
 overview 36.07–36.11
 United Kingdom 39.12.01
 United States 39.6.01–39.6.29
 estoppel effects of *inter partes*
 re-examination 39.6.26–39.6.29
ex parte procedures 39.6.12–39.6.16
ex parte requests 39.6.06–39.6.10
inter partes procedure 39.6.19–39.6.25
inter partes requests 39.6.17, 39.6.18
- reasonable man**
 notional addressee 1.04–1.08
 use 1.05
- regional agreements**
 international agreements 2.33
- regulatory approval**
see also agricultural chemicals regulatory approval;
 biological regulatory approval; generic
 company filing strategies; innovator company
 strategies; medical device regulatory approval;
 pharmaceutical regulatory approval; regulatory
 bodies; regulatory legislation
 overview 64.01–64.09
 strategy 64.08, 64.09
- regulatory bodies**
 Australia
 Therapeutic Goods Administration 65.1.01–65.1.03
 Canada 65.2.01–65.2.07
 China 65.3.01, 65.3.02
 Europe 65.7.08, 65.7.09, 65.7.13, 65.7.18, 65.7.19
 France 65.8.01, 65.8.05
 Germany 65.9.01, 65.9.03
 medical devices 65.9.05, 65.9.06
 India 65.4.01
 Italy 65.10.14
 Japan
 Ministry of Health, Labour and
 Welfare 65.5.01–65.5.04
 Pharmaceutical Affairs and Food Sanitation
 Council 65.5.06, 65.5.07
 Pharmaceuticals and Medical Devices
 Agency 65.5.05

regulatory bodies (cont.)

- Netherlands 65.11.04, 65.11.06, 65.11.08
- United Kingdom 65.12.02
- United States
 - biologics 65.6.14–65.6.15
 - Centers for Medicare and Medicaid Services 65.6.22
 - Customs and Border Protection 65.6.22
 - Department of Justice 65.6.22
 - Drug Enforcement Administration 65.6.22
 - drugs 65.6.08–65.6.13
 - FDA 65.6.20, 65.6.21
 - Federal Trade Commission 65.6.22
 - medical devices 65.6.16–65.6.19
 - overview 65.6.01–65.6.03
 - Patent and Trademark Office 65.6.22
 - penalties 65.6.04–65.6.06
 - prohibited acts 65.6.04–65.6.06
 - requirements 65.6.07

regulatory legislation

- Australia
 - Therapeutic Goods Act 1989 65.1.04
 - Therapeutic Goods (Charges) Act 1989 65.1.07
 - Therapeutic Goods (Charges) Regulations 1990 65.1.08
 - Therapeutic Goods (Medical Devices) Regulations 2002 65.1.06
 - Therapeutic Goods Regulations 1990 65.1.05
- Canada 65.2.08–65.2.13
- China 65.3.03–65.3.05, 65.5.08–65.5.11
- Europe
 - agricultural chemicals 65.7.14–65.7.17
 - Community Code 65.7.01–65.7.04
 - medical devices 65.7.10–65.7.12
 - Regulation 726/2004 65.7.05, 65.7.06
 - Regulation 1394/2007 65.7.07
- France 65.8.03, 65.8.04
- Germany
 - agricultural chemicals 65.9.07
 - medicinal products 65.9.02
- Italy 65.10.01–65.10.13, 65.10.15
- Netherlands 65.11.01–65.11.03, 65.11.05, 65.11.07
- United Kingdom 65.12.01
- United States 65.6.24–65.6.70

reissue applications

- Australia 35.1.01–35.1.03
- Canada 33.2.03, 33.2.04, 35.2.11–35.2.27
- China 35.3.01–35.3.06
- Germany 35.9.02
- India 35.4.03
- overview 32.07, 32.08
- United States 35.6.05–35.6.12

remedies for infringement

- Australia
 - account of profits 47.1.03, 47.1.06, 47.1.07
 - amendment of patent specification 48.1.06–48.1.08
 - costs 47.1.10, 47.1.11
 - damages 47.1.03–47.1.05
 - delivery up 47.1.09

- generally 47.1.01
- injunctions 47.1.02
- innocent infringement 48.1.04, 48.1.05
- inspection 47.1.08
- limitation period 48.1.01, 48.1.02
- limitations on equitable remedies 48.1.09
- publication 48.1.03
- restored patents 48.1.10, 48.1.11
- restrictions 48.1.01–48.1.11

Canada

- account of profits 47.2.11–47.2.14
- costs 47.2.18–47.2.21
- damages 47.2.03–47.2.08
- delivery up 47.2.17
- equitable remedies 48.2.02
- injunctions 47.2.01, 47.2.02
- innocent infringement 48.2.03–48.2.05
- interest 47.2.15, 47.2.16
- limitation period 48.2.01
- reasonable compensation 47.2.09, 47.2.10
- restrictions 48.2.01–48.2.05

China 47.3.01–47.3.03

- restrictions 48.3.01, 48.3.02

Europe 47.7.01

- restrictions 48.7.01

France

- attorney's fees 47.8.19–47.8.21
- damages 47.8.03–47.8.17
- generally 47.8.01, 47.8.02
- good faith 48.8.02–48.8.13
- innocent infringement 48.8.01
- restrictions 48.8.01–48.8.13
- wilful infringement 47.8.18

Germany

- account of profits 47.9.09
- cease and desist order 47.9.01
- compensation for enrichment 47.9.07
- confiscation by customs 47.9.11
- criminal law 47.9.12
- damages 47.9.02–47.9.06
- destruction 47.9.10
- disclosure of third party involvement 47.9.08
- limitation period 48.9.01–48.9.04
- restrictions 48.9.01–48.9.04

India 47.10.01

- account of profits 47.4.11, 47.4.12
- background 47.4.01, 47.4.02
- costs 47.4.14
- damages 47.4.09, 47.4.10
- injunctions 47.4.03, 47.4.04
- prima facie case 47.4.06–47.4.08
- restrictions 48.4.01–48.4.03
- temporary injunctions 47.4.05
- wilful infringement 47.4.13

Italy

- damages 47.10.07–47.10.10
- destruction 47.10.06
- expiration date close 48.10.03
- generally 47.10.01
- injunctions 47.10.02–47.10.05
- innocent infringement 48.10.01, 48.10.02

- publication of the decision 47.10.11
- restrictions 48.10.01–48.10.03
- Japan
 - damages 47.5.05–47.5.11
 - destruction of infringing
 - articles 47.5.02–47.5.04
 - equitable remedies 48.5.02
 - failure to work patented
 - invention 48.5.06–48.5.08
 - injunction 47.5.01
 - limitation period 48.5.01
 - measures for recovery of reputation 47.5.12
 - presumption of negligence 48.5.03
 - rebuttal of presumption of
 - damage 48.5.04, 48.5.05
 - restrictions 48.5.01–48.5.08
- Netherlands
 - account of profits 47.11.07, 47.11.08
 - additional remedies 47.11.10
 - attorney's fees 47.11.09
 - cross-border injunctions 47.11.02–47.11.06
 - damages 47.11.07, 47.11.08
 - injunctions 47.11.01
 - restrictions 48.11.01
 - wilful infringement 47.11.06
- overview 42.18–42.25
- restrictions
 - Australia 48.1.01–48.1.11
 - Canada 48.2.01–48.2.05
 - China 48.3.01, 48.3.02
 - Europe 48.7.01
 - France 48.8.01–48.8.13
 - Germany 48.9.01–48.9.04
 - India 48.4.01–48.4.03
 - Italy 48.10.01–48.10.03
 - Japan 48.5.01–48.5.08
 - Netherlands 48.11.01
 - overview 42.26–42.29
 - United Kingdom 48.12.01–48.12.26
 - United States 48.6.01–48.6.12
- United Kingdom
 - account of profits 47.12.06, 47.12.07, 47.12.15–47.12.20
 - amended patent
 - specification 48.12.11–48.12.20
 - damages 47.12.06–47.12.14
 - delivery up 47.12.21, 47.12.22
 - destruction 47.12.21, 47.12.22
 - injunctions 47.12.02–47.12.05
 - innocent infringement 48.12.03–48.12.06
 - limitation period 48.12.01, 48.12.02
 - non-registration, effect of 48.12.25, 48.12.26
 - partially valid patent,
 - infringement of 48.12.21–48.12.24
 - restored patents 48.12.07–48.12.10
 - restrictions 48.12.01–48.12.26
 - statutory provisions 47.12.01
- United States
 - attorneys' fees 47.6.20, 47.6.21
 - damages 47.6.06–47.6.17
 - injunctions 47.6.01–47.6.05
 - innocent infringement 48.6.04–48.6.08
 - interest 47.6.18, 47.6.19
 - intervening rights 48.6.09–48.6.12
 - ITC actions 47.6.22, 47.6.23
 - limitation period 48.6.01
 - marking and notice requirement 48.6.02, 48.6.03
 - restrictions 48.6.01–48.6.12
- renewal fees
 - Australia 16.1.08, 16.1.09
 - Canada 16.2.03–16.2.12
 - China 16.3.09
 - Europe 16.7.02–16.7.05, 16.7.07, 16.7.08
 - France 16.8.02–16.8.05
 - Germany 16.9.04–16.9.07
 - India 16.4.02
 - Italy 16.10.02
 - Japan 16.5.02, 16.5.03
 - Netherlands 16.11.03, 16.11.04
 - non-payment 15.05
 - requirement 15.04
 - United Kingdom 16.12.02
 - United States 16.6.03
- research and development collaboration
 - Australia 94.1.01–94.1.10
 - Canada 94.2.01–94.2.16
 - China 94.3.01–94.3.05
 - Europe
 - competition law 94.7.18–94.7.21
 - confidentiality 94.7.12–94.7.15
 - overview 94.7.01–94.7.04
 - ownership of intellectual
 - property 94.7.05–94.7.09
 - payment 94.7.16
 - right to use intellectual property 94.7.10, 94.7.11
 - termination 94.7.17
 - France
 - overview 94.8.01, 94.8.02
 - research programme 94.8.03
 - usual clauses 94.8.04–94.8.10
 - Germany
 - confidentiality 94.9.15
 - content of rights 94.9.09
 - costs 94.9.10–94.9.14
 - generally 94.9.01
 - ownership 94.9.02–94.9.08
 - revenues 94.9.10–94.9.14
 - India 94.4.01–94.4.04
 - Italy 94.10.01–94.10.09
- Japan
 - alliances 94.5.16–94.5.20
 - assign-back 94.5.07
 - employee invention 94.5.11–94.5.15
 - estoppels 94.5.08
 - foreign filing licence 94.5.09
 - grant-back 94.5.07
 - joint ownership 94.5.02–94.5.06
 - no contest provisions 94.5.08
 - remuneration for employee's invention 94.5.10
- Netherlands 94.11.01–94.11.05
- overview 93.02–93.07
- United Kingdom 94.12.01–94.12.04

research and development collaboration (cont.)

- United States
 - antitrust 94.6.13
 - Bayh-Dole Act 94.6.06, 94.6.07
 - defences 94.6.12
 - funding support 94.6.08–94.6.11
 - improvements 94.6.03–94.6.05
 - inventorship 94.6.03–94.6.05
 - joint research agreements 94.6.08–94.6.11
 - overview 94.6.01, 94.6.02
 - ownership of inventions 94.6.03–94.6.05
 - safe harbour 94.6.08–94.6.11

restitutio in integrum

- Europe 16.7.17–16.7.29

revocation

- Australia 40.1.01–40.1.03
- Canada 40.2.01–40.2.22
- China 40.3.01–40.3.15
- Europe 40.7.01
- France
 - alternative procedures 40.8.12, 40.8.13
 - effects of invalidation 40.8.14–40.8.18
 - generally 40.8.01–40.8.06
 - standing 40.8.07–40.8.11
- Germany 40.9.01–40.9.23, 57.9.19–57.9.23
- India
 - atomic energy cases 40.4.04
 - counterclaim 40.4.06
 - generally 40.4.01
 - non-working patent 40.4.05
 - petition of central government 40.4.02
 - procedure 40.4.07–40.4.11
 - public interest 40.4.03
- Japan 40.5.01–40.5.11
- Netherlands
 - accelerated proceedings 40.11.01, 40.11.02
 - advisory report 40.11.06, 40.11.07
 - counterclaims 40.11.03
 - Dutch patents 40.11.04, 40.11.05
 - preliminary relief
 - proceedings 40.11.08–40.11.10
- overview 36.12–36.15
- United Kingdom
 - applicant for *inter partes*
 - revocation 40.12.07–40.12.29
 - generally 40.12.01
 - grounds for *ex parte*
 - revocation 40.12.02, 40.12.03
 - grounds for *inter partes*
 - revocation 40.12.04–40.12.06
 - post-grant procedure 40.12.32–40.12.40
 - strategy 40.12.30, 40.12.31
- United States 40.6.01

secret use

- Australia 28.1.01, 28.01.02
- Canada 28.2.01–28.2.11
- China 28.3.01–28.3.06
- Europe 28.7.01
- France 28.8.01, 28.8.2
- Germany 28.9.01

- India 28.4.01
- Italy 28.10.01–28.10.11
- Japan 28.5.01–28.5.03
- Netherlands 28.11.01, 28.11.02
- overview 18.38
- United Kingdom 28.12.01
- United States 28.6.01–28.6.09

selection patents

- Canada 19.2.21–19.2.25
- India 19.4.09
- Japan 19.5.06

settlement of litigation

- Australia 63.1.01–63.1.03, 88.1.01–88.1.09
- Canada 63.2.01–63.2.19, 88.2.01–88.2.19
- China 63.3.01–63.3.04

competition law

- Australia 88.1.01–88.1.09
- Canada 88.2.01–88.2.19
- China 88.3.01–88.3.03
- Europe 88.7.01–88.7.10
- France 88.8.01–88.8.07
- Germany 88.9.01–88.9.03
- India 88.4.01
- Italy 88.10.01–88.10.18
- Japan 88.5.01–88.5.06, 88.5.01–88.5.061
- Netherlands 88.11.01
- overview 81.21, 81.22
- United Kingdom 88.12.01
- United States 88.6.01–88.6.17

Europe 63.7.01**France**

- agreement 63.8.01
- licence agreement 63.8.02
- withdrawal of case 63.8.03–63.8.07

Germany 63.9.01–63.9.04**India 63.4.01****Italy 63.10.01, 63.10.02****Japan 63.5.01–63.5.06****Netherlands 63.11.01****overview 55.41–55.43****United Kingdom 63.12.01–63.12.04****United States**

- ANDA action 6.6.24, 63.6.23
- arbitration 63.6.14–63.6.22
- interference proceedings 5.6.34
- mediation 63.6.08–63.6.13
- overview 63.6.01–63.6.06
- without help of outside individuals 63.6.07

skilled addressee**attributes**

- Australia 3.1.05, 3.1.06
- Europe 3.7.02–3.7.05
- Italy 3.10.05–3.10.07
- Netherlands 3.11.05–3.11.07

Australia

- attributes 3.1.05, 3.1.06
- generally 3.1.01, 3.1.02
- international character of patent
 - evidence 3.1.07–3.1.09
- skilled team 3.1.10–3.1.13
- use in patent proceedings 3.1.03, 3.1.04

- Canada 3.2.01–3.2.12
- China 3.3.01–3.3.06
- common general knowledge
 - Europe 3.7.14–3.7.16
 - United Kingdom 3.12.07–3.12.10
- Europe
 - background 3.7.01
 - biotechnology/genetic engineering field 3.7.06–3.7.09
 - characteristics 3.7.02–3.7.05
 - common general knowledge 3.7.14–3.7.16
 - neighbouring technical fields 3.7.10–3.7.13
 - state of the art 3.7.14–3.7.16
- France
 - disclosure 3.8.12
 - inventive step 3.8.12
 - level of skill 3.8.11
 - overview 3.8.01–3.8.03
 - technical field 3.8.04–3.8.10
- Germany
 - art 3.9.07, 3.9.08
 - importance 3.9.01–3.9.03
 - neighbouring fields of art 3.9.07, 3.9.08
 - statutory provisions 3.9.04–3.9.06
- India 3.4.01
- Italy
 - attributes 3.10.05–3.10.07
 - overview 3.10.01–3.10.04
- Japan
 - definition 3.5.01–3.5.03
 - patent practice 3.5.04–3.5.06
- Netherlands
 - attributes 3.11.05–3.11.07
 - overview 3.11.01–3.11.04
 - scope of protection 3.11.08–3.11.10
- notional 1.04–1.08
- skilled team
 - Australia 3.1.10–3.1.13
- state of the art
 - Europe 3.7.14–3.7.16
- United Kingdom
 - attributes 3.12.03, 3.12.04
 - common general knowledge 3.12.07–3.12.10
 - overview 3.12.01, 3.12.02
 - teams 3.12.05, 3.12.06
- United States 3.6.01–3.6.05
- somatic cell therapy products
 - United States 72.6.21–72.6.24
- split trials
 - Australia 59.1.01–59.1.06
 - Canada 59.2.01–59.2.16
 - Markman hearings 59.2.05–59.2.08
 - separate determination of infringement and invalidity issues 59.2.12–59.2.16
 - separate determination of liability of damages 59.2.09–59.2.11
 - China 59.3.01–59.3.03
 - Europe 59.7.01
 - France
 - infringement/validity splits 59.8.03
 - liability/quantum splits 59.8.02
 - Markman hearings 59.8.01
 - Germany 59.9.01–59.9.04
 - India 59.4.01
 - Italy 59.10.01–59.10.04
 - Japan 59.5.01–59.5.03
 - Netherlands 59.11.01, 59.11.02
 - overview 55.23–55.27
 - United Kingdom 59.12.01–59.12.04
 - United States
 - ANDA cases 59.6.11
 - bifurcation 59.6.02–59.6.04
 - claim construction hearings 59.6.18–59.6.21
 - counterclaims 59.6.12–59.6.16
 - damages 59.6.09, 59.6.10
 - defences 59.6.12–59.6.16
 - infringement 59.6.17
 - overview 59.6.01
 - preliminary injunction hearings 59.6.22
 - validity 59.6.17
 - wilfulness 59.6.05–59.6.08
- state of the art
 - Europe 3.7.14–3.7.16
- stem cells
 - Netherlands 19.11.27
 - United States 19.6.07, 19.6.08
- Strasbourg Agreement concerning the International Patent Classification 1971
 - provisions 2.15, 2.16
- subject matter *see* patentable subject matter
- subpoenas
 - France 57.8.05
- sufficiency
 - Australia 25.1.01, 25.1.02
 - Canada 25.2.01–25.2.15
 - China 25.3.01–25.3.08
 - Europe 25.7.01–25.7.30
 - France 25.8.01–25.8.06
 - full description 25.7.01–25.7.30
 - Germany 25.9.01–25.9.14
 - India 25.4.01–25.4.05
 - Italy 25.10.01–25.10.13
 - Netherlands 25.11.01–25.11.17
 - requirement 18.28–18.33
 - United Kingdom 25.12.01–25.12.26
 - United States 25.6.01–25.6.23
- summary judgments
 - Australia 60.1.01–60.1.07
 - Canada 60.2.01–60.2.17
 - China 60.3.01, 60.3.02
 - Europe 60.7.01
 - France 60.8.01–60.8.05
 - Germany 60.9.02–60.9.06
 - India 60.4.01–60.4.07
 - Italy 60.10.01, 60.10.2
 - Japan 60.5.01
 - Netherlands 60.11.01, 60.11.02
 - overview 55.28–55.34
 - United Kingdom 60.12.07, 60.12.08
 - United States 60.6.01–60.6.05
- supplementary protection certificates
 - China 17.3.01, 17.3.02

supplementary protection certificates (cont.)

- Europe 17.7.04, 17.8.01–17.8.26
 - challenging certificate 17.8.20
 - duration 17.8.14, 17.8.15
 - formal requirements 17.8.04–17.8.12
 - paediatric extensions 17.8.21–17.8.26
 - scope of protection 17.8.16–17.8.19
 - timing 17.8.13
- France 13.8.14
 - former legislation 17.9.05–17.9.07
 - practice 17.9.08–17.9.16
 - types of SPC 17.9.02–17.9.04
- Germany 13.9.06–13.9.15, 17.10.02–17.10.08
- India 17.4.02
- Italy 17.11.01–17.11.09
- Japan 17.5.01
- Netherlands 17.12.03–17.12.11
- purpose 15.10
- United Kingdom 12.12.12, 12.12.13, 17.13.02–17.13.07
 - formal requirements 17.13.03–17.13.05
 - paediatric extensions 17.13.07
 - timing 17.13.06

surrender of patent

- India 16.4.04
- United Kingdom 16.12.04, 16.12.05

Swiss form medical use claims

- United Kingdom
 - interpretation of patent claims/specifications 4.12.26

technology transfer arrangements

- Australia
 - block exemptions 83.1.09–83.1.13
 - confidentiality agreements 83.1.02
 - deed of assignment 83.1.04
 - generally 83.1.01
 - joint ventures 83.1.06
 - licensing 83.1.05
 - material transfer agreements 83.1.03
 - spin-out companies 83.1.07
 - technology incubators 83.1.08
- Canada 83.2.01–83.2.11
- China 83.3.01–83.3.10
- France 83.8.01–83.8.05
- Germany 83.9.01
- India 83.4.01, 83.4.02
- Italy 83.10.01–83.10.03
- Japan 83.5.01–83.5.10
- Netherlands 83.11.01–83.11.05
- overview 81.04, 81.05
- United Kingdom 83.12.01
- United States 83.6.01–83.6.04

term of patent see patent term**third party interventions**

- Australia 37.1.01–37.1.09
- Canada 37.2.01–37.2.09
- China 37.3.01–37.3.04
- Europe 37.7.01–37.7.09
- France 37.8.01, 37.8.02
- Germany 37.9.01–37.9.07
- India 37.4.01

- Italy 37.10.01
- Japan 37.5.01–37.5.06
- Netherlands 37.11.01
- overview 36.01–36.03
- United Kingdom 37.12.01–37.12.15
- United States 37.6.01–36.6.07

tie-in/tie-out clauses

- Australia 84.1.01–84.1.07
- Canada 84.2.01–84.2.10
- China 84.3.01–84.3.03
- Europe 84.7.01–84.7.10
- France 84.8.01–84.8.07
- Germany 84.9.01–84.9.03
- India 84.4.01, 84.4.02
- Italy 84.10.01–84.10.06
- Japan 84.5.01–84.5.03
- Netherlands 84.11.01–84.11.02
- overview 81.08–81.10
- United Kingdom 84.12.01
- United States 84.6.01–84.6.09

timing of amendment

- Australia 33.1.01–33.1.14
- Canada 33.2.01–33.2.13
- China 33.3.01, 33.3.02
- Europe 33.7.01–33.7.06
- France 33.08.01–33.8.11
- Germany 33.9.01–33.9.11
- India 33.4.01–33.4.06
- Italy 33.10.01–33.10.03
- Japan 33.5.01–33.5.09
- Netherlands 33.11.01–33.11.06
- overview 32.02–32.04
- United Kingdom 33.12.01–33.12.18
- United States 33.6.01, 33.6.02

TLT see Trademark Law Treaty (TLT)**trade marks**

- Australia
 - application process 92.1.09, 92.1.10
 - deceptive similarity 92.1.17–92.1.21
 - defences 92.1.22
 - enforcement 92.1.12
 - overview 92.1.01
 - pharmaceutical trade marks 92.1.11
 - registrability issues 92.1.02–92.1.08
 - substantially identical 92.1.16
 - use as trade mark 92.1.13–92.1.15
- Canada 92.2.01–92.2.51
- China 92.3.01–92.3.13
- Europe
 - absolute grounds of refusal 92.7.09–92.7.19
 - colours 92.7.15, 92.7.16
 - customary in current language or in bona fide established practices of trade 92.7.18
 - defences to infringement 92.7.55, 92.7.56
 - devoid of any distinctive character 92.7.12, 92.7.13
 - harmonization of law 92.7.04
 - indication, descriptive 92.7.17
 - infringement 92.7.50–92.7.54
 - invalidity 92.7.44–92.7.47
 - overview 92.7.01–92.7.03
 - parallel imports 92.7.57–92.7.78
 - registrability 92.7.05–92.7.08

- revocation 92.7.48, 92.7.49
 - shapes 92.7.20–92.7.43
 - three-dimensional shape-of-product marks 92.7.14
 - use, distinctive character acquired through 92.7.19
- France
 - absolute grounds examination 92.8.05–92.8.08
 - confusion, risk of 92.8.09–92.8.16
 - generic drugs 92.8.17–92.8.27
 - overview 92.8.01–92.8.04
 - pharmaceutical trade mark marketing authorization 92.8.28–92.8.30
 - shapes 92.8.06–92.8.08
 - word and figurative marks 92.8.05
- Germany
 - assignment 92.9.15
 - exclusive rights 92.9.14
 - overview 92.9.01, 92.9.02
 - preconditions for protection 92.9.03–92.9.06
 - relative grounds for refusal of protection 92.9.11–92.9.13
- India
 - criminal offences 92.4.07
 - overview 92.4.01
 - registered trade marks 92.4.02–92.4.05
 - term of trade mark 92.4.06
 - unregistered trade marks 92.4.08–92.4.10
- Italy
 - absolute grounds for refusal 92.10.07
 - acquiescence 92.10.23
 - distinctiveness 92.10.05, 92.10.06
 - enforcement 92.10.24–92.10.26
 - infringement 92.10.12–92.10.18
 - loss of rights 92.10.19, 92.10.20
 - non-use 92.10.21, 92.10.22
 - overview 92.10.01, 92.10.02
 - registrability 92.10.03, 92.10.04
 - relative grounds for refusal 92.10.10, 92.10.11
 - remedies 92.10.24–92.10.26
 - shapes 92.10.08, 92.10.09
- Japan
 - famous trade mark protection 92.5.09, 92.5.10
 - protection of registered trade marks 92.5.01, 92.5.02
 - well-known trade mark protection 92.5.06–92.5.08
- Netherlands 92.11.01–92.11.05
- overview 89.11–89.16
- United Kingdom
 - advertising of medicines 92.12.07
 - Advertising Standards Authority 92.12.06
 - comparative advertising 92.12.05
 - misleading advertising 92.12.05
 - overview 92.12.01
 - threats 92.12.02, 92.12.03
 - unfair commercial business-to-consumer practices 92.12.04
- United States
 - chemical names 92.6.12
 - colour 92.6.10
 - dilution 92.6.23
 - distinctiveness 92.6.07, 92.6.08
 - enforcement 92.6.16–92.6.21
 - false advertising 92.6.22
 - FDA approval 92.6.14
 - generic names 92.6.13
 - overview 92.6.01–92.6.03
 - pharmaceutical trade marks 92.6.15
 - product configuration 92.6.09, 92.6.10
 - trade dress 92.6.09, 92.6.10
- trade secrets *see* confidential information
- Trademark Law Treaty (TLT)
 - provisions 2.27
- traditional knowledge
 - Australia 72.1.35–72.1.37
- trial
 - see also* split trials
 - Australia 46.1.11, 46.1.12
 - Canada 57.2.38–57.2.44
 - France 57.8.14
 - Japan 57.5.04–57.5.06
 - United Kingdom 57.12.32–57.12.35
 - United States 57.6.01, 57.6.11–57.6.13
- TRIPS
 - acquisition of IP rights 2.08
 - availability of IP rights 2.06
 - basic provisions 2.05
 - commencement 2.03
 - dispute resolution 2.09
 - enforcement 2.07
 - general provisions 2.05
 - harmonization 2.04
 - implementation 2.03
 - maintenance of IP rights 2.08
 - National Treatment meaning 2.05
 - obligations 2.04
 - patent term 15.01
 - scope of IP rights 2.06
 - use of IP rights 2.06
- unfair competition
 - Australia 92.1.27–92.1.35
 - Europe
 - comparative advertising 92.7.89, 92.7.91, 92.7.92
 - misleading advertising 92.7.89, 92.7.90
 - overview 92.7.79
 - unfair business-to-consumer commercial practices 92.7.80–92.7.88
 - Germany 92.9.16–92.9.32
 - India 92.4.15–92.4.22
 - Italy 92.10.27–92.10.29
 - overview 89.11–89.16
- United Kingdom
 - acceleration of grant procedure 12.12.02–12.12.08
 - account of profits 47.12.06, 47.12.07, 47.12.15–47.12.20
 - agricultural chemicals regulatory approval competent authorities 69.12.04
 - legislation 69.12.01–69.12.03
 - allowable amendments 34.12.01–34.12.23
 - amended specification 35.12.01–35.12.07

United Kingdom (*cont.*)

amendment

- allowable amendments 34.12.01–34.12.23
- amended specification 35.12.01–35.12.07
- definitions 33.12.01, 33.12.02
- patents 34.12.19–34.12.23
- post-grant amendments 33.12.10–33.12.18
- pre-grant of patent 33.12.03–33.12.09, 34.12.03–34.12.18

appeals 56.12.07–56.12.12

applications

- conversion applications 13.12.12–13.12.14
- divisional applications 13.12.02–13.12.08
- replacement applications 13.12.09–13.12.11
- types 13.12.01–13.12.14

approval of generic drugs 77.12.01

assignments

- estoppel 97.12.09
- formalities 97.12.02–97.12.06
- generally 97.12.01
- registration 97.12.07, 97.12.08

biodiversity 72.12.01

biological regulatory approval 67.12.01–67.12.04

Bolar exemption 52.12.01–52.12.09

case management 57.12.14–57.12.18

certified patents 77.12.01

clarity 27.12.01–27.12.03

commercialization strategies 95.12.01–95.12.13

common general knowledge 3.12.07–3.12.10

competition law

- disclosure to standard setting
 - organizations 86.12.01
- intellectual property rights
 - as exception 82.12.01–82.12.05
- licences 85.12.01
- technology transfer arrangements 83.12.01
- tie-in/tie-out clauses 84.12.01

unjustified infringement

- proceedings 87.12.01–87.12.04

compulsory licensing

- abuse of monopoly 99.12.02–99.12.06
- Doha declaration 99.12.07
- generally 99.12.01
- licences of right 99.12.08–99.12.14

confidential information

- definition of confidential information 90.12.05
- duty of confidentiality 90.12.06
- employee confidentiality 90.12.10–90.12.14
- overview 90.12.01–90.12.04
- public interests 90.12.07–90.12.09

costs 62.12.07–62.12.09

court hierarchies

- Court of Appeal 56.12.07–56.12.10
- courts of first instance 56.12.01–56.12.06
- Supreme Court 56.12.11, 56.12.12

Crown use 100.12.04–100.12.07

damages 47.12.06–47.12.14

data exclusivity

- comparison with other rights 74.12.01, 74.12.02
- generic companies 79.12.01
- innovator companies 78.12.01

medical devices 80.12.01

new chemical entity 75.12.01

other periods 76.12.01

data exclusivity strategies for generic

companies 79.12.01

data exclusivity strategies for innovator

companies 78.12.01

declarations of validity 41.12.01, 41.12.02

defences to infringement

- Bolar exemption 52.12.01–52.12.09
- exhaustion of rights 54.12.01–54.12.07
- experimental use 51.12.01–51.12.13
- non-infringement
 - declarations 53.12.01–53.12.12
 - prior secret use 50.12.01–50.12.12

delivery up 47.12.21, 47.12.22

disclosure 57.12.19–57.12.22

disclosure of information to patent

offices 14.12.01, 14.12.02

disclosure to standard setting

organizations 86.12.01

drafting bioscience patents

- basic principles 8.12.01
- biological material 8.12.29, 8.12.30
- biotechnological inventions 8.12.02
- claims 8.12.11–8.12.13
- example of claims 8.12.14–8.12.28
- exclusions from patentability 8.12.03–8.12.10
- information 8.12.31
- sequence listing 8.12.29, 8.12.30

drafting pharmaceutical patents

- composition claims 9.12.02–9.12.09
- first medical use claims 9.12.10–9.12.17
- generally 9.12.01
- information 9.12.28
- second medical use claims 9.12.18–9.12.27

due diligence 98.12.01

emergency use of patented invention 100.12.08

enablement 24.12.01

entitlement to the invention 31.12.01–31.12.12

- alternative remedies 31.12.08, 31.12.09
- grounds for disputed
 - ownership 31.12.04–31.12.06

legal framework 31.12.01–31.12.03

rules governing disputes 31.12.10–31.12.12

subject matter of dispute 31.12.07

equivalents doctrine 44.12.01–44.12.03

examination 11.12.01, 11.12.02

exhaustion of rights 54.12.01–54.12.07

experimental use

- clinical trials 51.12.12
- exemptions 51.12.01
- pharmacy use 51.12.13
- private use 51.12.02
- scope of protection 51.12.03–51.12.11

expert evidence 57.12.29–57.12.31

extensions of term 17.13.01

file wrapper estoppel 4.12.17, 4.12.18

fraud 30.12.01

full description 25.12.01–25.12.26

generic company filing strategies 71.12.01

- genetic modified organisms 72.12.02, 72.12.03
- government use or acquisition
 - of licences 100.12.01–100.12.08
- grace periods 22.12.01
- indirect infringement
 - claims limited by use 45.12.14
 - inducements to infringe 45.12.15
 - joint tortfeasors 45.12.16
 - staple commercial product 45.12.10–45.12.13
 - statutory provisions 45.12.01–45.12.09
- inequitable conduct 30.12.01
- infringement proceedings
 - burden of proof 46.12.06–46.12.09
 - defendants 46.12.15–46.12.21
 - entitlement to bring
 - proceedings 46.12.10–46.12.14
 - forum 46.12.01–46.12.03
 - split hearings 46.12.04, 46.12.05
- infringing acts 43.12.01–43.12.10
- injunctions 47.12.02–47.12.05
- innocent infringement 48.12.03–48.12.06
- innovator company strategies 70.12.01
- internal fair basis 24.12.01
- interpretation of patent claims/specifications
 - ambiguous patent 4.12.19–4.12.22
 - case law 4.12.08
 - combinations 4.12.25
 - conduct of patentee 4.12.17, 4.12.18
 - date of construction 4.12.15
 - definition of terms used in patent 4.12.16
 - dosing regimes 4.12.26
 - file wrapper estoppel 4.12.17, 4.12.18
 - improver questions 4.12.11, 4.12.12
 - numerical ranges 4.12.23, 4.12.24
 - overview 4.12.01–4.12.03
 - protocol questions 4.12.11, 4.12.12
 - purposive construction 4.12.09–4.12.14
 - relevant legislation 4.12.04–4.12.07
 - Swiss form medical use claims 4.12.26
 - variants 4.12.11, 4.12.12
- inventive step
 - background 23.12.03–23.12.07
 - commercial success 23.12.18, 23.12.19
 - mindset of skilled man 23.12.15, 23.12.16
 - obviousness 23.12.08–23.12.19
 - selection patents 23.12.17
 - statutory provisions 23.12.01, 23.12.02
 - technical vs commercial obviousness 23.12.14
 - unforeseen benefits 23.12.13
 - Windsurfing* test 23.12.08–23.12.19
- inventorship
 - entitlement disputes 5.12.04–5.12.15
 - procedure 5.12.16–5.12.21
 - who may apply for patent 5.12.01–5.12.03
- licences 85.12.01
- licensing
 - assignment of licences 96.12.19
 - competition law 96.12.20
 - estoppel 96.12.11
 - exclusive licences 96.12.02–96.12.05
 - exhaustion 96.12.17, 96.12.18
 - formalities 96.12.06–96.12.08
 - know-how 96.12.12
 - non-exclusive licences 96.12.02–96.12.05
 - overview 96.12.01
 - registration 96.12.09, 96.12.10
 - royalties 96.12.13, 96.12.14
 - sole licences 96.12.02–96.12.05
 - termination 96.12.15, 96.12.16
- limitation period 48.12.01, 48.12.02
- litigation
 - case management 57.12.14–57.12.18
 - commencement of claims 57.12.08–57.12.10
 - counterclaims 57.12.11–57.12.13
 - defence 57.12.11–57.12.13
 - disclosure 57.12.19–57.12.22
 - experiments 57.12.23–57.12.26
 - expert evidence 57.12.29–57.12.31
 - generally 57.12.01–57.12.05
 - interim applications 57.12.27, 57.12.28
 - practicalities 62.12.01–62.12.09
 - timescales 57.12.06, 57.12.07
 - trial 57.12.32–57.12.35
- medical device regulatory approval
 - competent authorities 68.12.03
 - legislation 68.12.01, 68.12.02
 - process of approval 68.12.04
- misrepresentation 30.12.01
- non-infringement
 - declarations 53.12.01–53.12.12
 - act or product 53.12.03, 53.12.04
 - applicability 53.12.07, 53.12.08
 - full written particulars 53.12.05, 53.12.06
 - generally 53.12.01
 - legislation 53.12.02
 - licensees 53.12.09
 - strategy 53.12.12
 - streamlined procedure 53.12.11
 - validity 53.12.10
- novelty
 - definition of novelty 21.12.01, 21.12.02
 - disclosure 21.12.12–21.12.14
 - enablement 21.12.15–21.12.18
 - made available to the public 21.12.07–21.12.11
 - prior publication 21.12.08, 21.12.09
 - prior use 21.12.10, 21.12.11
 - state of the art 21.12.03–21.12.06
- opposition proceedings 38.12.01
- ownership
 - assignment 6.12.03
 - bypassing employee compensation
 - scheme 6.12.17–6.12.19
 - co-ownership 6.12.20–6.12.25
 - compensation of employees 6.12.09–6.12.14
 - employee inventions 6.12.04–6.12.19
 - licences 6.12.03
 - normal duties 6.12.06, 6.12.08
 - proprietor 6.12.01, 6.12.02
 - special obligation 6.12.08
- parallel importing 54.12.01–54.12.07
- passing off 92.12.08–92.12.11
- patent term 16.12.01

United Kingdom (*cont.*)

patentable subject matter
 aesthetic works 19.12.05
 biotechnological inventions 19.12.17, 19.12.18
 business methods 19.12.06–19.12.09
 computer programs 19.12.06–19.12.09
 discoveries 19.12.04
 excluded inventions 19.12.03
 immoral inventions 19.12.11–19.12.13
 medical use 19.12.14–19.12.16
 presentation of information 19.12.10–19.12.13
 requirement of patentability 19.12.01, 19.12.02
 scientific theories 19.12.04
 treatment methods 19.12.14–19.12.16
 pharmaceutical regulatory approval 66.12.01–66.12.12
 plant breeders' rights
 compulsory licences 91.12.12
 exceptions 91.12.11
 infringement 91.12.09, 91.12.10
 obtaining rights 91.12.02
 overview 91.12.01
 priority 91.12.06
 qualification for protection 91.12.03–91.12.05
 rights conferred 91.12.07, 91.12.08
 practicalities of litigation 62.12.01–62.12.09
 preliminary injunctions 58.12.01–58.12.13
 preliminary issues 60.12.09
 prior secret use 50.12.01–50.12.12
 priority dates 20.12.01–20.12.04
 procedure from filing to grant
 filing application 10.12.01–10.12.05
 preliminary examination 10.12.06, 10.12.07
 publication 10.12.13, 10.12.14
 searches 10.12.08–10.12.12
 substantive examination 10.12.15–10.12.21
 prosecution strategies 12.12.01–12.12.13
 purposive construction 4.12.09–4.12.14
 re-examination 39.12.01
 regulatory bodies 65.12.02
 regulatory legislation 65.12.01
 remedies for infringement
 account of profits 47.12.06, 47.12.07,
 47.12.15–47.12.20
 amended patent specification 48.12.11–48.12.20
 damages 47.12.06–47.12.14
 delivery up 47.12.21, 47.12.22
 destruction 47.12.21, 47.12.22
 injunctions 47.12.02–47.12.05
 innocent infringement 48.12.03–48.12.06
 limitation period 48.12.01, 48.12.02
 non-registration, effect of 48.12.25, 48.12.26
 partially valid patent, infringement
 of 48.12.21–48.12.24
 restored patents 48.12.07–48.12.10
 restrictions 48.12.01–48.12.26
 statutory provisions 47.12.01
 renewal fees 16.12.01, 16.12.02
 research and development
 collaboration 94.12.01–94.12.04
 restoration application 16.12.03
 restored patents 48.12.07–48.12.10
 revocation

applicant for *inter partes*
 revocation 40.12.07–40.12.29
 generally 40.12.01
 grounds for *ex parte* revocation 40.12.02, 40.12.03
 grounds for *inter partes*
 revocation 40.12.04–40.12.06
 post-grant procedure 40.12.32–40.12.40
 strategy 40.12.30, 40.12.31
 secret use 28.12.01
 settlement of litigation 63.12.01–63.12.04
 skilled addressee
 attributes 3.12.03, 3.12.04
 common general knowledge 3.12.07–3.12.10
 overview 3.12.01, 3.12.02
 teams 3.12.05, 3.12.06
 slowing down grant procedure 12.12.09–12.12.11
 split trials 59.12.01–59.12.04
 streamlined procedure 60.12.10, 60.12.11
 striking out 60.12.02–60.12.06
 sufficiency 25.12.01–25.12.26
 summary judgments 60.12.07, 60.12.08
 supplementary protection certificates 12.12.12,
 12.12.13, 17.13.02–17.13.07
 formal requirements 17.13.03–17.13.05
 paediatric extensions 17.13.07
 timing 17.13.06
 surrender of patent 16.12.04, 16.12.05
 Swiss form medical use claims
 interpretation of patent claims/specifications 4.12.26
 technology transfer arrangements 83.12.01
 third party interventions 37.12.01–37.12.15
 tie-in/tie-out clauses 84.12.01
 timing of amendment 33.12.01–33.12.18
 trade marks
 advertising of medicines 92.12.07
 Advertising Standards Authority 92.12.06
 comparative advertising 92.12.05
 misleading advertising 92.12.05
 overview 92.12.01
 threats 92.12.02, 92.12.03
 unfair commercial business-to-consumer
 practices 92.12.04
 trial 57.12.32–57.12.35
 unity of invention 29.12.01–29.12.13
 criteria for determining lack
 of unity 29.12.07–29.12.09
 dependent claims 29.12.05
 generally 29.12.01
 genetic inventions 29.12.10, 29.12.11
 intermediate products 29.12.06
 plurality of independent
 claims 29.12.02–29.12.04
 search and examination
 procedure 29.12.12, 29.12.13
 unjustified infringement
 proceedings 87.12.01–87.12.04
 utility 26.12.01–26.12.07
 written description 25.12.01–25.12.26

United States

accelerated examination 11.6.05, 11.6.06
 agricultural chemicals regulatory approval
 FDC Act 69.6.02–69.6.06

- FIFRA 69.6.07–69.6.10
 - overview 69.6.01
- allowable amendments 34.6.01–34.6.04
- amendment
 - allowable amendments 34.6.01–34.6.04
 - certificates of correction 35.6.01–35.6.03
 - disclaimers 35.6.04
 - re-examination 35.6.13–35.6.15
 - reissue applications 35.6.05–35.6.12
 - timing 33.6.01, 33.6.02
- anti-counterfeiting initiatives 72.6.13–72.6.16
- appeals
 - interference proceedings 5.6.36
- applications
 - continuation applications 13.6.10
 - continuation-on-part applications 13.6.12
 - continuing applications 13.6.07–13.6.09
 - divisional applications 13.6.11
 - non-provisional utility applications 13.6.06
 - original applications 13.6.02
 - overview 13.6.01
 - provisional applications 13.6.03–13.6.05
 - reissue applications 13.6.02
 - requests for continued examination 13.6.13, 13.6.14
 - types 13.6.01–13.6.14
- approval of generic drugs
 - approval 77.6.09–77.6.19
 - Orange Book listing 77.6.01–77.6.19
 - overview 77.6.01–77.6.04
 - therapeutic equivalence 77.6.20–77.6.28
- assignments
 - generally 97.6.01–97.6.03
 - recording assignments 97.6.04
 - witnessing assignments 97.6.05
- bioengineered foods 72.6.17–72.6.20
- bioinformatics 19.6.23–19.6.25
- biological regulatory approval 67.6.01–67.6.08
 - biological product approval 67.6.02–67.6.03
 - follow-on biologics 67.6.04–67.6.08
 - overview 67.6.01
- Bolar exemption 52.6.01–52.6.16
- business methods 19.6.15–19.6.17
- calculation of 20 year term of patent 16.6.02
- case management 57.6.02–57.6.06
- certificates of correction 35.6.01–35.6.03
- certified patents 77.6.01–77.6.28
- clarity 27.6.01–27.6.08
- cloning 19.6.07, 19.6.08
- commercialization strategies
 - 180-day exclusivity 95.6.15
 - biologics 95.6.16
 - clearance search 95.6.20
 - drafting patent claims 95.6.19
 - due diligence 95.6.20
 - FDA approval process 95.6.03–95.6.05
 - generic biologics 95.6.16
 - new chemical entity exclusivity 95.6.11
 - new clinical study exclusivity 95.6.12
 - non-patent exclusivity periods for drugs 95.6.10–95.6.15
 - Orange Book practice 95.6.06–95.6.09
 - orphan drugs 95.6.13
 - overview 95.6.01, 95.6.02
 - patent licensing 95.6.25
 - patent term extension 95.6.23, 95.6.24
 - pediatric exclusivity 95.6.14
 - prior art 95.6.17, 95.6.18
 - safe harbour 95.6.21, 95.6.22
- competition law
 - disclosure to standard setting
 - organizations 86.6.01–86.6.14
 - intellectual property rights as
 - exception 82.6.01–82.6.11
 - licences 85.6.01–85.6.04
 - technology transfer arrangements 83.6.01–83.6.04
 - tie-in/tie-out clauses 84.6.01–84.6.09
 - unjustified infringement
 - proceedings 87.6.01–87.6.04
- compulsory licensing
 - Bayh-Dole Act 99.6.08–99.6.10
 - march-in rights 99.6.08–99.6.10
 - overview 99.6.01–99.6.07
- confidential information
 - disclosure of a trade secret 90.6.10–90.6.13
 - overview 90.6.01, 90.6.02
 - patent protection 90.6.14–90.6.16
 - protection of trade secrets 90.6.07–90.6.09
 - trade secrets 90.6.03–90.6.06
- confidentiality 57.6.07
- court hierarchies 56.6.01–56.6.09
- damages 47.6.06–47.6.17
- data exclusivity
 - combination drugs 75.6.06, 75.6.07
 - drug, meaning of 75.6.03–75.6.05
 - extensions of patent term 74.6.05–74.6.09
 - generic companies 79.6.01–79.6.07
 - innovator companies 78.6.01–78.6.09
 - interim patent term extensions 74.6.10–74.6.13
 - medical devices 80.6.01–80.6.03
 - new chemical entity 75.6.01–75.6.14
 - old antibiotics 75.6.11–75.6.14
 - orphan drugs 76.6.10–76.6.35
 - other periods 76.6.01–76.6.35
 - pediatric exclusivity 76.6.07–76.6.09
 - single enantiomers of previously approved racemates 75.6.08–75.6.10
 - term of patents 74.6.04
 - three-year exclusivity 76.6.01–76.6.06
- data exclusivity strategies for generic companies 79.6.01–79.6.07
- data exclusivity strategies for innovator companies 78.6.01–78.6.09
 - authorized generics 78.6.05–78.6.07
 - citizen positions 78.6.08, 78.6.09
 - discontinued labelling 78.6.04
 - follow-on products 78.6.02, 78.6.03
- date of filing or invention 4.6.18
- declarations of validity 41.6.01
- declaratory judgments 60.6.06–60.6.12, 60.7.01
- defences to infringement
 - Bolar exemption 52.6.01–52.6.16
 - non-infringement declarations 53.6.01
 - parallel importing 54.6.01–54.6.11
 - prior secret use 50.6.01–50.6.04

- United States** (*cont.*)
- deferred examination 11.6.08, 11.6.09
 - dictionaries 4.6.21
 - disclaimers 35.6.04
 - disclosure of information to patent
 - offices 14.6.01–14.6.12
 - disclosure to standard setting
 - organizations 86.6.01–86.6.14
 - discovery 57.6.02–57.6.06
 - interference proceedings 5.6.32–5.6.34
 - drafting bioscience patents
 - antibodies 8.6.38–8.6.42
 - antisense nucleic acids 8.6.28–8.6.32
 - bioinformatics 8.6.53, 8.6.54
 - deposits 8.6.44, 8.6.45
 - different technologies 8.6.09
 - dosages 8.6.46
 - expressed sequence tags 8.6.22–8.6.25
 - gene therapy 8.6.33
 - interfering RNA 8.6.28–8.6.32
 - nucleic acids 8.6.10–8.6.21
 - proteins 8.6.34–8.6.42
 - reach-through claims 8.6.50–8.6.52
 - research tools 8.6.47–8.6.49
 - scope of claims 8.6.02–8.6.06
 - single nucleotide polymorphism 8.6.26, 8.6.27
 - strategy 8.6.01
 - types of claims 8.6.07, 8.6.08
 - drafting pharmaceutical patents
 - compositions, pharmaceutical 9.6.29–9.6.31
 - drug discovery 9.6.44–9.6.46
 - manufacturing methods 9.6.36–9.6.38
 - product-by-process claims 9.6.33–9.6.35
 - research tools 9.6.44–9.6.46
 - scope of claim 9.6.02–9.6.07
 - screening methods 9.6.44–9.6.46
 - strategy 9.6.01
 - treatment methods 9.6.39–9.6.43
 - type of claim 9.6.08–9.6.16
 - due diligence
 - analysis of patent rights 98.6.14–98.6.21
 - confidentiality 98.6.08–98.6.10
 - counsel's opinion 98.6.08–98.6.10
 - deal documents 98.6.11–98.6.13
 - freedom to operate issues 98.6.22–98.6.32
 - general procedures 98.6.04–98.6.07
 - overview 98.6.01–98.6.03
 - representations 98.6.11–98.6.13
 - warranties 98.6.11–98.6.13
 - employee inventions
 - ownership 6.6.08
 - enablement 24.6.01–24.6.19
 - entitlement to the invention 31.6.01–31.6.05
 - bona fide purchasers 31.6.03
 - correcting inventorship 31.6.05
 - employee/employer relationship 31.6.04
 - limitations on ownership 31.6.04
 - equivalents doctrine 44.6.01–44.6.13
 - examination 11.6.01–11.6.09
 - experimental use 51.6.01–51.6.03
 - expert evidence 57.6.08
 - extensions of term
 - agencies responsible 17.6.19–17.6.20
 - calculation of extension period 17.6.17, 17.6.18
 - delays 17.6.24–17.6.28
 - determination of term from face of patent 17.6.29
 - disclosure duty 17.6.21–17.6.23
 - first permitted commercial marketing or use
 - limitation 17.6.11–17.6.14
 - one extension per patent 17.6.15
 - one extension per regulatory review period 17.6.16
 - regulatory review 17.6.02
 - requirements for extension 17.6.03, 17.06.04
 - scope of extension 17.6.08–17.6.10
 - types of patents that may be
 - extended 17.6.05–17.6.07
 - fraud 30.6.01–30.6.21
 - full description 25.6.01–25.6.23
 - generic company filing strategies
 - biowaivers 71.6.02–71.6.04
 - inactive ingredient changes 71.6.05–71.6.12
 - overview 71.6.01
 - government use or acquisition of
 - licences 100.6.01–100.6.03
 - grace periods 22.6.01–22.6.04
 - hire-to-invent doctrine 6.6.09–6.6.11
 - human gene therapy 72.6.21–72.6.24
 - indefinite articles 4.6.25
 - indefiniteness 27.6.01–27.6.08
 - indirect infringement
 - acts in foreign countries 45.6.05
 - contributory infringement 45.6.04
 - inducement 45.6.01–45.6.03
 - inequitable conduct 30.6.01–30.6.21
 - infringement proceedings
 - abbreviated new drug
 - applications 46.6.21–46.6.27
 - appeals 46.6.33–46.6.35
 - District Court proceedings 46.6.01–46.6.09
 - international trade commission 46.6.28–46.6.32
 - multi-district litigation 46.6.20
 - stages in litigation 46.6.10–46.6.19
 - infringing acts 43.6.01–43.6.20
 - innocent infringement 48.6.04–48.6.08
 - innovator company strategies
 - overview 70.6.01
 - regulated accelerated approval 70.6.02–70.6.04
 - statutory accelerated approval 70.6.05–70.6.10
 - subpart E status 70.6.11–70.6.14
 - interference proceedings
 - appeals 5.6.36
 - discovery 5.6.32–5.6.34
 - District Court 5.6.37, 5.6.38
 - inventorship 5.6.30–5.6.38
 - procedure 5.6.31
 - settlement 5.6.34
 - USPTO 5.6.30–5.6.36
 - internal fair basis 24.6.01–24.6.19
 - interpretation of patent claims/specifications
 - claim construction 4.6.01
 - conventional transitional phases 4.6.22, 4.6.23
 - date of filing or invention 4.6.18
 - dictionaries 4.6.21
 - extrinsic evidence 4.6.20

- indefinite articles 4.6.25
- intrinsic evidence 4.6.02
- limitations by preamble of claim 4.6.05, 4.6.06
- meaning in the context of claim 4.6.05, 4.6.06
- non-conventional transitional language 4.6.24
- preferred embodiments 4.6.09, 4.6.10
- product-by-process claims 4.6.28–4.6.30
- prosecution history 4.6.11
- public policy 4.6.17
- specification 4.6.07, 4.6.08
- upholding validity of claims 4.6.26, 4.6.27
- words of the claim 4.6.03
- intrinsic evidence 4.6.02
- inventive step
 - biotechnological processes 23.6.15–23.6.21
 - collaboration 23.6.22, 23.6.23
 - common ownership 23.6.22, 23.6.23
 - Graham v John Deere* 23.6.02
 - KSR Int'l Co v Teleflex, Inc* 23.6.03–23.6.06
 - level of ordinary skill in the art 23.6.10
 - non-obviousness 23.6.01
 - prior art 23.6.09
 - reasonable expectation of success 23.6.07, 23.6.08
 - secondary considerations of
 - non-obviousness 23.6.11–23.6.14
- inventorship
 - basic principles 5.6.01
 - burden of proof 5.6.26
 - conception 5.6.03
 - correcting inventorship 5.6.15, 5.6.17
 - corroboration 5.6.17–5.6.20
 - declaration of an interference 5.6.23, 5.6.24
 - determination 5.6.09, 5.6.10
 - District Court, interference
 - proceedings in 5.6.37, 5.6.38
 - elements of invention 5.6.02–5.6.08
 - interference proceedings 5.6.30–5.6.38
 - interfering subject matter 5.6.25
 - joint inventorship 5.6.11, 5.6.12
 - ownership 6.6.01, 6.6.02
 - presumption of correct inventorship 5.6.13, 5.6.14
 - priority of invention 5.6.21–5.6.29
 - proof 5.6.27–5.6.29
 - reasonable diligence 5.6.28
 - reduction to practice 5.6.04
 - simultaneous conception and reduction
 - to practice 5.6.05–5.6.08
 - USPTO, interference proceedings at 5.6.30–5.6.36
- lapse of patent applications 16.6.03
- licences 85.6.01–85.6.04
- licensing 96.6.01–96.6.18
 - Bayh-Dole Act 96.6.15
 - competition law 96.6.18
 - contesting validity 96.6.16, 96.6.17
 - default rules 96.6.05
 - overview 96.6.01–96.6.03
 - points to specify in licence 96.6.06–96.6.14
 - state contract law 96.6.04
- limitation period 48.6.01
- litigation
 - case management 57.6.02–57.6.06
 - confidentiality 57.6.07
 - discovery 57.6.02–57.6.06
 - expert evidence 57.6.08
 - practicalities 62.6.01–62.6.18
 - privilege 57.6.09, 57.6.10
 - trial 57.6.01, 57.6.11–57.6.13
 - waiver 57.6.09, 57.6.10
- living matter 19.6.06
- maintenance fees 16.6.03
- medical device regulatory approval
 - classification of medical devices 68.6.02–68.6.06
 - investigational device exemptions 68.6.07, 68.6.08
 - overview 68.6.01
 - PMA route to market 68.6.09–68.6.13
 - pre-market notification route 68.6.14–68.6.18
- medical devices data exclusivity 80.6.01–80.6.03
- misrepresentation 30.6.01–30.6.21
- multi-jurisdictional strategy 61.6.01–61.6.04
- nanotechnology 72.6.08–72.6.12
- non-infringement declarations 53.6.01
- novelty
 - accidental anticipation 21.6.07
 - anticipation 21.6.02
 - enablement standard for anticipation 21.6.05
 - generally 21.6.01
 - incorporation by reference 21.6.04
 - inherent anticipation 21.6.06
 - single reference's significance 21.6.03
 - species-genus relationships 21.6.08
 - types of prior art 21.6.09
- nullification proceedings 40.6.01
- opposition proceedings 38.6.01
- orphan drugs
 - approval 76.6.20–76.6.26
 - benefits 76.6.27–76.6.35
 - designation 76.6.11–76.6.19
 - exclusivity 76.6.10
- ownership
 - assignment 6.6.05–6.6.07
 - employee inventions 6.6.08
 - hire-to-invent doctrine 6.6.09–6.6.11
 - inventorship 6.6.01, 6.6.02
 - joint ownership 6.6.03, 6.6.04
 - shop-right doctrine 6.6.12, 6.6.13
 - transfer 6.6.05–6.6.07
 - universities 6.6.14
- parallel importing 54.6.01–54.6.11
- patent term 16.6.01, 16.6.02
- patentable subject matter
 - abstract ideas 19.6.15–19.6.17
 - bioinformatics 19.6.23–19.6.25
 - business methods 19.6.15–19.6.17
 - cloning 19.6.07, 19.6.08
 - ethics based limitations 19.6.06
 - human beings 19.6.10–19.6.13
 - living matter 19.6.06
 - made by man 19.6.04, 19.6.05
 - manufacturing methods 19.6.07, 19.06.08
 - medical diagnostics 19.6.14
 - natural phenomena 19.6.15–19.6.22
 - nature, laws of 19.6.15–19.6.17
 - non-human animals 19.6.09
 - overview 19.6.01, 19.6.02

- United States (*cont.*)
- patentable subject matter (*cont.*)
 - scope 19.6.03
 - stem cells 19.6.07, 19.6.08
 - pharmaceutical regulatory approval
 - generic drugs 66.6.14–66.6.24
 - innovator new drug development and approval 66.6.02–66.6.13
 - marketing unapproved drugs 66.6.31–66.6.39
 - OTC drug monographs 66.6.25–66.6.30
 - overview 66.6.01
 - pharmacogenomics 72.6.02–72.6.07
 - plant breeders' rights
 - certificates 91.6.14–91.6.17
 - infringement of certificates 91.6.18–91.6.21
 - infringement of legislation 91.6.10, 91.6.11
 - new plant protection 91.6.01, 91.6.02
 - overview of legislation 91.6.03–91.6.05
 - Plant Variety Protection Act
 - of 1970 91.6.12, 91.6.13
 - requirements of legislation 91.6.06–91.6.09
 - utility patents 91.6.22–91.6.26
 - practicalities of litigation 62.6.01–62.6.18
 - preliminary injunctions 58.6.01–58.6.13, 59.6.22
 - prior secret use
 - background 50.6.01
 - earlier inventor defence 50.6.02
 - earlier inventor must abandon, suppress or conceal 50.6.03, 50.6.04
 - priority dates 20.6.01–20.6.08
 - application filed in foreign country 20.6.03
 - chains, priority 20.6.06, 20.6.07
 - exceptions 20.6.08
 - formalities 20.6.08
 - international application 20.6.05
 - non-provisional application filed in US 20.6.04
 - provisional application filed in US 20.6.02
 - rules 20.6.08
 - priority of invention 5.6.21–5.6.29
 - privilege 57.6.09, 57.6.10
 - procedure from filing to grant
 - allowance 10.6.34
 - appeals 10.6.32, 10.6.33
 - declaration 10.6.06
 - drawings 10.6.05
 - examination of application 10.6.11–10.6.31
 - fee for filing 10.6.07
 - oath 10.6.06
 - overview 10.6.01, 10.6.02
 - process after filing 10.6.08–10.6.10
 - provisional patent application 10.6.35
 - required elements 10.6.03–10.6.07
 - specification 10.6.04
 - prosecution strategies 12.6.01–12.6.22
 - re-examination 35.6.13–35.6.15, 39.6.01–39.6.29
 - estoppel effects of *inter partes* re-examination 39.6.26–39.6.29
 - ex parte* procedures 39.6.12–39.6.16
 - ex parte* requests 39.6.06–39.6.10
 - inter partes* procedure 39.6.19–39.6.25
 - inter partes* requests 39.6.17, 39.6.18
 - regulatory bodies
 - biologics 65.6.14–65.6.15
 - Centers for Medicare and Medicaid Services 65.6.22
 - Customs and Border Protection 65.6.22
 - Department of Justice 65.6.22
 - Drug Enforcement Administration 65.6.22
 - drugs 65.6.08–65.6.13
 - FDA 65.6.20, 65.6.21
 - Federal Trade Commission 65.6.22
 - medical devices 65.6.16–65.6.19
 - overview 65.6.01–65.6.03
 - Patent and Trademark Office 65.6.22
 - penalties 65.6.04–65.6.06
 - prohibited acts 65.6.04–65.6.06
 - requirements 65.6.07
 - regulatory legislation 65.6.24–65.6.70
 - reissue applications 35.6.05–35.6.12
 - remedies for infringement
 - attorney's fees 47.6.20, 47.6.21
 - damages 47.6.06–47.6.17
 - injunctions 47.6.01–47.6.05
 - innocent infringement 48.6.04–48.6.08
 - interest 47.6.18, 47.6.19
 - intervening rights 48.6.09–48.6.12
 - ITC actions 47.6.22, 47.6.23
 - limitation period 48.6.01
 - marking and notice requirement 48.6.02, 48.6.03
 - restrictions 48.6.01–48.6.12
 - renewal fees 16.6.03
 - research and development collaboration
 - antitrust 94.6.13
 - Bayh-Dole Act 94.6.06, 94.6.07
 - defences 94.6.12
 - funding support 94.6.08–94.6.11
 - improvements 94.6.03–94.6.05
 - inventorship 94.6.03–94.6.05
 - joint research agreements 94.6.08–94.6.11
 - overview 94.6.01, 94.6.02
 - ownership of inventions 94.6.03–94.6.05
 - safe harbour 94.6.08–94.6.11
 - revocation 40.6.01
 - secret use 28.6.01–28.6.09
 - settlement
 - interference proceedings 5.6.34
 - settlement of litigation
 - ANDA action 63.6.23, 63.6.24
 - arbitration 63.6.14–63.6.22
 - mediation 63.6.08–63.6.13
 - overview 63.6.01–63.6.06
 - without help of outside individuals 63.6.07
 - skilled addressee 3.6.01–3.6.05
 - somatic cell therapy products 72.6.21–72.6.24
 - special applications 11.6.01–11.6.04
 - split trials
 - ANDA cases 59.6.11
 - bifurcation 59.6.02–59.6.04
 - claim construction hearings 59.6.18–59.6.21
 - counterclaims 59.6.12–59.6.16
 - damages 59.6.09, 59.6.10
 - defences 59.6.12–59.6.16

- infringement 59.6.17
- overview 59.6.01
- preliminary injunction hearings 59.6.22
- validity 59.6.17
- wilfulness 59.6.05–59.6.08
- stem cells 19.6.07, 19.6.08
- sufficiency 25.6.01–25.6.23
- summary judgments 60.6.01–60.6.05
- technology transfer arrangements 83.6.01–83.6.04
- third party interventions 37.6.01–36.6.07
- tie-in/tie-out clauses 84.6.01–84.6.09
- timing of amendment 33.6.01, 33.6.02
- trade marks
 - acquisition through use in
 - commerce 92.6.04–92.6.06
 - chemical names 92.6.12
 - colour 92.6.09, 92.6.10
 - dilution 92.6.23
 - distinctiveness 92.6.07, 92.6.08
 - enforcement 92.6.16–92.6.21
 - false advertising 92.6.22
 - FDA approval 92.6.14
 - generic names 92.6.13
 - overview 92.6.01–92.6.03
 - pharmaceutical trade marks 92.6.15
 - product configuration 92.6.09, 92.6.10
 - trade dress 92.6.09, 92.6.10
- trial 57.6.01, 57.6.11–57.6.13
- unity of invention 29.6.01–29.6.10
 - criteria for determining lack of
 - unity 29.7.12–29.7.19
 - dependent claims 29.7.08
 - divisional applications 29.6.03
 - election of species 29.6.04–29.6.10
 - intermediate products 29.7.09–29.7.11
 - non-payment of further
 - search fee 29.7.20, 29.7.21
 - plurality of independent claims 29.7.02–29.7.07
 - restriction practice 29.6.01, 29.6.02
- universities
 - ownership 6.6.14
- unjustified infringement
 - proceedings 87.6.01–87.6.04
- utility
 - burden of proof 26.6.03, 26.06.04
 - credible utility 26.6.10, 26.6.11
 - enablement 26.6.05, 26.6.06
 - examination guidelines 26.6.11
 - pharmacologic utility 26.6.12–26.6.14
 - question of law 26.6.03, 26.06.04
 - requirement 26.6.01, 26.6.02
 - research tools 26.6.15–26.6.19
 - specific utility 26.6.08
 - standards for determination 26.6.07
 - substantial utility 26.6.09
 - therapeutic utility 26.6.12–26.6.14
 - withdrawal of patent applications 16.6.04, 16.6.05
 - written description 25.6.01–25.6.23
- unity of invention**
 - Australia 29.1.01
 - Canada 29.2.01–29.2.13
 - China 29.3.01–29.3.09
 - France
 - appreciation 29.8.04
 - principle 29.8.01–29.8.03
 - Germany
 - definition of unity 29.9.02
 - generally 29.9.01
 - intermediate products 29.9.06
 - overcoming
 - objection 29.9.07–29.9.09
 - plurality of claims 29.9.03–29.9.05
 - India 29.4.01–29.4.04
 - Italy 29.10.01–29.10.06
 - Japan 29.5.01, 29.5.02
 - Netherlands 29.11.01–29.11.06
 - overview 18.39, 18.40
 - United Kingdom 29.12.01–29.12.13
 - criteria for determining lack of
 - unity 29.12.07–29.12.09
 - dependent claims 29.12.05
 - generally 29.12.01
 - genetic inventions 29.12.10, 29.12.11
 - intermediate products 29.12.06
 - plurality of independent
 - claims 29.12.02–29.12.04
 - search and examination
 - procedure 29.12.12, 29.12.13
 - United States 29.6.01–29.6.10
 - criteria for determining lack of
 - unity 29.7.12–29.7.19
 - dependent claims 29.7.08
 - divisional applications 29.6.03
 - election of species 29.6.04–29.6.10
 - intermediate products 29.7.09–29.7.11
 - non-payment of further
 - search fee 29.7.20, 29.7.21
 - plurality of independent
 - claims 29.7.02–29.7.07
 - restriction practice 29.6.01, 29.6.02
- universities**
 - United States
 - ownership 6.6.14
- unjustified infringement proceedings**
 - Australia 87.1.01–87.1.04
 - Canada 87.2.01–87.2.08
 - China 87.3.01–87.3.03
 - Europe 87.7.01–87.7.07
 - France 87.8.01–87.8.10
 - Germany 87.9.01–87.9.10
 - India 87.4.01
 - Italy 87.10.01–87.10.04
 - Japan 87.5.01–87.5.04
 - Netherlands 87.11.01
 - overview 81.17–81.20
 - United Kingdom 87.12.01–87.12.04
 - United States 87.6.01–87.6.04
- utility**
 - Australia 26.1.01, 26.1.02
 - Canada 26.2.01–26.2.20
 - China 26.3.01–26.3.06
 - Europe 26.7.01–26.7.03

utility (cont.)

France

- case law 26.8.03
- principle 26.8.01, 26.8.02
- treatment methods 26.8.04

Germany 26.9.01, 26.9.02

India 26.4.01, 26.4.02

Italy 26.10.01–26.10.03

Japan

- gene, vector protein, transformant,
cell, antibody etc 26.5.03
- generally 26.5.01, 26.5.02
- treatment methods 26.5.04, 26.5.05

Netherlands 26.11.01–26.11.04

overview 18.34, 18.35

United Kingdom 26.12.01–26.12.07

United States

- burden of proof 26.6.03, 26.06.04
- credible utility 26.6.10, 26.6.11
- enablement 26.6.05, 26.6.06
- examination guidelines 26.6.11
- pharmacologic utility 26.6.12–26.6.14
- question of law 26.6.03, 26.06.04
- requirement 26.6.01, 26.6.02
- research tools 26.6.15–26.6.19
- specific utility 26.6.08
- standards for determination 26.6.07
- substantial utility 26.6.09
- therapeutic utility 26.6.12–26.6.14

utility models

- Germany 9.9.29–9.9.34, 11.9.09

veterinary medicinal products

- France 72.8.03–72.8.05

withdrawal of patent applications

- Australia 16.1.10–16.1.15
- Canada 16.2.17, 16.2.18
- Europe 16.7.30–16.7.40
- France 16.8.06–16.8.11
- Germany 16.9.08–16.9.11
- India 16.4.03
- Italy 16.10.03–16.10.09
- Japan 16.5.04
- Netherlands 16.11.05–16.11.12
- overview 15.06
- United States 16.6.04, 16.6.05

World Trade Organization Agreement on**Trade-Related Aspects of Intellectual Property
Rights *see* TRIPS****written description**

- Australia 25.01.01
- Canada 25.2.01–25.2.15
- China 25.3.01–25.3.08
- Europe 25.7.01–25.7.30
- France 25.8.01–25.8.06
- Germany 25.9.01–25.9.14
- India 25.4.01–25.4.07
- Italy 25.10.01–25.10.13
- Netherlands 25.11.01–25.11.17
- requirement 18.28–18.33
- United Kingdom 25.12.01–25.12.26
- United States 25.6.01–25.6.23